VASCULAR STIFFENING IN ATHEROSCLEROSIS:  CELL CONTRACTILITY AND MATRIX MECHANICAL HETEROGENEITIES MEDIATE BARRIER INTEGRITY by Lampi, Marsha Christine
  
VASCULAR STIFFENING IN ATHEROSCLEROSIS:  
CELL CONTRACTILITY AND MATRIX MECHANICAL HETEROGENEITIES 
MEDIATE BARRIER INTEGRITY 
 
 
 
 
 
  
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
 
by 
Marsha Christine Lampi 
August 2017
  
 
 
 
 
 
 
 
 
 
 
 
© 2017 Marsha Christine Lampi
  
VASCULAR STIFFENING IN ATHEROSCLEROSIS:  
CELL CONTRACTILITY AND MATRIX MECHANICAL HETEROGENEITIES 
MEDIATE BARRIER INTEGRITY 
 
Marsha Christine Lampi, Ph.D. 
Cornell University 2017 
 
Cardiovascular pathologies are a leading cause of death in the Western world. 
Atherosclerosis is the development of lipid-rich plaques within the arterial wall, and is 
considered the major underlying pathology that contributes to cardiovascular disease 
development. Intriguingly, age is a primary risk factor for atherosclerosis, and increased 
artery stiffness increases with advanced age and atherosclerosis. It is now established that 
endothelial cell feedback to mechanical stimuli on the cellular level, including age-related 
arterial stiffness can promote a pro-atherogenic endothelium. In response to increased 
matrix rigidity, endothelial cells exert increased RhoA-mediated contractile forces that 
disrupt monolayer barrier function and increase endothelium permeability. Identifying 
therapeutic approaches to overcome the cellular response to extracellular matrix stiffness 
cues and understanding how the altered mechanical properties of the arteries associated 
with aging contribute to endothelium disruption is important to the prevention of 
atherosclerosis. 
 
Using hydrogel scaffolds with tunable crosslinking, I fabricated physiologically relevant 
models to study the effects of age-related matrix mechanical cues on endothelial cell 
behaviors in the translational context of atherosclerosis. I identified that therapeutically 
targeting the Rho GTPase family members RhoA and Rac1 with the available statin, 
 simvastatin, attenuated the endothelial cell response to increased matrix stiffness. 
Importantly, the altered GTPase activity was associated with endothelial cell-cell junction 
reorganization and decreased intercellular junction tension to promote an atheroprotective 
endothelium. Motivated by the increased spatial stiffness heterogeneity observed in the 
aged arterial intima, I then developed and characterized a second hydrogel platform that 
employed photocrosslinking to vary the presentation of matrix stiffness. My data 
demonstrated that increased complexity of a heterogeneously stiff substrate in addition to 
a mean increase in the elastic modulus was deleterious to monolayer integrity and disrupted 
cell-cell junctions. Collectively, these two studies identified a pharmacological approach 
to overcome the cellular response to extracellular matrix stiffening and identified a novel 
matrix mechanical factor that has implications for the development of age-related 
atherosclerosis. Finally, because pathological matrix stiffening drives disease progression, 
I investigated the emerging field of mechano-medicine and potential therapeutic 
approaches to overcome stiffness-mediated pathologies. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
Portions of this chapter were published in Frontiers in Genetics  
(Kohn,* Lampi,* and Reinhart-King, 2015, *denotes equal contribution) 
 
 
1.1 Introduction to Atherosclerosis 
 
Cardiovascular diseases are a leading cause of death in the United States and 
atherosclerosis is often the underlying pathology that contributes to their development (1). 
During atherogenesis, the accumulation of lipid rich plaques in the arterial wall narrows 
the vessel lumen and impedes blood flow (Figure 1.1) (2). These changes in artery structure 
impose increased stress on the heart muscle that can lead to cardiac failure (3, 4). 
 
 
Figure 1.1. Large artery structure and atherosclerotic plaque development. Arteries 
are composed of three concentric layers: the adventitia, the media, and the intima. 
Atherosclerotic plaque development begins in the innermost artery layer, the intima and 
hinders blood flow through the vessel lumen.   
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In addition, a fraction of atherosclerotic plaques become unstable and release debris into 
the circulation that can cause thrombus, heart attacks, and strokes (4, 5). Thus, research 
efforts to mitigate atherosclerosis have important clinical health implications.  
 
Increased age is a primary risk factor for atherosclerosis and nascent asymptomatic lesions 
know as fatty streaks that are found during childhood develop into plaques throughout 
adulthood (6–8). Endothelial cells line the arterial lumen and help to maintain vascular 
homeostasis by acting, in part, as a semi-permeable barrier preventing circulating 
macromoelcules, such as lipids from entering the arteries (9–11). When endothelium 
integrity becomes compromised, apoB-lipoproteins, primarily low density lipoprotein 
(LDL) cholesterol, can permeate into the artery wall and initiate a chronic inflammatory 
immune response that culminates in atherosclerotic plaque development (12, 13). Lipids 
are retained in the arterial wall through interactions with subendothelial extracellular 
matrix proteoglycans and subsequently oxidized by reactive oxygen species, enzymes, and 
lipases (13–15). Oxidized LDL triggers endothelial cells to express chemokines and 
adhesion molecules that recruit monocytes into the arterial wall (16–19). Once within the 
arterial wall, monocytes differentiate into macrophages that recognize oxidized LDL 
through scavenger receptors (20, 21). Subsequent macrophage uptake of oxidized LDL 
leads to lipid-filled foam cells that comprise the characteristic fatty streaks of early 
atherosclerosis (22, 23). Macrophages also secrete chemokines to recruit additional 
monocytes and sustain the inflammatory response that drives plaque formation (24, 25).  
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During intermediate atherogenesis, vascular smooth muscle cells (VSMCs) are stimulated 
by endothelial and macrophage secreted growth factors, namely platelet derived growth 
factor (PDGF) to migrate to the plaque site (26, 27). Here, they adopt a synthetic phenotype 
and produce large amounts of extracellular matrix that, in combination with increased 
proliferation, cause localized vessel thickening (28, 29). Matrix proteoglycans synthesized 
by VSMCs contribute to increased retention of lipids, and the production of additional 
matrix is stimulated when these lipids become oxidized (30, 31). Thus, VSMCs play an 
important role in plaque growth through a feed forward cycle of lipid retention, oxidation, 
and extracellular matrix production. VSMCs also participate in lipid uptake to become 
foam cells and release cytokines that further drive immune cell recruitment and 
atherogenesis (32–34).  
 
In advanced atherosclerosis, a characteristic necrotic core within developed plaques arises 
when excess foam cell apoptosis exceeds phagocytic clearance rates, and is deleterious to 
plaque stability (35). In addition, VSMC death occurs at high rates and causes a significant 
reduction in collagen matrix synthesis. A lack of extracellular matrix production in concert 
with increased matrix metalloproteinase activity thins the protective fibrous cap on the 
surface of atherosclerotic lesions (36, 37). Advanced atherosclerotic plaques pose a serious 
patient health risk because they are prone to rupture, particularly at weakened cap sites in 
close proximity to the necrotic core (38). Upon rupture, thrombus at the plaque surface and 
released debris can cause heart attacks and strokes (2, 4).  
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1.2 Large Artery Structure 
Arteries are composite materials, containing multiple concentric layers, each with a distinct 
composition and function (Figure 1.1). The intima is the innermost artery layer and is a 
composite of two layers. The luminal layer, known as the basal lamina, is comprised of a 
thin basement membrane with a proteoglycan rich matrix and small amounts of collagen 
(39, 40) Endothelial cells (ECs) attach to the intimal basement membrane and exist as a 
monolayer lining the arterial lumen. The second intimal layer is musculoelastic and 
consists of elastin fibers, individual smooth muscle cells, and collagen (41). Continuing 
inwards from the lumen, a collection of organized fenestrated elastin fibers known as the 
internal elastic lamina separates the intima from the media, the middle artery layer. Elastin 
within the internal elastic lamina is oriented longitudinally in the direction of luminal blood 
flow, while in the medial layer it is oriented circumferentially (42). The media is composed 
of lamellar units that are composites of elastin fibers, circumferentially oriented VSMC 
layers, collagen fibers, and a mucopolysaccharide viscoelastic gel, commonly referred to 
as a “ground substance” (41). The characteristic lamellae of the media comprise the 
majority of the arterial wall bulk and are responsible for its elastic properties, allowing for 
the artery to expand and contract with the blood pulse. The outermost artery layer is the 
adventitia. The adventitia is composed of circumferentially arranged, wavy collagen fibrils 
intermixed with elastin and is surrounded by loose connective tissue. Fibroblasts are 
dispersed within the adventitia, but are generally absent from the intima and media artery 
layers (43). 
 
 
 26 
 
1.3 Arterial Mechanics 
When analyzed as a composite material, large arteries exhibit a non-linear stress-strain 
pattern, and therefore, are best described in terms of an elastic modulus evaluated at a given 
physiological stress along the stress-strain curve, termed the incremental elastic modulus 
(44). The extracellular matrix (ECM) proteins collagen and elastin account for 
approximately half of the vessel dry weight, and play a crucial role in artery mechanics 
(45). Overall, Type I and Type III collagens account for 60% of the artery wall, and elastin 
30% (46, 47). At low degrees of stretch, the compliant elastin fibers dominate the 
mechanics, while at higher levels of deformation, helically oriented collagen fibers are 
recruited (48, 49). Collagen fibers are 100–1,000 times stiffer than elastin which causes a 
sharp increase in the incremental elastic modulus at higher levels of circumferential stretch 
(50–53). Under physiological strain loads, the incremental elastic modulus is a function of 
strain and the combined contributions of elastin and collagen (53). 
The distinct composition of each artery layer lends itself to layer-specific mechanical 
properties that can vary from person to person, and also between large and small arteries 
(54, 55). For example, measured under axial stretch and using non-axisymmetric 
deformations, the media is significantly less compliant than the adventitia (56, 57). The 
media and adventitia also have different load bearing proportions. Under circumferential 
tension, the media bears ∼60% of the load and the adventitia bears 40%. Longitudinal 
tension is primarily assumed by the adventitia which bears ∼75% of the load (58). It is 
important to note that cells only sense the mechanical properties of their microenvironment 
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to a depth of 5 µm (59, 60). As such, measurements and analysis of each individual layer 
is essential when considering cellular level mechanobiology. 
 
Intima 
The mechanical properties of the healthy intima are not well-established largely because 
artery mechanics are traditionally studied on the macroscale, where properties of the media 
and adventitia dominate. Several studies have analyzed the aorta as a two-layer construct 
consisting of a combined intima-media layer surrounded by the adventitial layer (61, 62). 
Because recent evidence has shown that endothelial cells are mechanosensitive to matrix 
stiffness and that increased intimal stiffness promotes endothelial dysfunction; the 
mechanical properties of the intima alone may be important factors in cardiovascular 
disease progression and warrant further investigation (63, 64). The healthy human intima 
has been reported to have an elastic modulus of 34.4 kPa and is considered a compliant 
material, with an elastic modulus similar to adipose tissue and lower than muscle (65–68). 
 
Media 
Medial mechanics are dominated by elastin within the lamellar units at physiological 
pressures (69). When the artery is subjected to a transmural pressure, the elastin fibers 
which possess high entropically driven recoil properties are initially stretched, followed by 
the stretching of stiffer collagen fibers (70). The number of concentric lamellae layers in 
the media remains constant with age but scales with arterial radius and vessel wall tensional 
strength (71). The mechanical contribution of VSMCs dispersed within the aortic lamellae 
is still somewhat unclear. Contractile activation of VSMCs has been shown to increase the 
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medial elastic modulus; but separate studies have shown that lamellar mechanical 
properties are unchanged after VSMC activation with noradrenaline (72–74). 
 
Adventitia 
The mechanics of the adventitia are attributed to collagen organization. In the zero-load 
state, the fibers assume a crimped morphology (75). As an axial load is placed on the vessel, 
the collagen fibers deform and straighten, exhibiting their high tensile strength. In the inner 
adventitia, collagen fibers are oriented, thin, and intermixed with elastin allowing for vessel 
distension and protection against rupture, whereas the outer adventitia is primarily 
composed of thick, non-oriented collagen fibers that support the vessel (76). 
 
1.4 Causes of Age-Related Arterial Stiffening 
It is well established that the aorta stiffens with age, and that increased aortic stiffness is 
correlated with increased cardiovascular risk and mortality (7, 77, 78). Clinical studies 
report a 1% increase in bulk artery stiffness, followed by more rapid stiffening after age 55 
in otherwise healthy adults, independent of sex or other cardiovascular risk factors (7, 79–
81). Age-related stiffening within the aorta is primarily caused by changes to elastin and 
collagen, the primary constituents of the vessel wall.   
 
Elastic fibers have an extremely low turnover rate in vivo, and this longevity allows for 
fragmentation, calcification, and MMP-degradation effects to accumulate over the lifespan 
(82). As elastin fibers decay, they lose functionality and shift load bearing onto stiffer 
collagen fibrils, which directly contributes to significant increases in bulk arterial stiffness. 
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Fatigue failure from pulsatile wall stress can also cause elastin fragmentation (83–85). 
Moreover, calcium in the arterial wall increases with age facilitating the direct binding of 
calcium ions to elastin fibers causing calcification (86–88). Animal models that induce 
elevated elasto-calcinosis have demonstrated increased medial elastin fragmentation and 
arterial stiffness (89, 90). 
 
Enzymatic degradation of elastin is mediated by matrix metalloproteinases which have low 
basal activity in healthy arteries to balance the absence of new elastin synthesis. The 
dysregulation of MMPs is already known to play a role in the cardiovascular pathologies 
hypertension and aneurysm (91, 92). With age, increased activity of the elastases MT1-
MMP and MMP-2 has been observed, and MMP-2 has been found near fragmented elastin 
fibers within the aorta (92–94). Notably, even though the absolute elastin content in the 
aorta remains relatively stable with age, the elastin concentration decreases and is 
accompanied by a substantial increase in collagen concentration (55, 95–97). Age is also 
associated with changes on the amino acid scale that can contribute to decreased arterial 
compliance caused by a loss of elastin functionality. The compounds desmosine and 
isodesmosine are formed from four lysine amino acids and are critical for crosslinking 
elastin fibers to give them their elastic properties (98). The concentrations of desmosine 
and isodesmosine and their crosslinks decrease with age (99, 100). 
In contrast to elastin, the collagen concentration in all three layers of the arterial wall 
increases with age, shifting the optimal elastin:collagen balance that governs healthy 
arterial mechanics. Aged endothelial cells have morphological changes resembling a 
VSMC phenotype and express alpha smooth muscle actin and collagen I, indicating they 
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may deposit collagen that contributes to intimal thickening (101). In the media, collagen 
fibers replace VSMCs causing medial fibrosis (82). Furthermore, in general, in individuals 
over the age of 50, collagen redistributes within the media to bundle near lamellae units 
(82, 102). Finally, within the adventitia, collagen I and III deposition by fibroblasts 
increases with age and is accompanied by vessel stiffening (103). 
 
In concert with increased collagen concentrations, collagen crosslinking by non-enzymatic 
glycation causes age-related arterial stiffening (104, 105). Glycation is a reaction between 
reducing sugars and proteins, and directly stiffens tissues in addition to producing 
deleterious end products. Advanced glycation end products (AGEs) accumulate through 
the Maillard reaction. Amino groups on proteins react with aldehydes or ketones on the 
reducing sugars to form shift bases that rearrange to Amadori products and are further 
modified to produce AGEs (106, 107). In addition to collagen crosslinking, AGEs are 
harmful to vascular health because they reduce nitric oxide availability, an important 
vasodilator used to maintain vascular tone that also has anti-inflammatory effectors on the 
endothelium (108–111). AGEs also interact with the receptor for advanced glycation end 
products (RAGE) which results in downstream effects that include the production of 
reactive oxygen species, NF-κB inflammatory signaling, and endothelial 
hyperpermeability (112–116). 
 
1.5 Clinical Interventions to Mitigate Arterial Stiffening 
Because increased arterial stiffness is a negative indicator of cardiovascular health, clinical 
interventions to prevent or reverse arterial stiffening have been explored. Assuming an 
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active lifestyle remains one of the safest, most successful, and cost-effective interventions 
to prevent cardiovascular diseases (1). Numerous human studies have demonstrated that 
habitually active adults have more compliant arteries when compared to their age-matched 
sedentary peers and that moderate aerobic exercise interventions successfully increased 
macroscale arterial compliance in healthy aged populations (117–119). Brisk walking can 
improve arterial compliance in as little as 3 months in healthy middle aged men (117). 
Notably, the protective benefits of exercise appear to be most effective as a preventative 
precaution prior to the onset of cardiovascular pathologies. In two separate studies of 
individuals with hypertension, arterial stiffness did not improve after short-term aerobic 
exercise interventions (120, 121). In addition to improvements in macroscale arterial 
compliance, it has also been demonstrated that layer specific microscale intima stiffening 
is attenuated by exercise in aged mouse populations (122). The mechanism by which 
exercise restores arterial compliance is not fully understood and appears to vary with the 
type of exercise. Mouse studies show that voluntary wheel running decreases Type I 
collagen levels in the media and adventitia of old mice, while studies involving swimming 
and treadmill running did not detect altered arterial collagen compositions (103, 123, 124). 
Exercise may increase collagen turnover, thus preventing the accumulation of AGEs. 
However, while increased markers of collagen synthesis and turnover have been found in 
response to exercise for cardiac, tendon, and bone collagens, studies with arterial collagen 
still need to be completed (67, 125, 126). It is important to note that collagen deposition in 
bone and tendon in response to exercise is indicative of beneficial strengthening while 
collagen deposition in the arteries contributes to pathological stiffening; therefore, it is 
possible that the effects of exercise on collagen deposition may be tissue specific. 
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Pharmacological interventions for arterial stiffening can be primarily organized into two 
categories that are targeted at preventing or breaking AGE crosslinks in collagen. Several 
chemical compounds to prevent arterial stiffening by inhibiting AGE accumulation have 
been studied, but thus far, none have made it past clinical trials. Aminoguanidine was the 
first well-studied inhibitor of AGEs. Early studies in diabetic rats showed that it was able 
to inhibit AGE formation by blocking carbonyl reactivity on early glycation products even 
when animals were fed high glucose diets (127). Later studies with an aged, non-diabetic 
rat model showed aminoguanidine prevented arterial stiffening in 24-month old, end-of-
life rats without altering collagen content (128). Despite the early promise of 
aminoguanidine, clinical trials were terminated when it caused impaired liver functionality 
and the initiation of lupus-like illnesses in patients (129). An alternative AGE inhibitor, 2,3 
diaminophenazine (2,3 DAP) did not make it past pre-clinical toxicity tests (130). ALT-
946 and OPB-9195 are other examples of AGE blockers that possess similar hydrazine 
structures to aminoguanidine, that have not yet reached clinical trials (131). The continued 
failure of the AGE inhibitors mentioned here, and others, to succeed in clinical trials 
highlights the difficulty of safely and effectively reducing AGE accumulation in vivo. 
 
The second class of pharmaceutical interventions used to overcome arterial stiffness are 
compounds that break AGE crosslinks. The most widely studied of these is a thiazelium 
based compound, ALT-711 (alagebrium chloride). ALT-711 was discovered as a more 
stable form of the very first AGE breaker,  n-phenacylthiazolium bromide (PTB) (132). 
AGE breakers are commonly designed to be nucleophilic compounds that break carbon–
carbon bonds between adjacent carbonyl groups in crosslinked proteins (132, 133). ALT-
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711 showed efficacy in vitro and in vivo at cleaving AGE crosslinks. The resulting collagen 
fragmentation increased the elasticity of cardiac and arterial tissue (132, 134, 135). 
However, despite multiple Phase 2 and Phase 3 clinical trials, a randomized factorial study 
comparing the interaction between ALT-711 and exercise in older sedentary adults showed 
the treatment did not decrease arterial stiffness. Additionally, cardiovascular health 
measured using the Lifetime Risk Score (LRS) improved with exercise, but not the drug 
intervention (136). All ongoing clinical trials for ALT-711 were terminated by Synvista 
Therapeutics Inc. for financial reasons (131). The safety, pharmacokinetics, and tolerance 
of another AGE crosslink breaking compound, TRC4186, were established during a 
successful phase 1 clinical trial and published in 2009 (137). However, the necessary phase 
2 and 3 clinical trials showing efficacy and continued safety have not been completed. 
Preliminary studies on a safer AGE breaker, C36 (3-benzyloxycarbonylmethyl-4-methyl-
thiazol-3-ium bromide) showed decreased systemic arterial stiffness and improved 
collagen composition in diabetic rats (138). There currently are no AGE blockers or 
breakers on the market today, indicating the difficulty of successfully and safely 
overcoming the effects of tissue stiffening that occur with age. 
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Table 1.1. Selected interventions with humans to reduce arterial stiffness. 
Intervention 
Type Intervention Study Outcome Reference 
Lifestyle 
Aerobic 
exercise 
Brisk 
walking in 
healthy 
sedentary 
male adults 
Increased central 
arterial 
compliance 
Tanaka et al. 
(2000) 
Pharmaceutical 
AGE blocker 
Aminoguanidine 
Phase III 
clinical trial 
Early 
termination due 
to safety and 
efficacy 
Freedman et al. 
(1999) 
Thornalley 
(2003) 
Pharmaceutical 
AGE breaker 
Alagebrium 
chloride (ALT-
711) 
Phases II & 
III clinical 
trials 
No increase in 
cardiovascular 
health; Clinical 
trials terminated 
Oudegeest-
Sander et al. 
(2013) 
clnicaltrials.gov 
Pharmaceutical 
AGE breaker 
TRC4186 
Phase I 
clinical trial 
Safety, 
tolerance, and 
kinetics 
established 
Chandra et al. 
(2009) 
 
1.6 Vascular Stiffening and Atherosclerosis 
Bulk measurements of vessel stiffness measurements using pulse wave velocity  and 
ultrasound are widely used in the clinic as indicators of vascular health, but the importance 
of vascular stiffening, especially on the microscale, in promoting disease is not well-
understood (139). Layer specific heterogeneous stiffening of the arterial intima occurs with 
age and may contribute to atherogenesis (63, 122). The combined effects of increased mean 
stiffness and increased spatial stiffness heterogeneity with in the arterial intima with age 
remain to be elucidated. However, recent studies have provided evidence for a paradigm 
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shift in the role of vascular stiffness in cardiovascular diseases as a contributing cause 
rather than an outcome of the pathologies (140–142). 
 
It has been shown in both clinical studies and animal models that arterial stiffening 
precedes hypertension, and that preventing arterial stiffening can attenuate atherosclerosis 
(140–142). Kothapalli and colleagues demonstrated that treatment with the lysyl oxidase 
inhibitor BAPN (B-aminopropionitrile) to prevent collagen crosslinking reduced luminal 
arterial stiffness and decreased plaque size by ~50% in an atherosclerotic mouse model 
(142). In addition, the more compliant arteries exhibited decreased deposition of a pro-
atherogenic extracellular matrix by VSMCs and had reduced monocyte infiltration. Ex vivo 
studies have also revealed that arteries with stiffer intima layers exhibit disrupted 
endothelial cell-cell junctions and increased permeability (63). Reducing arterial stiffness 
in the lumen where endothelial cells reside resulted in a significant reduction in 
atherosclerotic plaque formation (142). Conversely, when bulk artery stiffness was reduced 
by changing elastin within the lamellar units of the media, the same reduction in 
atherosclerotic burden was not achieved (143). These conflicting reports describing the 
effects of artery stiffness on atherosclerosis underscore the importance of localized artery 
mechanics on cell behaviors that contribute to atherogenesis.  
 
1.7 Rho GTPase Family 
One avenue by which localized age-related arterial stiffening is thought to contribute to 
atherogenesis is the activation of Rho family signaling cascades in endothelial cells. The 
Rho family of GTPases are small G-protein signaling molecules that are involved in a 
 36 
multitude of cellular processes and pathologies (144). GTPase activity is dependent on 
guanine nucleotide exchange factors (GEF)s and GTPase-activating proteins (GAPs) for 
rapid switch-like signaling. GEFs catalyze the exchange of GDP for GTP in the conversion 
to an active GTPase state that interacts with downstream effectors. Conversely, GAPs 
catalyze the hydrolysis of GTP to GDP to turn off GTPase signaling. Because GTPases 
have high, nearly equal affinities for GTP and GDP and slow intrinsic exchange rates, 
GEFs and GAPs are necessary for quick cellular responses. Importantly, GEFs and GAPs 
are critical to initiating G-protein signaling cascades; therefore, their spatiotemporal 
regulation is an underlying mechanism regulating G-protein signaling (145). Cellular 
localization on the GTPase level is regulated by post-translational modifications with lipid 
anchors used for membrane and organelle targeting (146). Within the Rho family, RhoA, 
Rac1, and Cdc42 are the most well studied, and have important functions regulating the 
cytoskeleton that contribute to endothelial barrier formation, stability, and disruption (147). 
Deletion of RhoA, Rac1, or Cdc42 is embryonic lethal which underscores their overall 
importance to cellular function (148).  
 
RhoA is primarily associated with endothelial barrier disruption, although basal levels of 
RhoA activity are necessary for junction integrity (149). The formation of actin stress fibers 
and myosin mediated contraction of actin filaments are primary outputs of RhoA activation 
that disrupt endothelial barriers. Briefly, GTP-bound RhoA activates Rho-associated 
coiled-coil kinase (ROCK). ROCK directly phosphorylates myosin light chain (MLC) and 
also inhibits myosin light chain phosphatase to increase the overall concentration of active 
myosin (Figure 1.2) (150, 151). Increased extracellular matrix stiffness is a mechanical cue 
 37 
that activates RhoA, and thrombin is a pharmacological agent that activates RhoA. In 
response to both stimuli, cell contractility is increased and elevated intercellular tension 
disrupts cell-cell junctions (152, 153). 
 
Figure 1.2. RhoA cell contractility pathway. GTP-bound RhoA activates its major 
downstream effector ROCK. Kinase activity by ROCK results in elevated levels of 
phosphorylated myosin light chain contributing to actin contraction and cellular force 
generation.    
 
Rac1 is primarily associated with endothelial barrier protection and repair, although its 
effect on endothelial junctions can vary based on the activation of other co-current 
signaling cascades (154, 155). Consistent with their phenotypic functions, an inverse 
relationship exists between RhoA and Rac1 where active RhoA downregulates Rac1 and 
vice versa (156, 157). Rac1 is activated during lamellipodia formation and membrane 
ruffling, and as such, is integral to the annealing of cell membranes to form adherens 
junctions (151, 158). Thrombin challenges that destabilized endothelial barriers by 
elevating RhoA activity were followed by Rac1 activation during endothelium recovery 
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(147). In mature endothelial cell-cell junctions, GTP-bound Rac1 caused VE-cadherin 
clustering, stabilized VE-cadherin conformations that favored stable adhesions, and  
decreased junction tension (159). Active Rac1 also stimulates cortactin localization and 
actin rearrangement to form cortical actin structures that enhance endothelial junction 
integrity (160, 161). 
 
Cdc42 is also associated with endothelial barrier strengthening and restoring. More 
generally, Cdc42 is activated during filopodia formation (162). In both cell and mouse 
models, decreased Cdc42 levels caused disorganized actin organization and prevented actin 
protrusions that are necessary for nascent and mature junction formation (163). In confluent 
endothelial monolayers, membrane localization and activation of Cdc42 coincided with 
junction repair after thrombin challenges, and Cdc42 depletion impaired endothelium 
recovery (164). It has been proposed that Cdcd42 controls basal endothelial adherens 
junction tension, and therefore, integrity. Downstream effectors of Cdc42 contribute to 
myosin filament assembly, actin polymerization, and moderate myosin phosphorylation 
(155).   
 
1.8 Matrix Stiffness and Endothelial Cell Behavior 
It is now well accepted that numerous cell types respond to extracellular matrix stiffness 
and that stiffness can promote stem cell differentiation, tissue morphogenesis, gene 
expression and tumor malignancy (165–169). Cells also respond to temporal stiffening or 
softening of their matrix (170, 171). Intimal stiffening, which occurs with age, promotes 
aberrant endothelial cell behaviors (63, 172).  
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Cells adhere to, sense, and exert forces against their extracellular matrix using 
transmembrane proteins, namely integrin complexes. External signals are integrated in an 
outsideàinàoutside signaling mechanism (173). In the extracellular space, integrin 
heterodimers cluster and bind ECM ligands. Within the cytoplasm, integrins bind to 
scaffolding proteins that link to actin filaments. Collectively these adhesion protein 
complexes are termed focal adhesions and act to mechanically couple ECM cues and 
cytoskeletal responses (174). Cellular forces generated by actin polymerization or myosin 
mediated actin contraction within the cytoplasm are transmitted to the extracellular matrix 
via integrins. Integrin conformational changes are dependent on force dissipation to the 
ECM, thus allowing for local rigidity sensing on a subcellular scale (175, 176). Scaffolding 
proteins within focal adhesions also undergo force-dependent conformational changes in 
response to extracellular matrix stiffness to induce cellular responses. Specifically, talin 
unfolds under tension to expose a cryptic vinculin binding site, and subsequent vinculin 
binding stabilizes nascent focal adhesions (177, 178). As described by clutch models of 
cell-matrix adhesion, contractile force is needed to form and strengthen focal adhesions, 
but excessive force loading leads to matrix detachment (176). In response to increased 
extracellular matrix rigidity, RhoA signaling cascades that mediate actin stress fiber 
formation and cell contractility are activated (179). The resulting contractile forces exerted 
against the extracellular matrix are known as traction forces and are traditionally calculated 
from substrate deformations on compliant matrices (180, 181). Polyacrylamide gels and 
micropillar elastomer arrays are the most widespread platforms used to measure traction 
forces, and represent both continuous and discrete matrices, respectively (182). Because 
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cellular force transmission can occur over long distances within a cell, matrix mechanical 
cues can have cell-wide implications including altering cytoskeletal tugging forces at cell-
cell adhesions (183).  
 
Endothelial cell studies have previously established that age-related increased extracellular 
matrix stiffness alone may play a significant pathogenic role in promoting atherogenesis 
by compromising endothelial barrier integrity (Figure 1.3). In the absence of other cues, 
increased matrix stiffness elevated RhoA-mediated cell contractility that contributed to 
disrupted cell-cell junctions and increased permeability both in vitro and in vivo (63). 
Endothelial barrier recovery after pharmacological disruption was also impaired by 
increased extracellular matrix stiffness (184).  Moreover, increased matrix mechanics were 
also identified as detrimental during later stages of atherogenesis as demonstrated by in 
vitro models showing elevated leukocyte recruitment, transmigration, and persistent 
monolayer gap formation that were associated with increased matrix stiffness (63, 185, 
186). Endothelial expression of the adhesion molecules VCAM-1, ICAM-1, and E-selectin 
were unaffected by substrate stiffness in vitro, suggesting the changes in endothelium 
integrity were largely driven by mechanics (63). 
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Figure 1.3. Matrix stiffness-mediated cell contractility destabilizes endothelial cell-
cell junctions. Endothelial cells exert increased contractile forces with increasing 
extracellular matrix (ECM) stiffness. Traction forces against the matrix are proportional to 
cell-cell tensional forces that destabilize intercellular junctions and promote increased 
endothelium permeability.  
 
1.9 Endothelial Cell Adherens Junctions and Mechanotransduction at Cell-Cell 
Contacts 
A critical function of endothelial cells within the vasculature is to exist as a semi-permeable 
barrier lining the arterial lumen. As such, endothelial cells exist as part of a monolayer and 
adherens junctions connect neighboring cells to give the endothelium its integrity (11). 
Cellular force that is generated in response to matrix mechanical cues is transmitted across 
the cytoskeletal network and results in cell-cell junction tension (187, 188). Importantly, 
adhesions between adjacent cells are also mechanosensitive and transmit forces that result 
in global endothelial monolayer responses (189).  
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Vascular endothelium cadherin (VE-cadherin) is the primary component of endothelial 
adherens junctions and exists as a dimer with intercellular and extracellular domains. The 
extracellular domain of VE-cadherin dimers from adjacent cells form homotypic bonds at 
cell-cell contacts to give the endothelium its integrity (11).  Intracellularly, the cytoplasmic 
tail of VE-cadherin forms a complex with scaffolding proteins, primarily catenins. VE-
cadherin directly binds p120 catenin, beta catenin, and gamma catenin. A fourth catenin, 
alpha catenin is the only catenin known to have an actin binding domain, and thus links 
VE-cadherin to the actin cytoskeleton through beta catenin binding (155, 190). Alpha 
catenin undergoes force-dependent conformation changes under tension that alter junction 
stability (191).  
 
Vinculin, which has already been identified as a critical component of force sensing 
through focal adhesions, is also associated with cadherin mediated mechanotransduction 
(192–194). Junction tension, for example from increased cytoskeletal contractility, induces 
the stretching of alpha catenin to expose a hidden vinculin binding site (191). Subsequent 
vinculin recruitment and binding to the complex protects the adherens junction adhesion 
from opening (191). Consistent with a junction strengthening function, vinculin 
localization to focal adhesions or intercellular junctions is associated with endothelial 
barrier disruption or strengthening, respectively (195). Other junctional proteins that 
regulate actin polymerization, are also recruited to adherens junctions in a tension 
dependent manner (196).  
 
 43 
Despite a role for force in mediating VE-cadherin adhesions and endothelial junction 
integrity, mechanotransduction by VE-cadherin at cellular junctions was not immediately 
established (159, 188). A force sensing role for VE-cadherin was first revealed when it was 
identified as part of the mechanosensory complex that in concert with PECAM-1 mediated 
the endothelial cell response to fluid shear stress. Data now indicate that cadherins at cell-
cell junctions are mechanosensitive (193). Force is transmitted to adjacent cells through 
VE-cadherin and actin filaments that extend between cells (193). Direct force application 
to VE-cadherin using magnetic twisting cytometry resulted in ROCK dependent 
cytoskeletal remodeling and most notably, caused monolayer disruption and gap formation 
distant from the site of the applied force (189).   
 
Many of the same scaffolding proteins found at focal adhesions are also components of 
adherens junction complexes suggesting that spatial and temporal regulation is necessary 
to maintain integrity at both cell-matrix and cell-cell adhesions (197). Indeed, significant 
crosstalk exists between the two cellular events, as already demonstrated by their direct 
cytoskeletal linkages and studies showing that intercellular junction forces are an output of 
chemical and mechanical substrate cues (187). Understanding how localized matrix cues 
contribute to aberrant endothelial behaviors that are transmitted across adherens junctions 
into monolayer responses may elucidate how the altered mechanical properties of the 
intima associated with aging contribute to a disrupted endothelial barrier.  
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1.10 Organization of the Dissertation 
The objective of this work is to investigate the integration of extracellular matrix stiffness 
cues by endothelial cells within the context of compromised endothelium barrier integrity 
that contributes to age-related atherogenesis. Because vessel stiffening that occurs as part 
of aging may contribute to atherogenesis and pharmacological efforts to overcome arterial 
stiffness have had poor clinical success; an alternative approach is to modulate the cellular 
response to matrix mechanics. Herein, I present data demonstrating that pharmacologically 
interrupting endothelial cell contractility on stiff matrices or presenting a substrate with 
heterogeneous stiffness cues, restores or disrupts endothelium integrity. I then discuss 
clinically relevant approaches to attenuate matrix stiffness-mediated pathologies. 
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CHAPTER 2 
 
SIMVASTATIN AMEOLIORATES MATRIX STIFFNESS-MEDIATED  
 
ENDOTHELIAL MONOLAYER DISRUPTION 
 
Portions of this chapter were published in PLoS One (Lampi et al., 2016). 
 
2.1 Abstract 
Arterial stiffening accompanies both aging and atherosclerosis, and age-related stiffening 
of the arterial intima increases RhoA activity and cell contractility contributing to increased 
endothelium permeability. Notably, statins are 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors whose pleiotropic effects include disrupting small 
GTPase activity; therefore, it was hypothesized the statin simvastatin could be used to 
attenuate RhoA activity and inhibit the deleterious effects of increased age-related matrix 
stiffness on endothelial barrier function. Using polyacrylamide gels with stiffnesses of 2.5, 
5, and 10 kPa to mimic the physiological stiffness of young and aged arteries, endothelial 
cells were grown to confluence and treated with simvastatin. RhoA and phosphorylated 
myosin light chain activity increased with matrix stiffness, but were attenuated when 
treated with the statin. Readouts of intercellular tension that increased with matrix stiffness, 
and are correlated with matrix stiffness-dependent increases in monolayer permeability, 
also decreased with the statin treatment. Furthermore, simvastatin increased activated Rac1 
levels that contributed to endothelial barrier enhancing cytoskeletal reorganization.  
Simvastatin, which is prescribed clinically due to its ability to lower cholesterol, altered 
the endothelial cell response to increased matrix stiffness and restored endothelial 
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monolayer barrier function; and therefore, presents a possible therapeutic intervention to 
prevent atherogenesis initiated by age-related arterial stiffening.  
 
2.2 Introduction 
Age is a primary risk factor for atherosclerosis, and vascular stiffness increases with age 
due to changes in the extracellular matrix that include increased elastin fragmentation, 
collagen deposition, and collagen crosslinking by advanced glycation end products (AGEs) 
(63, 198–200). While the connection between macroscale arterial stiffness and 
cardiovascular diseases is well characterized, the relationship between increased vessel 
stiffness and endothelium behavior on a cellular level is less clear (201, 202).  
 
Within the vasculature, endothelial cells maintain vascular homeostasis, in part, by forming 
a monolayer barrier along the arterial lumen. Endothelium integrity is dependent upon 
extracellular VE-cadherin interactions between adjacent cells and intracellular VE-
cadherin anchoring to the actin cytoskeleton through catenins (11). Cellular 
mechanotranduction occurs at both cell-matrix and cell-cell contacts (183). Our group and 
others have shown that the mechanical stiffness of the cellular microenvironment plays a 
key role in dictating endothelial cell behaviors including cell area, adhesion, spreading, 
network formation, and sprouting (64, 203–206). Permeability of the endothelium is a key 
feature of atherosclerosis, as cholesterol flux across the vessel wall is an initiating step in 
atherogenesis (207–209). Using in vitro and ex vivo models of vessel stiffness and aging, 
we previously showed that increasing substrate stiffness alone promoted RhoA/ROCK 
mediated endothelial monolayer disruption and increased endothelium permeability (63). 
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RhoA-mediated actomyosin contractility is increased on stiff matrices, with increasing 
substrate stiffness leading to increased traction stresses (63, 206, 210, 211). Increased 
cellular traction stresses leads to the disruption of cell-cell junctions.  As such, inhibition 
of cellular contractility is one potential avenue for the prevention of increased endothelial 
permeability in response to the matrix stiffening that occurs with age and atherosclerosis 
progression.  
 
Interestingly, statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors that are traditionally prescribed to lower blood cholesterol levels by inhibiting 
the production of the intermediate mevalonate during cholesterol synthesis, but are now 
recognized to have pleiotropic cardiovascular benefits (212–214). Clinically, 
improvements in patient cardiovascular health that are not correlated to decreased 
cholesterol levels have been observed in as little as 4 weeks after initiating a statin regimen 
(215). Statins improve vascular inflammation and reduce the risk of myocardial infarction 
and stroke (216, 217). Statins also reduce all-cause mortality in patients with and without 
histories of coronary artery disease (218, 219). It is now evident that inhibiting cholesterol 
biosynthesis with statins leads to aberrant activity of small GTPase signaling molecules. 
Mechanistically, it is well established that statins prevent the synthesis of isoprenoids that 
are post-translationally added to G-proteins (212–214) and it has been demonstrated that 
the addition of mevalonate or the isoprenoids directly rescues the effect of statins (220, 
221). Within the Rho family of G-proteins, RhoA, Rac1, and Cdc42 are post-translationally 
prenylated with a geranylgeranyl pyrophosphate lipid anchor that is important for 
membrane localization, anchoring, and activation (222, 223). The statin, simvastatin, 
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originally marketed by Merck under the brand name Zocor®, has been shown to attenuate 
RhoA activity and increase cytosolic activation of Rac1 by disrupting geranylgeranyl 
pyrophosphate synthesis to improve endothelial barrier function (221, 224). Notably, 
although also geranylgeranylated, altered Cdc42 activity does not contribute to the 
significant improvements in endothelial barrier function after simvastatin treatment (221). 
 
In this study, we investigate the use of simvastatin to restore endothelial barrier integrity 
by altering pathways that contribute to increased RhoA-mediated cell contractility on stiff 
matrices. We also investigate Rac1 activity and cytoskeletal reorganization in response to 
simvastatin treatment. To date, previous studies have demonstrated that simvastatin pre-
treatment attenuates barrier disruption caused by the known endothelial agonists thrombin 
and lipopolysaccharide (221, 224, 225), but have not accounted for physiological 
biomechanical stimuli such as extracellular matrix stiffness, which is altered with age and 
also disrupts the arterial endothelium (63). To investigate the effects of statin treatment on 
the disruption of endothelial barrier function due to matrix stiffness, we grew endothelial 
cell monolayers on polyacrylamide gels ranging in stiffness from 2.5 to 10 kPa to mimic 
the young and aged arterial intima respectively (172). Our data indicate that simvastatin 
treatment altered the cellular response to substrate mechanics and attenuated increased 
RhoA activity caused by increased matrix stiffness to restore endothelial barrier integrity. 
Simvastatin also increased Rac1 activity and correlated with barrier enhancing cytoskeletal 
reorganization. These results indicate that using simvastatin treatment to interrupt 
pathways that affect RhoA and Rac1 activity may be one method to mitigate endothelium 
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hyperpermeability that occurs in response to age-related arterial stiffening and prevent 
atherosclerosis.  
 
2.3 Materials and Methods 
Cell Culture and Polyacrylamide Gel Synthesis 
Bovine aortic endothelial cells purchased from VEC Technologies (Rensselaer, NY) were 
used from passages 7-12. Endothelial cells were maintained at 37 ºC and 5% CO2 in 
Medium 199 (Invitrogen, Carlsbad, CA) with 10% Fetal Clone III (HyClone, Logan, UT), 
1% MEM amino acids (Invitrogen), 1% MEM vitamins (Medtech, Manassas, VA), and 1% 
penicillin-streptomycin (Invitrogen) (complete Medium 199). Polyacrylamide (PA) gels 
with stiffnesses of 2.5, 5 and 10 kPa were made with bisacrylamide:acrylamide ratios of 
5:0.1, 7.5:0.175, and 7.5:0.35, respectively. The PA gels and glass controls were coated 
with 0.1 mg/mL rat tail type I collagen (BD Biosciences), as described previously (63, 
203).  
 
Simvastatin Treatments 
Simvastatin (Sigma-Aldrich) was activated as previously described (226–228). Briefly, 
simvastatin prodrug was dissolved in 200-proof ethanol and incubated with 0.1 N NaOH 
for 2 hours at 50 °C followed by the addition of MilliQ water. The solution was brought to 
a final pH of 7.0 using 0.1 N HCl and stored at 4 °C. Simvastatin was diluted to final 
concentrations of 1 µM and 10 µM in complete M199 for cell studies. Simvastatin 
treatment was 24 hours based on previous time course studies demonstrating greater effects 
on barrier enhancement with longer incubation times (221, 229).  
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RhoA and Rac1 Activity Assays 
The colorimetric RhoA and Rac1 activity assays (Cytoskeleton #BK124 and #BK128) 
were carried out according to the manufacturer protocol. Lysate was collected from 
endothelial cell monolayers on 2.5, 5, and 10 kPa PA gels and glass controls treated with 
0 or 10 µM simvastatin for 24 hours, two days post-confluence. The lysate from two gels 
at each condition was pooled and RhoA or Rac1 activity was normalized to the total protein 
content of the sample using the included Precision Red Protein Assay (#ADV02).  
 
Western Blotting 
Two days post-confluence, endothelial cell monolayers on 2.5, 5, and 10 kPa PA gels and 
glass controls were treated with 0 or 10 µM simvastatin for 24 hours. Samples for 
phosphorylated myosin light chain (pMLC) analysis were lysed directly into boiling 2x 
Laemmli buffer, followed by immediate heating of the lysate at 95 °C and heavy vortexing 
to disrupt nucleic acid structure. Lysate collected for the RhoA and Rac1 assays were used 
for quantifying total GTPase protein expression. Lysate was separated using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by protein 
transfer onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad). Total RhoA was 
probed with a mouse monoclonal antibody against full-length RhoA (1:100) (Abcam, No. 
ab54835). Phosphorylated myosin light chain (pMLC) was probed with a polyclonal rabbit 
antibody against pMLC at threonine-18 and serine-19 (1:50) (Cell Signaling Technology, 
No. 3674). Total Rac1 was probed with a mouse monoclonal antibody against full-length 
Rac1 (1:00) (Millipore, No. 23A8). Alpha tubulin was probed as a loading control with a 
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mouse polyclonal primary antibody (1:2000) (Sigma, No. T3559). Horseradish peroxidase 
(HRP) conjugated anti-rabbit and anti-mouse secondary antibodies were used (1:2000) 
(Rockland, No. 611-103-122 and Rockland, No. 610-103-121, respectively). The signal 
was developed with SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific). The membranes were exposed and imaged with a FujiFilm Image-Quant LAS-
4000, followed by protein quantification using ImageJ software (v2.0.0-rc-41/1.50d, 
National Institutes of Health, Bethesda, MD, USA). The pMLC, RhoA, and Rac1 signals 
were normalized to the alpha tubulin loading control at each condition. 
 
Vinculin Focal Adhesion Quantification and Cell-Cell Junction Localization 
Endothelial cells were seeded on 2.5, 5, and 10 kPa PA gels and allowed to adhere for 16 
hours (single cells) or cultured 2 days post-confluence (monolayers). The growth media 
was then removed and replaced with complete M199 containing 0 or 1 µM simvastatin for 
24 hours. Cells were fixed and permeabilized with 3.2% paraformaldehyde (EMS) and 1% 
Triton (VWR), respectively. Immunostaining was done with a mouse monoclonal vinculin 
antibody (1:100) (Santa Cruz, No. sc-59803) and a goat polyclonal VE-cadherin antibody 
(1:100) (Santa Cruz, No. sc-6458). Alexa Fluor 488 donkey anti-mouse (1:200) 
(Invitrogen, No. A21202) and Alexa Fluor 568 donkey anti-goat (1:200) (Invitrogen, No. 
A11057) secondary antibodies were used. 
 
A z-stack image of each sample was captured using a Zeiss LSM700 microscope (v. 2010, 
Carl Zeiss MicroImaging GmbH, Jena, Germany) using a 40X/1.1 NA water immersion 
objective and 488 nm and 568 nm excitation laser lines, for vinculin and VE-cadherin, 
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respectively. Images were then opened in ImageJ and converted into image sequences 
followed by automated image analysis performed with MatLab. To extract adhesion 
labeled structures, individual images were subjected to an adaptive Wiener filter filtering 
window (0.8 µm for vinculin and 0.6 µm for VE-cadherin) to remove background noise. 
Image sections presenting structures with a signal to noise ratio greater than 3:1 for vinculin 
and 2:1 for VE-cadherin where then subjected to a top-hat filter (1 µm diameter disk). 
Filtered images were further subjected to a median filter (0.48 µm filtering window) to 
correct for intensity variations while keeping necessary structures. To quantify FA length 
and area, confocal sections from vinculin stained single cells were used. To quantify 
vinculin:VE-cadherin overlap, corresponding vinculin and VE-cadherin stained 
endothelial cell monolayer confocal image stacks were filtered as described and then 
overlaid to generate the 3D overlapping volume data.  
 
Cell Circularity and Actin and Cortactin Arrangement 
Two days post-confluence, endothelial cell monolayers on 10 kPa PA gels were treated 
with 0, 1, and 10 µM simvastatin for 24 hours. Cells were fixed and permeabilized with 
3.7% formaldehyde (VWR) and 1% Triton (VWR), respectively. Immunostaining was 
done with a rabbit polyclonal cortactin primary antibody (1:100) (Santa Cruz, No. sc-
11408) and Alexa Fluor 488 donkey anti-rabbit secondary (1:200) (Invitrogen, No. 
A21206). Actin was visualized with 594 FITC-conjugated phalloidin (1:100) (Invitrogen, 
No. A12381). Fluorescent images were captured on a Zeiss Axio Observer.Z1m 
microscope equipped with a Hamamatsu ORCA-ER camera using a 20x objective. Cell 
perimeters were outlined and cell circularity was calculated in ImageJ software where
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 and a perfect circle has a value of 1. Cortactin organization was 
quantified using MatLab code to quantify the number of linear segments at cell-cell 
junctions.  
 
Statistical Analysis 
Statistical analysis was conducted in JMP v. 10. All data is mean ± SEM (standard error of 
the mean). Analysis of variance (ANOVA) followed by a Tukey’s Honestly Significant 
Difference (HSD) test were used for total RhoA expression, total Rac1 expression, focal 
adhesion size and length, cell circularity, cortactin arrangement, and vinculin localization 
analyses. Within stiffness changes in RhoA and Rac1 expression and vinculin localization 
were analyzed with a two-tailed Student’s t-test. Focal adhesion and vinculin localization 
data was log transformed to meet normality assumptions.  Least squares means (LS-Means) 
regression was used to analyze Western blotting and RhoA-GTP activity using experiment 
as a random effect to account for differences in baseline values between experimental 
replicates. Rac1-GTP activity was analyzed using a linear mixed effects model accounting 
for within experiment dependence. 
 
2.4 Results 
Simvastatin Alters the RhoA Pathway 
To investigate the effect of simvastatin on endothelial barrier disruption associated with 
elevated RhoA activity caused by increased matrix stiffness, we probed RhoA activity and 
markers of endothelium integrity in response to both substrate stiffness and simvastatin 
treatments. We also investigated the effect of simvastatin on Rac1 activity, noting that Rac1 
circularity = 4π Area( )
Perimeter( )2
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is reported to have inverse activation when compared to RhoA, and that Rac1 is also altered 
by simvastatin to improve endothelial barrier function (151, 221, 224). 
 
To modulate substrate stiffness and maintain physiological relevance, we grew bovine 
aortic endothelial cells on polyacrylamide gels with a lower stiffness level of 2.5 kPa to 
match the reported Young’s modulus of 2.7 ±1.1 kPa for the stiffness of the subendothelial 
matrix of healthy bovine carotid arteries (172). Higher stiffness 5 and 10 kPa gels were 
used as models of aged arteries. As matrix stiffness increased, RhoA activity increased 
(Figure 2.1A). At each stiffness level, simvastatin treatment resulted in a significant 
decrease in active RhoA levels. Interestingly, while total cellular RhoA showed no 
significant change in expression over the stiffness range tested in control conditions, there 
was a robust increase in total RhoA across all stiffnesses with simvastatin treatment 
(Figures 2.1B,C). These results suggest a compensatory cellular response to the production 
of unprenylated RhoA and indicate the decrease in active RhoA-GTP caused by the statin 
treatment is not a result of lower expression levels. To further assess the effect of 
simvastatin on the RhoA/ROCK contractility pathway, we probed endothelial monolayers 
for phosphorylated myosin light chain (pMLC) which is activated downstream of RhoA 
(Figure 2.1D). Similar to RhoA activity, activation of myosin light chain increased with 
stiffness, and the effect of matrix mechanics was attenuated with simvastatin treatment 
(Figure 2.1E). The significant decreases in active RhoA and phosphorylated myosin light 
chain levels suggest that simvastatin interferes with cell contractility pathways.  
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Figure 2.1. Simvastatin disrupts the RhoA pathway. The RhoA/ROCK pathway activity 
was elevated in endothelial monolayers with increased matrix stiffness but was attenuated 
with 10 µM simvastatin treatment. (A) Bar graphs of RhoA-GTP activity in response to 
matrix stiffness and simvastatin treatment normalized to total protein of lysate (n = 2, 
performed in triplicate). (B) Representative Western blot probing for total cellular RhoA 
expression and alpha tubulin (α-tub) loading control. (C) Quantification of total RhoA 
normalized to alpha tubulin loading control demonstrating that RhoA expression was 
significantly increased by the simvastatin treatment (n = 5). (D) Representative Western 
blot probing for phosphorylated myosin light chain (pMLC) and alpha tubulin loading 
control. (E) Western blot quantification normalized to alpha tubulin loading control 
demonstrating simvastatin attenuated increased pMLC caused by increased substrate 
stiffness, (n = 4). Data are presented as means ± standard error of the mean, *p<0.05, 
**p<0.01, ***p<0.001 when compared to the untreated control at each stiffness. 
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Simvastatin Alters Endothelial Cell Focal Adhesions 
RhoA-mediated cell contractility is necessary for focal adhesion assembly (230) and both 
focal adhesion size and traction forces increase with increased matrix stiffness (173, 231); 
therefore, we treated endothelial cells with and without 1 µM simvastatin and stained for 
vinculin to quantify individual cell-matrix interactions using length and area as metrics 
(Figure 2.1A). As predicted from a prior study where RhoA-mediated traction forces 
increased with increased matrix stiffness, focal adhesion length and area increased with 
increasing substrate stiffness, but were attenuated with simvastatin, most notably on the 
stiffer matrices (Figures 2.1B, C) (63). Since focal adhesion formation relies on feedback 
loops transmitting matrix cues from integrins to the cytoskeleton (192), and it is established 
that stable focal adhesions are elevated on stiff matrices (173), our data demonstrate that 
simvastatin treatment is altering how mechanical signals from the underlying matrix are 
integrated into cellular responses.  
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Figure 2.2. Simvastatin decreases endothelial cell focal adhesion length and area. 
Endothelial cell focal adhesion length and area increased with matrix stiffness but 
decreased with 1 µM simvastatin treatment demonstrating that statins alter cell-matrix 
interactions. (A) Representative images of vinculin stained focal adhesions in individual 
endothelial cells with increasing matrix stiffness and 1 µM simvastatin treatment. Inset 
shows individual vinculin stained focal adhesions. (B) Focal adhesion (FA) length and (C) 
area increased with substrate stiffness but decreased with the statin treatment (n = 3, 38-56 
cells per condition).  Data are presented as means ± standard error of the mean,**p<0.01, 
***p<0.001.  
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Simvastatin Alters Endothelial Cell Cytoskeletal Organization and Rac1 Activity 
Since simvastatin had the greatest effect on focal adhesion formation on stiff matrices, and 
transverse actin stress fibers anchored at focal adhesions are used to exert contractile forces 
that are endothelial barrier disrupting, we investigated the effects of simvastatin on the 
cytoskeleton using 10 kPa polyacrylamide gels where high matrix stiffness-dependent 
contractile forces have been measured (63, 232). Previous work has shown that enhanced 
endothelial integrity by simvastatin treatment is associated with distinct patterns of actin 
reorganization from stress fibers into an endothelial barrier enhancing cortical actin ring 
(224). The formation of a cortical actin ring has also been associated with known barrier 
enhancing stimuli such as shear stress and sphingosine-1-phospate (S1P) (160, 233). As 
such, we were interested in whether simvastatin could attenuate the formation of prominent 
actin stress fibers and instead promote a barrier protective phenotype on stiff matrices.  
Endothelial cell monolayers on 10 kPa polyacrylamide gels were treated with 0, 1, or 10 
µM simvastatin and actin was visualized (Fig. 2.3A). Consistent with our RhoA activation 
data, we observed prominent actin stress fibers in the control monolayers that decreased in 
a dose-dependent manner with simvastatin treatment. At higher simvastatin concentrations, 
a cortical actin ring defined cell-cell junctions suggesting improved barrier integrity. 
Cortactin activates the Arp 2/3 complex for actin assembly (234) and its translocation to 
the cell periphery is necessary for cortical actin organization resulting in improved 
endothelial barrier integrity by S1P (160). Similarly, cortactin translocation to cell edges 
has been reported in endothelial cells after simvastatin treatment (224). Therefore, we 
fluorescently stained endothelial cell monolayers treated with 0, 1, or 10 µM simvastatin 
to determine if cortactin translocation could be an underlying mechanism mediating the 
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barrier protective cytoskeletal reorganization we observed on stiff matrices in response to 
simvastatin (Figure 2.3A). Whereas cortactin in control cells was found in concentrated 
puncta around the cell periphery, it was linearly organized along the entire perimeter in 
cells treated with 10 µM simvastatin. Cortactin reorganization, measured by quantifying 
the number of linear segments along the cell perimeter, significantly increased with the 
statin treatment (Figure 2.3B).  Cytoskeletal changes were accompanied by a distinct 
change in cell shape to a more elongated morphology with increasing statin treatment. The 
change in cell morphology was quantified using cell circularity where a perfectly circular 
cell has a value of 1 (Figure 2.3C).  
 
Since Rac1 has been identified as the upstream effector mediating cortactin translocation 
(235), and it is also a prenylated G-protein that regulates cytoskeletal dynamics in concert 
with RhoA (151), we investigated whether simvastatin was also altering Rac1 activity. 
While there was no significant difference in activated Rac1 with increasing physiological 
matrix stiffness, across all stiffnesses, endothelial cell monolayers receiving the statin 
treatment exhibited increased active Rac1-GTP levels that were consistent with the 
cortactin translocation we observed (Figure 3D). Expression of total cellular Rac1 was 
unchanged by either matrix stiffness or simvastatin treatment (Figures 2.3E, F). 
Interestingly, although both RhoA and Rac1 are post-translationally modified with a 
geranygeranyl moiety, our results demonstrate that simvastatin differentially affects RhoA 
and Rac1 pathways to alter downstream indicators of cellular mechanosensing such as 
cytoskeletal organization, stress fiber formation, and contractility.  
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Figure 2.3.  Simvastatin alters actin organization, cell morphology, and Rac1 activity 
in endothelial monolayers. Cytoskeletal organization and Rac1 activity in endothelial 
monolayers was altered by simvastatin treatment. (A) Representative images of endothelial 
monolayers demonstrating prominent actin stress fibers in control cells and a barrier 
enhancing cortical actin ring that formed with increasing simvastatin concentration. 
Cortactin changed from puncta to organized linear segments around the cell periphery and 
localized with actin with increasing statin treatment. (B) Cortactin organization, measured 
by quantifying linear segments at cell-cell junctions, increased with simvastatin (n = 3, 30 
fields of view per condition). (C) Endothelial cells adopted an elongated morphology as 
actin stress fibers diminished with increasing simvastatin treatment. Cell circularity, where 
a perfectly circular cell has a value of 1, decreased with increasing simvastatin 
concentration (n = 3, 50-54 cells per condition). (D) Rac1-GTP activity normalized to total 
protein of lysate increased across all stiffness levels with simvastatin treatment (n = 5, 
performed in duplicate or triplicate). (E) Representative Western blot probing for total 
cellular Rac1 expression and alpha tubulin (α-tub) loading control. (F) Quantification of 
total Rac1 normalized to alpha tubulin loading control demonstrated no significant change 
in expression with stiffness or statin treatment (n = 5) Data are presented as means ± 
standard error of the mean, ***p<0.001.  
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Simvastatin Attenuates Intercellular Tension in Monolayers 
Our prior studies have demonstrated that increased matrix stiffness elevates RhoA-
mediated cell contractility disrupting endothelial cell-cell junctions and decreasing barrier 
function. Here, we have demonstrated that simvastatin treatment decreased RhoA activity 
and resulted in barrier strengthening cortical actin arrangement.  To further characterize 
the role of simvastatin in attenuating the effect of increased matrix stiffness on cell-cell 
junctions in endothelial monolayers, the mechano-sensitive protein vinculin was used as a 
readout of intercellular junction tension. It has been established that vinculin localizes at 
adherens junctions under tension and during remodeling to prevent junction opening, but 
is absent from mature cell-cell contacts (193, 194). Furthermore, Huveneers et. al 
demonstrate that stable endothelial junctions are converted into remodeling, vinculin 
positive junctions after adding thrombin, thereby connecting endothelium permeability to 
RhoA activation, vinculin localization and cell-cell junction tension (194). Endothelial 
monolayers grown on polyacrylamide gels of increasing stiffness were treated with control 
or 1 µM simvastatin and fluorescently stained for vinculin and VE-cadherin (Figures 
2.4A,B). Vinculin localization was measured using confocal microscopy and automated 
image analysis to quantify the volume of vinculin per monolayer overlapping with VE-
cadherin at cell-cell junctions. Increased matrix stiffness correlated with a significant 
increase in vinculin at cell-cell contacts that is decreased at higher stiffnesses with 
simvastatin treatment (Figures 2.4C). These data indicate that cell-cell adhesions within 
endothelial monolayers on stiff matrices are under increased tension and are less-stable, 
but have improved integrity after simvastatin treatment.  
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Figure 2.4. Simvastatin reduces vinculin localization at cell-cell adhesions in 
endothelial monolayers. Endothelial monolayers treated with control and 1 µM 
simvastatin were stained for vinculin and VE-cadherin, and the vinculin volume 
overlapping with VE-cadherin was quantified. Representative images of endothelial cell-
cell junctions within a confluent monolayer fluorescently stained for VE-cadherin and 
vinculin on a 10 kPa polyacrylamide gel after 24 hour (A) control and (B) 1 µM simvastatin 
treatment demonstrating vinculin positive and vinculin negative junctions, respectively. 
(C) Vinculin localization per monolayer at cell-cell adhesions, a readout of intercellular 
junction tension, was quantified and increased with matrix stiffness but was significantly 
decreased with the statin treatment at higher matrix stiffnesses (n = 3, 70-90 fields of view 
per condition). Data are presented as means ± standard error of the mean, ###p<0.001 
compared to matrix stiffness, *p<0.05 compared to the untreated control. 
 
Collectively, our data suggests that simvastatin may provide age-related atheroprotective 
benefits by altering pathways that disrupt RhoA and Rac1 activity to contribute to restored 
endothelium integrity and barrier function on stiff matrices.  
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2.5 Discussion 
To date, there are no FDA-approved therapeutics to reverse age-related vessel stiffening 
even though arterial stiffness is well accepted to occur with age and is a negative predictor 
of cardiovascular health (236, 237). Stiffening of the arterial intima disrupts endothelium 
integrity, and the flux of cholesterol across the endothelium is the first-step in 
atherogenesis, suggesting that maintaining or restoring endothelial barrier function may be 
one method to mitigate atherosclerosis (63). Notably, the small GTPase RhoA is known to 
play a critical role in disrupted endothelial adherens junctions and its activity is elevated in 
response to increased matrix stiffness (63, 147, 210). Here, we demonstrate the use of 
simvastatin to inhibit the endothelial cell response to substrate stiffness and show that 
simvastatin alters RhoA and Rac1 pathways to restore endothelial monolayer integrity.  
 
An altered endothelium is known to precede atherosclerotic lesion development (238), and 
increased collagen crosslinking by advanced glycation end products (AGEs) is a major 
contributor to stiffening of the vascular wall (239). Therapeutics to reverse arterial 
stiffening by breaking AGE crosslinks or preventing AGE formation have been met with 
limited success despite reaching clinical trials (200). Therefore, new approaches to target 
vascular stiffening or the cellular response to stiffening are required.  Our data suggest that 
statins may be one approach to preventing the aberrant endothelial cell response to vascular 
stiffening.  
 
Numerous pleiotropic effects of statins can be attributed to the inhibition of isoprenoid 
production which disrupts post-translational prenylation of the Rho family of GTPases: 
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RhoA, Rac1, and Cdc42. Specific attention has been placed on RhoA because of its role in 
regulating contractility of the actin cytoskeleton and the importance of post-translational 
prenylation for its localization and activation at the cell membrane (147). In agreement 
with other studies, we report that simvastatin decreases RhoA activity. We also report 
attenuated cell-cell junction tension that suggests increased monolayer stability and 
integrity with simvastatin treatment. Furthermore, we report elevated Rac1 activity after 
the statin treatment that is correlated with barrier enhancing cytoskeletal rearrangements. 
This paradoxical activation of Rac1 has been previously attributed to the inability of 
unprenylated Rac1 to associate with its GDI (240), upstream activation of the AMP-
activated protein kinase (AMPK) pathway (241), and the inverse activation relationship 
between RhoA and Rac1 (151).  To date, improved barrier integrity by simvastatin has not 
been associated with altered Cdc42 activity, and therefore, was not included in this study 
(221). The pleiotropic effects of statins are not limited to altering the RhoA family of 
GTPases and there is significant crosstalk between cellular mechanotransduction pathways 
that continue to be elucidated, therefore, we acknowledge that simvastatin may also be 
acting through additional pathways to ameliorate the effects of increased matrix stiffness 
(for reviews on the pleiotropic effects of statins see references (212–214).  While other 
groups have shown the efficacy of simvastatin in response to exogenous chemical agonists 
such as thrombin or in diabetic disease models, we are the first to show that statins can 
counteract the deleterious effects of matrix stiffening that occurs with normal aging (221, 
224). Our results suggest that statins have the potential to benefit otherwise healthy adults 
as they age by maintaining endothelial barrier integrity to prevent the onset of 
atherosclerosis and subsequent cardiovascular diseases. 
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RhoA activity has generally been regarded as detrimental to endothelial barrier function 
(147); however, basal RhoA activity is required for intact endothelial junctions and VE-
cadherin expression (149). Szulcek and colleagues reported its role in promoting the 
formation of endothelial cell-cell junctions (242). Hotspots of RhoA activity were 
identified in regions of the cell membrane where endothelial protrusions were creating new 
junctions after spontaneous small gap formation. Interestingly, coordinated RhoA activity 
is also necessary for cell polarization and alignment in response to shear stress, hallmarks 
of a healthy endothelium (243, 244). Similarly, Rac1 can have barrier protective or 
disruptive effects depending on its specific localization and activation. Membrane bound 
Rac1 can produce deleterious reactive oxygen species at cell-cell adhesions (245), but also 
stabilizes adherens junctions by retaining VE-cadherin (159). Cytosolic Rac1, in agreement 
with our data, is necessary for cortactin shuttling and cortical actin polymerization (220). 
Since precise regulation of RhoA and Rac1 are necessary for endothelial functionality, 
developing barrier-restoring therapeutics presents a particular challenge and should not 
focus on complete suppression or amplification of their activity. 
 
Endothelial cells are modulators of vascular homeostasis and exhibit improved 
functionality after statin treatment. Notably, endothelial cells are also mechanosensitive, 
incorporating matrix signals from basal integrins and flow stimuli from the apical 
glycocalyx (246, 247). The crosstalk between mechanical cues and statin treatment is not 
well understood. Previous work has shown that a synergistic response between statins and 
mechanical force exists, where laminar shear stress with statin treatment provided 
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enhanced protection against oxidative stress. However, under disturbed flow conditions, 
the protective benefit of the statin was diminished (248). This prior work lays the 
foundation to suggest that there is an intersection in mechanotransductive effects of shear 
stress and the signaling pathways affected by statin treatment. Our data furthered this work 
by demonstrating that other mechanical cues, specifically matrix stiffening, also exhibit 
crosstalk with the pathways targeted by statins.  
 
Cardiovascular stiffening is well known to occur with age, and the role of vascular 
stiffening as a cause rather than a consequence of cardiovascular diseases has been 
demonstrated in several recent studies (236). Weisbrod and colleagues recently 
demonstrated that microscale vessel stiffening preceded hypertension in a mouse model of 
diet-induced obesity (140), and clinical trials have shown that macroscale arterial stiffening 
also precedes hypertension (249). Our group has shown that intimal stiffness causes 
endothelial barrier disruption due to increased RhoA-mediated cell contractility, and that 
the endothelial response to increased matrix stiffness, and not adhesion molecule 
expression, contributed to enhanced leukocyte transmigration (63). Moreover, endothelial 
monolayers cultured on stiff matrices, are unable to recover from leukocyte transmigration 
events leading to persistent gaps in the endothelial layer (185), through which subsequent 
leukocytes can transmigrate at increased rates (250). In vivo, delayed repair of the 
endothelium could promote a local inflammatory response and drive atherosclerotic plaque 
formation. These recent advances in the literature indicate that vascular stiffening may be 
a potential target to mitigate cardiovascular disease pathologies associated with a 
compromised endothelium. As such, preventing the aberrant cellular response to age-
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related arterial stiffening to restore endothelial barrier function using statins, for example, 
as was done here, may be a promising approach to inhibiting atherosclerosis. 
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CHAPTER 3 
 
PHOTOPATTERNED HYDROGELS TO INVESTIGATE THE ENDOTHELIAL  
 
CELL RESPONE TO MATRIX STIFFNESS HETEROGENEITY 
 
Portions of this chapter were published in  
ACS Biomaterials and Engineering (Lampi et al., 2017) 
 
3.1 Abstract 
Age-related intimal stiffening is associated with increased endothelium permeability, an 
initiating step in atherosclerosis. Notably, in addition to a bulk increase in matrix stiffness, 
the aged intima also exhibits increased spatial stiffness heterogeneity; therefore, the effect 
of heterogeneous matrix stiffness on endothelial cells was investigated. Methacrylated 
hyaluronic acid hydrogels were fabricated and photopatterned to create substrates with 50 
and 100 µm squares containing soft and stiff matrix regions of 2.7 ± 0.7 and 10.3 ± 3.9 
kPa. On the patterned matrices, endothelial cells integrated subcellular matrix stiffness cues 
at stiffness interfaces, and focal adhesions were increased in the cell body adhered to stiff 
matrix regions. Increased matrix stiffness heterogeneity disrupted cell−cell junctions in 
confluent endothelial monolayers (Figure 3.1). Together, this work indicated that the 
spatial presentation of matrix mechanical cues, in addition to bulk substrate compliance, 
plays a role in governing endothelial single cell and monolayer behaviors. 
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Figure 3.1. Graphical abstract. Hydrogels with heterogeneous stiffness were patterned 
by photocrosslinking and used to investigate the endothelial cell response to spatial matrix 
stiffness cues.  Endothelial cells responded to subcellular changes in matrix stiffness and 
endothelial monolayer cell-cell junction integrity was disrupted on the heterogeneous 
stiffness substrates. 
 
3.2 Introduction 
Extracellular matrix stiffening is associated with a diverse array of pathologies including 
cancer, diabetes, and cardiovascular diseases, and matrix mechanical cues can alter cellular 
behaviors to contribute to disease progression (173, 200, 251–253). Increased bulk artery 
stiffness is a hallmark of both aging and atherosclerosis and is used as a clinical marker to 
assess cardiovascular health (254, 255). Notably, macroscale measurements of arterial 
stiffness do not reflect the cell−scale matrix mechanics of the microenvironment where 
endothelial cells reside lining the arterial intima lumen and act in part, as a semipermeable 
barrier that maintains vascular homeostasis (256). Compromised endothelial adherens 
junctions that contribute to increased endothelial permeability and the accumulation of 
LDL cholesterol in the intima are initiating steps in atherosclerosis (2, 11). Endothelial 
junction integrity relies on a critical balance between tensional forces and Rho family 
GTPase activity to promote the formation of stable junctional complexes without leading 
to their disassembly (149, 151, 152, 159, 221, 257). Evidence that intimal stiffening 
precedes cardiovascular disease, combined with prior reports that increased matrix 
stiffness elevates cell contractility and stress fiber formation, disrupts endothelial cell−cell 
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junctions, and inhibits endothelium barrier recovery, suggests that extracellular matrix 
mechanics may play a critical role in atherogenesis (63, 140, 149, 153, 184, 185, 230, 258). 
 
In addition to increased average intima stiffness with age, ex vivo mechanical 
characterization of murine aortas revealed that aged vessels also exhibit increased 
mechanical spatial heterogeneity within the intima over an area where a single endothelial 
cell would reside (122, 172). Within a 100 by 100 µm area, stiffness “hotspots” were 
detected, and intima stiffness increased as much as 50-fold from 2 to 100 kPa. Because 
focal adhesions individually probe the extracellular environment and in vitro models have 
shown that cells can discern subcellular differences in matrix compliance that alter cell 
polarization, local traction stresses, and durotactic behaviors, we hypothesize that 
endothelial cells in vivo are integrating distinct matrix mechanical cues from their 
extracellular environment that alter junction integrity (175, 179, 259, 260). Although 
increased bulk matrix stiffness is recognized to compromise endothelium integrity, the role 
of spatially heterogeneous matrix mechanics on endothelial cells remains unknown and is 
important to understanding how the altered mechanical properties of the intima associated 
with aging contribute to a disrupted endothelium.  
 
Here, we used methacrylated hyaluronic acid hydrogels that undergo sequential 
polymerization to fabricate and characterize substrates with regions of patterned 
crosslinking (171, 261). Motivated by the increased spatial heterogeneity and abrupt 
increases in extracellular matrix stiffness within the aged arterial intima, these stiffness 
patterned substrates were then used to study the endothelial cell response to stepwise spatial 
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changes in matrix stiffness. On the basis of the location of focal adhesion formation, within 
an individual endothelial cell, there was a local response to multiple matrix stiffness cues. 
Furthermore, matrix stiffness heterogeneity affected monolayer formation and disrupted 
cell−cell junction integrity. Average intercellular gap size increased with increased matrix 
stiffness heterogeneity, and the greatest cell−cell junction disruption occurred at stiffness 
interfaces. These findings suggest the spatial presentation of extracellular matrix 
mechanical cues, in addition to the average bulk modulus, contribute to atherogenesis 
caused by age related intimal stiffening. 
 
3.3 Materials and Methods 
Methacrylated Hyaluronic Acid Synthesis  
Methacylated hyaluronic acid (MeHA) was synthesized as described previously (171, 262). 
Sodium hyaluronate (51 kDa, Lifecore Biomedical, Chaska, MN) was dissolved in DI 
water at 1 wt% and reacted with 2.4 mL of methacrylic anhydride (Sigma-Aldrich, St. 
Louis, MO) per gram HA on ice at pH 8.0 for 8 h. The reaction mixture was incubated 
overnight at 4 °C followed by the introduction of an additional 1.2 mL of methacrylic 
anhydride per gram HA on ice at pH 8.0 for 4 h. The reaction product was dialyzed against 
DI water (6−8 kDa MWCO, SpectraPor, Rancho Dominguez, CA) and lyophilized. MeHA 
modification was determined to be ∼100% by 1H NMR (600 MHz Varian). 
 
Photopatterned MeHA Gel Fabrication  
MeHA hydrogels were synthesized as described previously (171, 261). Briefly, substrates 
were fabricated by dissolving the synthesized MeHA polymer in 0.2 M triethanolamine 
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(Sigma Aldrich, St. Louis, MO) in PBS, at pH 10.25 at 3 wt%. A custom synthesized RGD 
cell-binding peptide, GCGRGDSPG (Genscript, Piscataway, NJ) was added to the polymer 
solution at a final concentration of 1 mM and reacted for 45 min. Gels were then 
polymerized between two glass coverslips by Michael-type addition using dithiothreitol 
(DTT) (Sigma-Aldrich, St. Louis, MO) to consume 13% of the available methacrylates. 
Polymerized hydrogels were incubated overnight at room temperature in PBS prior to use 
or characterization. These hydrogels were used as uniform soft controls. To fabricate 
substrates with stiffness patterns, polymerized hydrogels were incubated in solutions of 
0.05 wt% Irgacure 2959 (BASF, Overland Park, KS) photoinitiator and 200 µM 
methacrylated rhodamine (Polysciences, Inc., Warrington, PA) in PBS for 30 min at 37 °C. 
Custom 24,500 DPI photomasks (CAD/Art Services, Bandon, OR) were then overlaid on 
the gel surface followed by immediate exposure to 320−500 nm collimated UV light at an 
intensity of 10 mW/cm2 for 4 min using an Omnicure S1500 (Excelitas Technologies, 
Waltham, MA). Gels were thoroughly rinsed with PBS prior to cell studies to remove 
excess photoinitiator and unreacted methacrylated rhodamine. Uniform stiff control 
hydrogels were fabricated by substituting the patterned photomask with a clear film of the 
same material. 
 
Atomic Force Microscopy  
Hydrogel elastic moduli of uniform gels were measured using an Asylum MFP-3D 
(Asylum Research, Santa Barbara, CA) AFM in contact mode at locations distributed 
throughout the gel surface. Elastic moduli of 50 and 100 µm patterned gels were measured 
in 10 µm increments over 100 or 200 µm distances, respectively, perpendicular to stiffness 
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interfaces. The gel surface was indented with a 1.0 µm diameter spherical silicon dioxide 
particle on a silicon nitride cantilever with a manufacturer precalibrated spring constant of 
0.06 N/m (Novascan Technologies, Ames, IA) (263). The resulting force vs. indentation 
curves were fit to the Hertz model assuming a Poisson’s ratio of 0.5 to extract the Young’s 
modulus using the Asylum software (264). Measurements taken at the interface point were 
excluded from the mean stiffness values calculated for the soft and stiff patterned regions. 
 
Patterned Hydrogel Characterization  
Stiffness pattern fidelity was assessed using a Zeiss LSM700 microscope using a 10x 
objective and the 568 nm excitation laser line to visualize the covalently bound rhodamine 
fluorophore in the stiffened gel regions. Color intensity profiles to distinguish soft and 
stiffened gel regions were obtained using ImageJ software (National Institutes of Health, 
Bethesda, MD). To visualize gel topographical features, phase contrast images of patterned 
hydrogels were acquired using a Zeiss Axio Observer.Z1m microscope using a 10x 
objective. For gel topography measurements, gels were incubated overnight at room 
temperature in 10 µM, 40 kDa FITC-dextran (Sigma Aldrich, St. Louis, MO) in PBS, and 
XZ confocal z-slices were acquired using a Zeiss LSM700 microscope using a 40x 
objective and the 488 nm excitation laser line. The distance between the highest and lowest 
z-positions at the gel surface within each field of view were measured using ImageJ. 
Because the width of the stripe pattern exceeded a single field of view, tile scans combining 
5 images were used.  
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Cell Culture  
Bovine aortic endothelial cells (VEC Technologies, Rensselaer, NY) from passages 7−12 
were used. Cells were maintained in Medium 199 (Invitrogen, Carlsbad, CA) 
supplemented with 10% Fetal Clone III serum (HyClone, Logan, UT), 1% MEM amino 
acids (Invitrogen), 1% MEM vitamins (MedTech, Manassas, VA), and 1% 
penicillin−streptomycin (Invitrogen) at 37 °C and 5% CO2. 
 
Immunofluorescence  
Endothelial cells were fixed with 3.2% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, PA) and permeabilized with 1% Triton (VWR, Radnor, PA). For focal adhesion 
studies, a mouse monoclonal vinculin primary antibody (Santa Cruz Biotechnology, 
Dallas, TX) and an Alexa Fluor 488 donkey antimouse secondary (Invitrogen) were used. 
Confocal z-stack images were acquired using a LSM700 microscope equipped with a 40x 
objective and the 488 nm and 568 excitation laser lines to visualize vinculin and the 
rhodamine marked stiffness patterns, respectively. For subconfluent monolayer studies, 
actin was visualized with Alexa Fluor 488 conjugated phalloidin (Invitrogen). Images were 
captured using a LSM700 microscope equipped with a 20x objective and the 488 nm and 
568 excitation laser lines to visualize actin and the rhodamine marked stiffness patterns, 
respectively. For confluent monolayer studies, a goat polyclonal VE-cadherin primary 
antibody (Santa Cruz Biotechnology) was used with an Alexa Fluor 488 donkey antigoat 
secondary antibody (Invitrogen). Actin was visualized using Alexa Fluor 350 phalloidin 
(Invitrogen). Fluorescent images were captured using a Zeiss Axio Observer.Z1m 
microscope with a 20x objective. 
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Quantification of Focal Adhesion Length and Area 
Focal adhesion length and area were quantified as described previously (258). Briefly, 
confocal z-stack images of endothelial cells stained for vinculin and the rhodamine labeled 
stiffness patterns were captured. Vinculin images were converted to maximum intensity z-
projections and subjected to an adaptive Wiener filter, a top-hat filter, and a median filter 
to extract focal adhesion structures using MatLab. Maximum intensity z-projections of the 
stiffness pattern images were converted to binary images to create a mask of the stiff 
hydrogel areas. The pattern mask was multiplied by the extracted focal adhesion image to 
quantify structures on the stiff substrate regions. To quantify focal adhesions on the soft 
substrate regions, a soft pattern mask was obtained from the complement image of the stiff 
pattern mask and multiplied by the extracted focal adhesion image. 
 
Quantification of Monolayer Intercellular Gap Size 
Intercellular gap size was quantified using ImageJ software and corresponding fluorescent 
images of VE-cadherin, actin, and the substrate stiffness pattern. Areas of endothelial 
cell−cell junction disruption were identified using the VE-cadherin images, and the 
corresponding actin image was used to trace and measure the gap area. The corresponding 
stiffness patterned image was used to identify the location of the monolayer disruption. 
 
Statistics  
Statistical analysis was conducted using GraphPad Prism, version 6.0d. All data in 
graphical form are presented as the mean ± standard error of the mean, and all numerical 
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values in the text are presented as the mean ± standard deviation. Statistical significance 
was evaluated using analysis of variance (ANOVA) with a Tukey’s Honestly Significant 
Difference (HSD) test for AFM and monolayer data. Two-tailed Student’s t-tests were used 
for focal adhesion data. Statistical significance was considered with a p-value <0.05. All 
images are representative of a minimum of 3 replicate studies. 
 
3.4 Results 
Hydrogel Fabrication and Photopatterning Approach 
To create substrates with stiffness heterogeneity, hyaluronic acid based hydrogels that had 
been modified to contain methacrylate groups on the polymer backbone were synthesized. 
Briefly, the addition of methacrylates permitted the synthesis of hyaluronic acid hydrogel 
substrates using a simple, two-step sequential crosslinking method, where a portion of the 
methacrylates were first crosslinked by a Michael-type addition reaction with DTT 
followed by radical polymerization using a photoinitiator and UV light (171). To create 
spatial stiffness patterns, high resolution photomasks were overlaid on the gel during the 
radical polymerization to spatially control UV light exposure and stiffening. Three 
photomask patterns were designed to vary the presentation of matrix stiffness 
heterogeneity: 50 by 50 µm checkerboard squares, 100 by100 µm checkerboard squares, 
and 500 µm stripes (Figure 3.2). 
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Figure 3.2. Photopatterning approach. (A) Methacrylated hyaluronic acid hydrogels 
were photopatterned to create substrates with stiffness heterogeneity. (B) Photomasks with 
50 by 50 µm squares, 100 by 100 µm squares, and 500 µm stripes were used to control the 
gel regions exposed to UV light and crosslinked; scale bar = 100 µm. 
 
 
Stiffness Patterned Hydrogel Characterization 
Base hydrogels containing an RGD cell-binding motif were fabricated at an initial gel 
stiffness of 2.2 ± 0.7 kPa to maintain physiological relevance and approximate the Young’s 
modulus of 2.7 ± 1.1 kPa that has been reported for the healthy bovine intima (172). Precise 
regions of the hydrogel substrates were then stiffened with exposure to 4 min of UV light 
through the photomask patterns. A clear photomask was used to fabricate uniform stiff 
control gels. Prior to UV cross linking, the gels were incubated with 200 µM methacrylated 
rhodamine. The rhodamine covalently incorporated into the hydrogel backbone only in 
regions where gel-stiffening radical polymerization had occurred and allowed for stiffness 
pattern visualization using fluorescence microscopy (261). Gel stiffening to 18.5 ± 2.9 kPa 
was confirmed using atomic force microscopy to measure the Young’s moduli of uniform 
control and UV stiffened gels (Figure 3.3A). Prior rheological characterization  
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Figure 3.3. Characterization of gel stiffening and pattern fidelity. (A) Atomic force 
microscopy measurements of hydrogel Young’s moduli in uniform control and UV 
stiffened gels (n = 3, 70−77 indentations per condition). Representative confocal images 
of the hydrogel stiffness patterning where rhodamine (red) was covalently bound to the gel 
backbone after radical polymerization in stiffened regions for the (B) 50 µm square, (D) 
100 µm square, and (F) 500 µm stripe patterns. Color intensity profiles of the confocal 
images at the white line demonstrated the photopattern feature size was conserved when 
transferred to the gel for (C) 50 µm square, (E) 100 µm square, and (G) 500 µm stripe 
patterns. Data are presented as the means ± standard error of the mean; ****p < 0.0001; 
scale bar = 250 µm. 
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demonstrated no change in loss modulus (G″) was accompanied by an increase in storage 
modulus after UV stiffening (G′) (171). Confocal imaging of the methacrylated rhodamine 
conjugated hydrogels and color intensity profiles revealed high pattern fidelity across all 
the patterns and conservation of the photomask feature sizes (Figures 3.3B-G). 
 
Noting that increased network crosslinking affected gel swelling, the effect of stiffness 
patterning on hydrogel surface topography was evaluated. Stiffened regions of the gels 
exhibited decreased swelling, and topographical features were visible using phase-contrast 
imaging (Figure 3.4A,C,E). No cracks or gel separation at interface regions were found in 
any of the stiffness patterned substrates. To quantify the swelling behavior of the patterned 
hydrogels, the substrates were saturated with a FITC-dextran solution, and confocal XZ 
slices were obtained to measure the maximum change in Z height for each pattern within a 
single field of view (Figure 3.4B,D,F). Gel swelling increased with pattern size, and the 
gel surface height varied by 4.5 ± 2.6 µm, 6.7 ± 3.5 µm, and 37 ± 7.0 µm for the 50 µm 
square, 100 µm square, and 500 µm stripe patterns, respectively (Figure 3.4G).  Because 
topographical surface cues can also influence cell behaviors and cannot be decoupled from 
the stiffness patterned substrate, the remainder of the study focused on the substrates 
patterned with 50 and 100 µm squares of stiffness heterogeneity where minimal surface 
swelling was detected (265).  
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Figure 3.4. Characterization of stiffness patterned hydrogel topography. 
Representative phase-contrast images of patterned hydrogels revealed gel surface 
topography caused by decreased swelling in stiffened regions for the (A) 50 µm square, 
(C) 100 µm square, and (E) 500 µm stripe patterns. Topographical features were quantified 
using XZ confocal scans of FITC dextran saturated gels to measure the maximum change 
in Z height for the (B) 50 µm square, (D) 100 µm square, and (F) 500 µm stripe patterns in 
a single field of view. The red bar indicates stiffened gel regions. (G) Changes in gel surface 
height increased with stiffness pattern feature size (n = 3, 50−60 fields of view). Data are 
presented as the means ± standard error of the mean; scale bar = 50 µm. 
 
De-swelling behavior caused by increased matrix crosslinking that began at stiffness 
interfaces and reached minima in the pattern centers indicated possible stiffness variation 
within the photocrosslinked gel regions. Starting at an interface, AFM stiffness 
measurements were collected at 10 µm intervals along a perpendicular line across soft and 
stiff gel regions (Figure 3.5A, B). Minimal variation in stiffness was measured in soft gel 
regions for both the 50 and 100 µm square patterned gels, and the mean Young’s moduli 
of 2.7 ± 0.7 of the soft patterned regions was not significantly different when compared to 
uniformly soft control gels (Figure 3.5C). Despite a uniform rhodamine signal which only 
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identified UV crosslinked regions and not the extent of crosslinking, stiffened gel areas 
exhibited spatial stiffness variation. Gel stiffness in UV crosslinked regions increased with 
increasing distance away from the stiffness interface, and maxima occurred in the pattern 
centers. These data are consistent with the surface topography data where maximal de-
swelling also occurred in the pattern centers. A much smaller interface effect was present 
within the 50 µm stiffness patterned region compared to that of the larger 100 µm pattern 
but may be partially explained by the lateral measurement sensitivity where 5 
measurements were collected for the smaller pattern compared with 10 for the larger 
pattern size. Although spatial characterization across soft and stiffened gel regions 
indicated that abrupt stepwise stiffening did not occur at pattern edges, increased stiffening 
still occurred over the length scale of an individual endothelial cell. Average stiffness in 
the photocrosslinked patterned regions significantly increased to 10.3 ± 3.9 compared to 
that of the soft gel regions (Figure 3.5C). Stiffened regions of the patterned substrates had 
lower mean stiffness when compared to that of uniformly stiff control gels (Figure 3.4C). 
The large standard deviation in the Young’s modulus of the stiffened gel areas resulted 
from the spatial variations in stiffness, especially near the interface regions. 
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Figure 3.5. AFM mechanical characterization of 50 and 100 µm square stiffness 
patterned hydrogels. Gel stiffness was measured at 10 µm increments beginning at a 
stiffness interface across soft and stiff gel regions on (A) 50 and (B) 100 µm square stiffness 
patterned gels (n = 3, 10 interface regions per condition). (C) Average hydrogel stiffness 
increased in UV stiffened regions when compared to soft gel regions on the patterned and 
uniform substrates (n = 3, 40−90 indentations per condition). Data are presented as the 
means ± standard error of the mean; ****p < 0.0001. 
 
 
Focal Adhesions Localize to Stiff Regions on Substrates Containing Subcellular 
Matrix Stiffness Heterogeneities  
Previous studies have demonstrated that an individual cell spanning a single substrate 
stiffness interface can sense and respond to the mechanical cues of their matrix by locally 
altering traction forces (175). Therefore, the integration of more complex substrate 
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mechanical cues, such as an endothelial cell spanning multiple matrix stiffness interfaces, 
was investigated. Because focal adhesions are mechanosensitive complexes that link cell-
ECM interactions to the cytoskeleton and are incorporated in feedback loops where 
increased traction forces are generated in response to increased matrix stiffness, focal 
adhesion formation was used as a readout of matrix stiffness sensing (192). Bovine aortic 
endothelial cells on 50 and 100 µm checkerboard patterned hydrogels were stained with 
vinculin to evaluate focal adhesions and compared to cells grown on uniformly soft and 
stiff hydrogels (Figure 3.6). On the uniformly soft matrices (2.2 ± 0.7 kPa), focal adhesions 
were small and sparse, while on the uniformly stiff matrices (18.5 ± 2.9 kPa), mature focal 
adhesions were greater in both size and number. Notably, in endothelial cells on the 
hydrogels patterned with matrix stiffness heterogeneity, focal adhesion localization was 
dependent on the underlying matrix stiffness. Mature focal adhesions were found on the 
stiff substrate regions (10.3 ± 3.9 kPa) and were largely absent in areas where the cell body 
was adhered to a soft matrix (2.7 ± 0.7 kPa). In addition to localization, focal adhesion 
length and area significantly increased on stiff matrix regions in cells adhered across 
stiffness interfaces and further indicated subcellular matrix stiffness sensing (Figure 
3.6D,E). 
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Figure 3.6. Endothelial cell focal adhesion localization and size were dependent on 
subcellular matrix stiffness. Representative confocal images of endothelial cells stained 
for vinculin to visualize focal adhesions on (A) uniform control, (B) 50 µm square, and (C) 
100 µm square patterned gels. Focal adhesion (D) length and (E) area within a single 
endothelial cell significantly increased on stiffened matrix regions for both the 50 and 100 
µm patterns (n = 3, 24−33 cells per condition). White dashed lines indicate stiffness pattern 
boundaries, and stiffened regions of the gel are red. Data are presented as the means ± 
standard error of the mean; **p < 0.01, *p < 0.05; scale bar = 50 µm. 
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Endothelial Monolayer Formation and Junction Integrity is Disrupted by Spatial 
Matrix Stiffness Heterogeneity  
In vivo, endothelial cells lining the arterial intima exist as a monolayer, and cell−cell 
junction integrity is paramount to preventing cholesterol flux into the arterial wall where it 
can initiate atherosclerotic plaque formation. Therefore, the effect of spatial matrix 
stiffness heterogeneity on endothelial monolayer formation and integrity using the 
patterned hydrogel substrates was investigated. During monolayer growth, subconfluent 
endothelial cells preferentially grew on regions of stiff matrix, while cell growth on the 
soft regions was dramatically reduced (Figure 3.7).  
 
Figure 3.7. Endothelial cells preferentially grew on stiff matrix regions during 
monolayer formation. Representative confocal images visualizing actin in subconfluent 
monolayers on (A) 50 and (B) 100 µm square stiffness patterned gels where red areas 
indicate stiffened gel regions. Scale bar = 50 µm. 
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These data could have important in vivo implications where circulating debris in the blood 
can denude the endothelium, and efficient recellularization is important to prevent 
permeability. 
 
To directly assess the effects of matrix stiffness heterogeneity on endothelium integrity, 
confluent endothelial monolayers were stained for the cell−cell junctional protein VE-
cadherin, and the actin cytoskeleton was visualized with phalloidin. Consistent with our 
prior studies, on uniformly stiff matrices, VE-cadherin staining revealed disrupted cell−cell 
junctions and intercellular gaps (63, 258). Increased endothelial cell−cell junction 
disruption occurred on the heterogeneous stiffness matrices. Average intercellular gap size 
increased with increasing matrix stiffness heterogeneity when gap area on 50 µm square, 
100 µm square, and uniformly stiff patterned substrates was measured (Figure 3.8A). 
Notably, intercellular gaps on the heterogeneous matrices were significantly greater in area 
when compared to that of the monolayer disruption that occurred on a uniformly stiff 
substrate with a greater overall bulk modulus. Intercellular gaps were predominantly 
located at matrix stiffness interfaces on the 50 µm square patterned substrates but were 
approximately evenly distributed among soft, stiff, and interface regions on the less 
heterogeneous 100 µm square patterned substrates (Figure 3.8B). On both of the 
heterogeneous stiffness substrates, the largest areas of monolayer disruption were found at 
stiffness interfaces, when compared to those of soft and stiff gel regions (Figure 3.8C-E). 
The increased intercellular gap size measured at stiffness interfaces and with increased 
matrix stiffness heterogeneity provides evidence that balancing distinct matrix cues within 
one cell compromises endothelial monolayer cell−cell junction stability. Cutiongco and 
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colleagues demonstrated that micron sized surface topographies on hydrogels enhanced 
endothelial monolayer formation compared to that of planar controls; therefore, although 
we cannot decouple the topographical surface swelling features characterized in Figure 3.3, 
we assume matrix stiffness heterogeneities and not the surface topographies are the 
dominant extracellular matrix cues contributing to endothelial cell−cell junction disruption 
on the stiffness patterned substrates (266).  
 
Together, our data indicate that endothelial cells are able to sense and respond to 
subcellular spatial stiffness cues from their substrate and that spatial stiffness heterogeneity 
in addition to a bulk increase in matrix stiffness disrupts endothelial cell−cell junction 
integrity. 
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Figure 3.8. Matrix stiffness heterogeneity disrupted endothelial monolayer junction 
integrity. Endothelial monolayers were stained for VE-cadherin, and the actin 
cytoskeleton was visualized with phalloidin. (A) Average intercellular gap area increased 
with increasing matrix stiffness heterogeneity (n = 3, 10−12 fields of view per condition). 
(B) Monolayer gaps were found with increased frequency at stiffness interfaces on the 50 
µm square stiffness patterned substrates and were evenly distributed among soft, stiff, and 
interface regions on the less heterogeneous 100 µm square stiffness patterned substrates. 
Intercellular monolayer gaps found at interface regions were larger when compared to areas 
of monolayer disruption located at stiff and soft regions on the (C) 50 µm square and (D) 
100 µm square stiffness patterned substrates (n = 3, 10−12 fields of view per condition). 
Representative images of intercellular gaps found at soft, stiff, and interface regions in 
endothelial monolayers on 50 µm square stiffness patterned substrates. Data are presented 
as the means ± standard error of the mean; ****p < 0.0001, ***p < 0.001, **p < 0.01, and 
*p < 0.05; scale bar = 10 µm. 
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3.5 Discussion 
In this study, we fabricated hyaluronic acid based hydrogels with photopatterned regions 
of increased crosslinking to study endothelial cell behavior in response to matrix stiffness 
heterogeneity. The data demonstrate that endothelial cells integrate multiple subcellular 
matrix stiffness cues and that substrate stiffness heterogeneity disrupts endothelial 
monolayer junction integrity. Notably, increases in substrate stiffness from 2.7 to 10.3 kPa, 
which are significantly smaller than the intima stiffness heterogeneity increases that have 
been measured ex vivo, resulted in endothelium disruption and provide compelling 
evidence that the mechanics of the aged intima may contribute to endothelium permeability 
and atherogenesis. The ability of extracellular matrix stiffness to influence a diverse array 
of endothelial cell behaviors including cell spreading, focal adhesion formation, traction 
forces, and monolayer permeability has been appreciated for some time (63, 64, 206, 258). 
However, the in vivo extracellular matrix of endothelial cells within the arterial intima is 
more complex than the synthetic uniform stiffness substrates commonly used to study these 
behaviors in vitro. Age-related mechanical heterogeneity within the aorta exists on both 
the macro- and microscales, and atherosclerotic plaques are associated with regions of 
increased arterial wall thickness (122, 267–269). Intimal stiffening is a dynamic process 
that occurs throughout the lifespan, largely due to the combined effects of collagen 
crosslinking and increased extracellular matrix deposition (200). Developing new in vitro 
substrates to recapitulate the in vivo complexity of the arterial intima, such as the stiffness 
patterned substrates presented here, are important to understanding how age-related intimal 
stiffening contributes to endothelium disruption and atherogenesis. 
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Single cell studies have identified many of the molecular mechanisms that underlie the 
mechanotransduction feedback loops between a cell and extracellular matrix stiffness 
sensing (176, 270, 271). It is well accepted that environmental sensing through integrin 
complexes leads to the assembly of nascent focal adhesions, which then undergo force 
dependent conformational changes to bind F-actin and require RhoA-mediated contractile 
force generation to mature (177, 192, 230). However, in vivo, isolated individual 
endothelial cells are rare, and most cells exist as part of a collective where both direct 
cell−cell as well as cell−matrix cues influence cellular behavior. Intercellular interactions 
are critical for endothelium function, which requires intact adherens junctions mediated by 
VE-cadherin to maintain a vascular barrier (11, 256). Opposing activation of the GTPases 
RhoA and Rac1 are associated with stress fiber formation and cytoskeletal rearrangements 
that promote endothelium disruption or strengthening, respectively (153, 160, 272). 
Importantly, the cytoskeleton is able to transmit force generated by GTPase activity over 
long ranges from cell−matrix to cell−cell contacts and from the cell surface to focal 
adhesions (188, 273, 274). Within cell pairs, it has been demonstrated that RhoA and Rac1 
activity affects the tugging force at cell−cell junctions and that traction forces, which are 
mediated in part by RhoA activity, are directly proportional to the cell−cell junction tension 
(187, 188). Varying either matrix stiffness or chemistry to alter cell−matrix interactions 
and consequentially, traction forces, alters the cell−cell force (187). These foundational 
studies demonstrate the interdependence between matrix cues and cell−cell junction 
tension. Within endothelial monolayers, both traction stresses and VE-cadherin junction 
forces increase with matrix stiffness (210). Monolayer traction stresses exhibit spatial 
variance, and subcellular hotspots of increased traction stress are correlated with high force 
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fluctuation and intercellular gap formation (275). Here, a localized increase in focal 
adhesions in subcellular regions of increased matrix stiffness is demonstrated, and 
endothelial cell−cell junctions in monolayers on a heterogeneously stiff matrix are 
disrupted, thereby suggesting that matrix mechanical cues may augment traction force 
hotspots that contribute to endothelium instability and disruption. 
 
A role for aberrant traction forces contributing to endothelium disruption is also supported 
by work from Cai and colleagues investigating the mechanisms of cytoplasmic coherence 
where nonmuscle myosin-IIA crosslinks actin filaments to form a mesh networking 
extending across the cell cytoplasm. The actin network creates a stabilizing contractile 
force that counterbalances high traction forces located at the cell periphery (276, 277). 
Within endothelial monolayers, localized cytoskeletal tension has been associated with 
both endothelial barrier disruption and strengthening. Pharmacological treatment with a 
barrier disruptive agonist caused concentrated cytoskeletal tension away from the cell 
periphery, and an opposite shift occurred after treatment with barrier protective agents 
(278). Because the cytoskeleton transmits force from cell end to end to achieve equilibrium, 
an important requirement for cytoplasmic coherence is that traction forces located at one 
side of a cell are symmetrically balanced by opposing forces on the opposite side (277). As 
already noted, we found that on a heterogeneously stiff matrix, focal adhesion sizes were 
dependent on the underlying matrix stiffness suggesting that traction force distribution was 
also altered due to localized matrix mechanical cues and therefore may not meet the 
symmetrically balanced criteria necessary for cytoplasmic coherence. Indeed, single cell 
studies on micropillar arrays have demonstrated that matrix rigidity interfaces polarize 
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traction forces normal to the interface and that sharp increases in cellular forces occur in 
migrating cells as they cross a soft to stiff boundary (179). On the basis of exaggerated cell 
membrane spreading and fragmentation that occurred when bulk cell contractility was 
modulated pharmacologically and the importance of membrane tension for cadherin 
aggregation, a misbalance of contractile forces and disrupted cytoplasmic coherence may 
in part explain the disrupted endothelial monolayer junctions observed on stiffness 
patterned substrates (277, 279). 
 
Parallels between the mechanotransduction machinery used at cell−matrix and cell−cell 
contacts to anchor to the cytoskeleton suggest a prominent role for cell−cell force 
transmission in regulating endothelial monolayer behaviors. At focal adhesions, 
mechanical stretching of talin exposes a vinculin binding site, and similarly force-
dependent conformational unfolding of alpha catenin at adherens junctions is necessary for 
vinculin recruitment to the junctional complex (177, 191). Both focal adhesions and 
adherens junctions undergo force-dependent strengthening (230, 280, 281). Although it has 
been known that cadherin complexes at cell−cell junctions are mechanotransducers and 
that VE-cadherin is an integral part of the mechanosensitive response to fluid shear stress 
in endothelial monolayers, only recently has VE-cadherin been directly identified as a 
mechanotransducer (189, 193, 282). Direct force application to VE-cadherin caused global 
endothelial monolayer remodeling distant from the site of the applied force and 
demonstrated that force propagation between endothelial cells can disrupt monolayer 
integrity (189). These results suggest that exogenous cues that cause increased cell−cell 
junction tension across VE-cadherin, can have global ramifications on endothelial cell−cell 
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monolayer integrity. Consistent with this finding, and noting that matrix stiffness alters 
traction stresses and cell−cell junction tension, our data indicate that localized matrix 
stiffness heterogeneity may contribute to aberrant VE-cadherin forces to disrupt cellular 
junction integrity.  
 
The molecular mechanisms underlying force-dependent endothelial cell−cell junction 
maintenance and disruption continue to be elucidated; however, an overlap in important 
cytoskeletal regulatory proteins found at both focal adhesions and cell−cell junctions 
suggest a necessary role for spatial and temporal regulation (194, 196, 270). It has recently 
been identified that vinculin localization to focal adhesions or cell−cell junctions is 
associated with endothelial barrier disruption or enhancement, respectively (195). 
Increased matrix stiffness that contributes to the recruitment of shared proteins to form 
focal adhesions at the cell−matrix interface likely alters cell−cell adhesion dynamics. 
Future studies should modulate matrix heterogeneity with respect to feature size and 
stiffness magnitude to develop an increased understanding of the matrix mechanical cues 
and molecular mechanisms that are most critical to endothelium integrity. 
 
3.6 Conclusion 
Hyaluronic acid hydrogels with regions of patterned stiffness were fabricated to study the 
endothelial cell response to matrix stiffness heterogeneity. Focal adhesions were localized 
in regions of increased subcellular stiffness and increased matrix stiffness heterogeneity 
disrupted endothelial monolayer cell−cell junctions. Although bulk increases in matrix 
stiffness have been shown to increase the force at intercellular junctions and disrupt 
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endothelial monolayers, to our knowledge, our data is the first to show that the spatial 
presentation of matrix mechanical cues in addition to the magnitude of matrix compliance 
disrupts cell−cell junctions (63, 187). Because intima stiffness heterogeneity increases with 
age, our findings have important clinical implications for understanding the mechanisms 
that contribute to age-related atherosclerosis. 
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CHAPTER 4 
 
ADDITIONAL DATA 
 
In addition to the data that resulted in peer-review manuscripts, there was a substantial 
amount of work invested into notable side projects, that ultimately were not pursued 
further. This chapter will discuss the motivation, methods, results, and conclusions for two 
of those studies.  
 
4.1 Effects of Temporal Matrix Stiffening on Endothelial Cell Monolayers 
Motivation 
Cardiovascular diseases are a leading cause of death worldwide and account for 17.5 
million deaths annually (283). Atherosclerosis is often an underlying pathology that 
contributes to cardiovascular diseases and age-related arterial stiffening on the cellular 
scale has been recognized as a mechanical cue that compromises endothelial barrier 
function, an initiating step in atherosclerosis development (2, 63, 210). As the stiffness of 
their extracellular matrix increases, endothelial cells lining the arterial lumen exhibit 
increased contractility leading to the disruption of cellular junctions and increased 
permeability (63, 210). Importantly, while the importance of artery stiffness is already 
recognized clinically where is it used as a marker of morbidity and mortality, mounting 
evidence indicates that increased arterial stiffness precedes cardiovascular pathologies and 
contributes to their development (77, 140). Understanding the endothelial cell response to 
temporal stiffening of the subendothelial matrix, which occurs over the lifespan may 
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provide important insights into the development of a compromised endothelial barrier and 
the prevention of atherosclerosis (200).  
 
Within the vasculature, endothelial cells reside in a highly dynamic mechanical 
microenvironment. Because of their location, extracellular matrix cues, hemodynamic 
shear and pulsatile forces from blood flow, and cyclic strain from artery contraction and 
relaxation are integrated into endothelial cell responses (284). These cues can vary 
throughout the lifespan and based on location within the vasculature. Indeed, arterial 
compliance decreases with age  and hemodynamic forces are varied throughout the arterial 
tree (7, 285).  Endothelial cells exhibit an adaptive response to fluid shear stress that 
includes signaling cascades and cytoskeletal reorganization that can promote or protect 
against atherogenesis, suggesting that an adaptive response to other mechanical cues, 
namely subendothelial matrix stiffening that occurs with age, may be integral to 
atherogenesis (282, 286, 287). Current in vitro models to study the effects of matrix 
stiffness on endothelium integrity rely on static synthetic substrates, primarily 
polyacrylamide gels or micropillar arrays to modulate mechanics. The aim of this project 
was to employ a cell compatible hydrogel system that dynamically stiffened by radical 
crosslinking to investigate the presence of an adaptive endothelial cell response to temporal 
matrix stiffening and its effect on endothelial monolayer integrity.  
 
Initial stages of the project included synthesizing a methacrylated hyaluronic acid polymer 
and fabricating hydrogel substrates for endothelial monolayer cell studies. The hydrogel 
substrate mechanics before and after UV initiated radical crosslinking were characterized. 
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Gel fabrication parameters were optimized to achieve an initial gel stiffness that 
approximated the measured Young’s modulus for the healthy bovine subendothelial matrix 
and to maximize the covalent incorporation of an RGD cell-binding motif.  Cell viability 
and morphology studies before-and-after in situ substrate stiffening with a photoinitiator 
and UV light were then completed to validate the system. The project was discontinued 
after the deleterious effects of free radicals generated to stiffen the matrix by 
photocrosslinking could not be overcome and persisted with two different photoinitiators. 
 
Methods 
Methacyrlated hyaluronic acid synthesis 
Methacrylated hyaluronic acid (MeHA) polymer was synthesized as previously described 
(171, 262). A 1 wt% solution of sodium hyaluronate (51 kDa, Lifecore Biomedical, 
Chaska, MN) in DI water was reacted with methacrylic anhydride (Sigma-Aldrich, St. 
Louis, MO) at a ratio of 2. 4 mL methacrylic anhydride per gram of HA on ice at pH 8 for 
8 h. The reaction mixture was maintained at 4 °C overnight followed by the addition of 1.2 
mL of methacrylic anhydride per gram HA on ice at pH 8.0 for 4 h. The synthesized product 
was dialyzed against DI water (6−8 kDa MWCO, SpectraPor, Rancho Dominguez, CA) 
and lyophilized. The synthesized product was confirmed by 1H NMR (600 MHz Varian). 
 
Cell Culture  
Bovine aortic endothelial cells (VEC Technologies, Rensselaer, NY) from passages 7−12 
were used. Base Medium 199 (Invitrogen, Carlsbad, CA) was supplemented with 10% 
Fetal Clone III serum (HyClone, Logan, UT), 1% MEM amino acids (Invitrogen), 1% 
 101 
MEM vitamins (MedTech, Manassas, VA), and 1% penicillin−streptomycin (Invitrogen). 
Cells were maintained at 37 °C and 5% CO2 and passaged at confluence. 
 
MeHA Gel Fabrication  
MeHA hydrogels were synthesized as already described (171, 261). Briefly, 3% MeHA 
was dissolved in 0.2 M triethanolamine (Sigma Aldrich, St. Louis, MO) in PBS. A custom 
RGD peptide for cell attachment, GCGRGDSPG (Genscript, Piscataway, NJ) was added 
to the polymer solution at a final concentration of 1 mM and reacted for 45 min with 
continuous vortexing.  The triethanolamine buffer pH was optimized to increase the 
reaction of the RGD peptide with the polymer backbone. Gels were polymerized between 
a glutaraldehyde functionalized bottom glass coverslip and an untreated top coverglass by 
Michael-type addition using dithiothreitol (DTT) (Sigma-Aldrich, St. Louis, MO). 
Hydrogels were incubated overnight at room temperature in PBS prior to use or 
characterization. For cell studies, the gels were sterilized with a germicidal lamp for 30 
minutes followed by cell seeding. Control cell studies with a static substrate were 
conducted on coverglass coated with 0.1 mg/mL rat tail type I collagen (BD Biosciences, 
San Jose, CA). 
 
To dynamically stiffen the gels, polymerized hydrogels with endothelial cells grown to 
confluence were incubated in solutions of 0.05wt% Irgacure 2959 (BASF, Overland Park, 
KS) photoinitiator in M199 with supplements for 30 min at 37 °C. The gels were then 
individually exposed to 320−500 nm collimated UV light at an intensity of 10 mW/cm2 
using an Omnicure S1500 (Excelitas Technologies, Waltham, MA) (171). Gels were 
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immediately rinsed 3 times with PBS, followed by an additional media change 30 minutes 
after the reaction to remove any remaining photoinitiator or free radical products. For 
lithium acylphosphinate (LAP) studies, a 0.067 wt % working solution (2.2 mM) in M199 
with supplements was used. Gels were incubated with the photoinitiator solution in 
complete media for 30 min at 37 °C followed by exposure to 470 or 320-500 nm collimated 
UV light at an intensity of 10 mW/cm2 using the Omnicure S1500 (288). UV stiffened 
MeHA gels without cells were used for mechanical characterization studies.  
 
Steel Ball Mechanical Testing 
Preliminary measurements of hydrogel elastic moduli were measured using the steel ball 
method as described previously (289). Prior to polymerization, 0.5 µm polystyrene 
fluorescent beads (Invitrogen, Carlsbad, CA) were added to the gel solution. To measure 
hydrogel elastic modulus, steel balls (Abbott Ball Co., West Hartford, CT) with a radius of 
0.32 mm and a density of 7,200 kg/m3 were then dropped onto the gel surface. A LSM700 
microscope with a 10x objective was used to locate the fluorescent bead field at the gel 
surface directly beneath the ball and the z-height was recorded. A magnet was then used to 
remove the steel ball and the surface bead field was re-located. The ball indentation depth 
was calculated from the change in z-height between the two bead fields and the gel elastic 
modulus was extracted using the Hertz model for spherical contact where a buoyancy 
corrected weight of the steel ball and a hydrogel Poisson’s ratio of 0.5 was assumed. 
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Atomic Force Microscopy 
Hydrogel elastic moduli were measured using an Asylum MFP-3D (Asylum Research, 
Santa Barbara, CA) AFM in contact mode at random locations distributed throughout the 
gel. Force vs. indentation curves were acquired by indenting the gel surface with a 1.0 µm 
diameter spherical silicon dioxide particle on a silicon nitride cantilever with a 
manufacturer precalibrated spring constant of 0.06 N/m (Novascan Technologies, Ames, 
IA) and fit to the Hertz model (263). A Poisson’s ratio of 0.5  was assumed and the Young’s 
moduli were extracted using the Asylum software (264).  
 
Live/Dead Viability Assay 
Cell viability was assessed using a commercial Live/Dead Viability Assay according to the 
manufacturer recommended protocol (Invitrogen, Carlsbad, CA). Briefly, ethidium 
homodimer-1 and calcein AM stocks were combined in sterile PBS to final concentrations 
of 4 µM and 2 µM, respectively. Cells were washed twice with sterile PBS and incubated 
with the reagent solution for 30 minutes at 37 °C and 5% CO2. Cells were then rinsed with 
PBS and complete media, followed by immediate fluorescence imaging using a Zeiss Axio 
Observer.Z1m microscope. 
 
Statistics 
GraphPad Prism version 6.0d (La Jolla, CA) was used to conduct all statistical analysis. 
(ANOVA) with a Tukey’s Honestly Significant Difference (HSD) test was used to evaluate 
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statistical significance and significance was considered with a p-value <0.05. Data in 
graphical form are presented as the means ± standard error of the mean.   
 
Results 
The synthesis of methacrylated hyaluronic acid (MeHA) polymer was confirmed by 1H 
NMR characterization (Figure 4.1).  
 
 
Figure 4.1. Methacrylated hyaluronic acid synthesis and 1H NMR spectrum. (A) 
Methacrylated hyaluronic acid was synthesized and (B) confirmed by 1H NMR. Spectrum 
peaks correspond to MeHA polymer features indicated in (A): (1) methacrylate protons, 
and (2,3) free methyl protons. 
 
The synthesized polymer was then used to fabricate hydrogel substrates that were initially 
polymerized by a Michael-type addition reaction with dithiothreitol (DTT) followed by 
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sequential radical crosslinking in situ to increase the gel elastic modulus. Gel crosslinking 
occurred through methacrylate groups on the MeHA backbone, and thus, initial gel 
stiffness was modulated by varying the consumption of methacrylates by DTT. (Figure 
4.2). A gel with 13 mol% consumption of the available methacrylates that had a Young’s 
modulus of 2.2 ± 0.8 kPa was selected as the base gel for cell studies to match the reported 
value of 2.7 ± 1.1 kPa for the healthy bovine intima (172). 
 
Figure 4.2. Characterization of base MeHA hydrogel elastic modulus. MeHA hydrogel 
elastic modulus after Michael-type addition polymerization was measured using the steel 
ball method (289). Gel elastic modulus increased with increasing methacrylate 
crosslinking.   
 
To create a temporally stiffening substrate, base hydrogels were sequentially stiffened by 
free radical crosslinking using the photoinitiator I2959 and UV light. UV light cleaved the 
photoinitiator into two radical components that then reacted with remaining methacrylate 
groups on the polymer backbone to further crosslink the hydrogel. Hydrogel elastic moduli 
increased with radical crosslinking, and the stiffness increase was time dependent because 
free radical generation from the photoinitiator was dependent on the UV light exposure 
time. The substrates underwent step-wise stiffening when exposed to sequential doses of 
radical crosslinking treatments, and the final gel elastic modulus was equivalent to a single 
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UV exposure that matched the cumulative exposure time of the individual treatments 
(Figure 4.3).     
 
Figure 4.3. MeHA hydrogels exhibited step-wise sequential stiffening by radical 
crosslinking with the photoinitiator I2959.  Polymerized hydrogels were sequentially 
stiffened by free radical crosslinking using the photoinitiator I2959 and UV light. Gel 
stiffening increased with increasing UV light exposure and was cumulative over multiple 
stiffening sessions, ***p<0.001.  
 
Surface functionalization was necessary for cell adherence to the hydrogel surface because 
hyaluronic acid does not engage integrins; therefore, a custom synthesized RGD motif was 
covalently bound to the MeHA backbone prior to polymerization (290). Initial cells studies 
were constrained by minimal cell attachment to the hydrogel surface that precluded 
monolayer growth.  When equal seeding densities were used, tissue culture plastic (TCP) 
controls were confluent while cells on gels where the RGD reaction occurred at pH 9.4 
with 1 mM RGD had sparse, poorly spread cells (Figure 4.4 A, D). Increasing the 
concentration of RGD from 1 mM to 4 mM did not significantly increase cell attachment 
to the gel surface suggesting that RGD incorporation into the MeHA backbone and not the 
reactant concentration was limiting cell adherence (Figure 4.4).  
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Figure 4.4. Endothelial cell adhesion to the MeHA gels did not increase with 
increasing RGD concentration. Representative images of low endothelial cell adhesion 
to the MeHA gel surface that prevented monolayer growth. Increasing the RGD 
concentration in the gel from 1 to 4 mM while maintaining constant seeding densities did 
not increase cell binding. Control cells on tissue culture plastic controls (TCP) grew to 
confluence; scale bar = 20 µm. 
 
The Michael-type addition reaction to conjugate RGD onto the MeHA macromer is pH 
sensitive and favored under basic conditions; therefore, the reaction pH was varied between 
9.4 and 10.5 to select the reaction conditions that resulted in optimal RGD incorporation 
for monolayer studies (Figure 4.5) (170). A RGD binding reaction at pH 10.25 was 
determined to be optimal because it yielded a well spread cell morphology and sufficient 
cell adherence numbers without becoming overconfluent.   
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Figure 4.5. Covalent binding of RGD to the MeHA macromer and cell adhesion to the 
gel surface increased with increasing pH. Representative images of endothelial cells at 
equal seeding densities with increasing pH reaction conditions to incorporate the RGD cell 
binding peptide. Cell binding to the hydrogel surface increased with increasing pH and was 
maximal on tissue culture plastic (TCP) controls; scale bar = 40 µm.  
 
To assess the validity of the methacrylated hyaluronic acid hydrogel system as an in vitro 
method to study the endothelial cell response to temporal substrate stiffening in situ, 
endothelial cells were grown into confluent monolayers on control collagen coated 
coverglass substrates to determine viability under the radical crosslinking reaction 
conditions. The monolayers were incubated with I2959 photoinitiator and exposed in situ 
to 2 minutes of UV light, the equivalent reaction conditions to stiffen the MeHA substrates 
to ~5 kPa (Figure 4.3).  Cell health was assessed on the basis of a live/dead assay (Figure 
4.6). 
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Figure 4.6. Endothelial monolayers exhibited high viability to the radical crosslinking 
reaction conditions. Representative images of endothelial monolayer viability where 
green indicates live cells and red indicates dead cells. Media (A) and ethanol controls (B) 
had nearly 100% live or dead cells, respectively. Endothelial monolayers also had nearly 
100% viability after free radical generation with the photoinitiator I2959 and 2 min UV 
light exposure (C); scale bar = 20 µm. 
 
Notably, although cell viability was high after the UV treatments, cells adopted an 
elongated morphology on both stiffened MeHA gels and glass controls after just one 2 
minute stiffening treatment. An elongated cell morphology ocurred when the UV stiffening 
treatment was reduced to 1 minute. Cell elongation persisted on control glass substrates in 
A
B
C
DEADLIVE
Media Control 
LIVE DEAD
70% Ethanol
DEADLIVE
I2959 + 2 min UV
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the presence of the UV-activated photoinitiator. UV light alone, even with repeated 
exposure periods, did not induce cell morphological changes indicating the elongation was 
occurring in response to free radical generation and was not a cellular response to increased 
matrix stiffness (Figure 4.7). 
 
Figure 4.7. I2959 free radical species caused endothelial cell elongation. Representative 
images of endothelial monolayers on collagen coated coverglass after the radical stiffening 
reaction conditions. Endothelial cells elongated after free radicals were generated (A,B) 
but morphology was unchanged with UV light exposure alone (C) when compared to media 
controls (D); scale bar = 20 µm. 
 
Because radical generation was necessary for the in situ gel crosslinking, these data 
indicated that changes in cell-cell junction dynamics caused by increased matrix stiffness 
would not occur independently from junction reorganization caused by cell elongation in 
response to the stiffening process. In addition, the observed change in cell morphology 
suggested that other cellular processes were likely being affected, thereby limiting the 
utility of the system.  
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In an effort to mitigate the effects of free radical generation on the endothelial monolayers, 
delivering UV light in fractionated exposures was explored, where the both UV exposure 
time and recovery time between treatments were modulated. The maximum amount of UV 
exposure for which free radical generation did not cause endothelial cell morphological 
changes was determined to be 30 s. However, AFM mechanical testing of MeHA hydrogels 
after 8, 30 s UV stiffening sessions did not detect any measureable increase in gel stiffness, 
compared to the unstiffened control. These results suggest that a minimum threshold of 
UV exposure, greater than 30 s, is necessary to cause measureable gel stiffening and that 
the MeHA platform with I2959 photoinitiator was not suitable for in situ substrate 
stiffening because sufficient matrix stiffening could not be achieved without altering cell 
morphology.  
 
Because the free radicals generated from the I2959 photoinitiator under UV light were 
altering cell morphology, an alternative photoinitiator that had also been used with the 
MeHA gel system for radical in situ substrate stiffening was investigated. The 
photoinitiator lithium acylphosphinate (LAP) can be activated with 470 nm blue visible 
light which is reported to be less damaging to cells compared to lower wavelength UV 
light. Importantly, it was tolerated by primary hepatic stellate cells suggesting the system 
may also be tolerated by primary endothelial cells (288). A bandpass filter was used to 
isolate 470 nm wavelength light and control monolayers on glass coverslips were exposed 
to blue light to determine endothelial tolerability to this wavelength of light (Figure 4.8). 
A 5 minute exposure period was reported to be well tolerated by primary stellate hepatic 
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cells, but caused significant endothelial cell death (Figure 5.8A). Lower exposure times 
caused an elongated endothelial cell morphology, similar to what was observed with the 
I2959 photoinitiator (Figure 4.8B). Collectively, these data indicated that 470 nm 
wavelength light was damaging to endothelial cells.   
 
Figure 4.8. Visible blue light at 470 nm damaged endothelial cell monolayers. 
Endothelial monolayers exhibited (A) high cell death after 5 minutes of blue light exposure 
and (B) an elongated morphology at 2 minutes when compared to untreated media controls 
(C); scale bar = 50 µm. 
 
The 470 nm wavelength for LAP radical crosslinking was used in prior studies because the 
higher wavelength is less damaging to some cell types. Notably, the absorption spectra for 
LAP is greater at lower wavelengths when compared to 470 nm, and 320-500 nm light was 
well tolerated by endothelial monolayers in the prior I2959 experiments; therefore, the 
application of LAP for in situ stiffening at 365 nm was investigated (291). AFM 
mechanical characterization of MeHA gels stiffened by LAP initiated free-radical 
crosslinking yielded moderate stiffness increases with 1 min UV light exposure, and 
demonstrated that a step-wise increase in elastic modulus occurred with a second 1 min 
stiffness treatment (Figure 4.9).  
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Figure 4.9. MeHA hydrogels exhibited step-wise sequential stiffening by radical 
crosslinking with the photoinitiator LAP.  MeHA hydrogels were sequentially stiffened 
by free radical crosslinking using the photoinitiator LAP and 1 minute UV light exposure. 
Gel stiffening was cumulative over multiple stiffening sessions, ****p<0.0001. 
 
Under these same conditions on glass coverslips, control tests determined that consistent 
with the I2959 photoinitiator, the generation of free radical species caused an elongated 
endothelial cell morphology (Figure 4.10).  
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Figure 4.10. LAP free radical species caused endothelial cell elongation.  Endothelial 
monolayers on control coverglass exhibited an elongated morphology when in the presence 
of hydrogel stiffening reaction conditions that generated free radicals from LAP (A,B). 
Cell morphology was unchanged after UV exposure alone (C) when compared to untreated 
controls (D); scale bar = 20 µm.   
 
Because the conditions needed to achieve even very moderate in situ substrate stiffening 
by radical crosslinking were altering cell morphology, and more specifically, the free 
radicals from two different photoinitiators were damaging to endothelial cells, it was 
concluded that the usefulness of this in vitro model was limited and the project was not 
pursued further.  
 
Conclusion 
A significant limitation of current in vitro methods to study pathologies characterized by 
increased extracellular matrix stiffness is that static models are used to modulate 
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environmental stiffness. During events such as disease progression or natural aging, a 
compliant to stiff extracellular matrix transition occurs gradually (200, 292). The 
development of models that incorporate temporal changes in stiffness are important to 
understanding the basic biological mechanisms underlying the cellular response to 
increased extracellular matrix mechanics, and its role in driving the progression of 
pathological states. Scaffolds that utilize photo-polymerization are one promising approach 
to in vitro stiffening studies because the investigator can tightly tune the degree of spatial 
and temporal matrix crosslinking. However, as demonstrated here, the widespread 
application of photo-polymerization is limited because of cell-type specific 
biocompatibility (290). A potential method to improve the cyto-compatibility of photo-
crosslinking approaches that rely on free-radical generation is to include free radical 
scavengers, for example, the antioxidant vitamin C, to consume excess radicals and prevent 
off-target cell damage  (293, 294).  
 
An alternative in vitro approach to studying the temporal effects of matrix stiffening is the 
use of substrates that soften over time through hydrolytic, proteolytic, or photocleaved 
matrix crosslink degradation (170, 295–297). Bioresponsive hydrogels are another 
platform that could be employed for adaptive cell studies (298). Although these substrates 
are less relevant as a disease progression model for atherogenesis or other pathologies 
characterized by matrix stiffening, they still provide important biological insights on cell 
priming and stiffness adaptive behaviors. Stellate stem cells with a myofibroblast 
phenotype exhibited phenotypic regression as their matrix softened (170).   
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A primary cause of age-related arterial stiffening is increased matrix crosslinking caused 
by the accumulation of advanced glycation end products (AGEs) over the lifespan (299); 
therefore, therapeutics that break AGEs have been pursued as one method to overcome 
arterial stiffening (131). Despite multiple candidate compounds, there are currently no 
products for which clinical trials were successfully completed. Softening substrates present 
a proof-of-concept method to validate that endothelial cells respond to matrix softening 
and that an AGE-breaking treatment could improve endothelium barrier integrity. In 
addition, significant crosstalk between cellular pathways that are altered by matrix 
softening and stiffening likely exist, albeit in opposite directions. Therefore, understanding 
the effects of matrix softening, could contribute to the identification of alternative targets 
to overcome the deleterious effects of matrix stiffening.   
 
4.2 Effects of Local Aberrant Cell Contractility on Global Endothelial Monolayer 
Integrity 
Motivation 
Cell-cell adhesions in confluent endothelial monolayers undergo dramatic reorganization 
in response to external mechanical and pharmacological stimuli that have important 
implications for endothelium integrity (149, 153, 160, 272). However, adherens junctions 
do not exist in a quiescent state in the absence of these exogenous cues (300). VE-cadherin 
binds to the actin cytoskeleton through the cadherin-catenin complex, and RhoA mediated 
cell contractility generates a tensional force at cell-cell adhesions (155). Cadherin 
adhesions are strengthened under force, and junctional tension contributes to 
conformational changes in adaptor proteins as well as their recruitment (191, 194, 196). 
The clustering, lateral diffusion, and disassociation of VE-cadherin within junctional zones 
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is an ongoing dynamic process, and transient junction associated lamellipodia (JAIL) are 
present during active remodeling in mature endothelial monolayers (159, 301). Notably, 
force is transmitted across adherens junctions and can alter collective cell behaviors, 
including migration and global monolayer barrier integrity (189, 193, 302).  
 
Endothelial junction integrity requires a balance between cell-cell and cell-matrix 
adhesions that are connected by intracellular cytoskeletal networks (183, 195). Under both 
basal and elevated contractility states, cells exert myosin dependent tensional forces across 
cadherin junctions that are proportional to the traction forces they exert against their matrix 
(188). RhoA activation from matrix cues, for example, increased stiffness, is one pathway 
that increases both traction stresses and tensional force across VE-cadherin junctions (187, 
188). Pathological states that alter extracellular matrix stiffness; therefore, also likely alter 
cell-cell junction tension.  
 
Arterial stiffness increases with both age and atherosclerosis. Importantly, the 
characterization of the aged murine arterial intima revealed that in addition to an overall 
increase in Young’s modulus, an increase in stiffness heterogeneity existed when compared 
to young controls.  Intima stiffness increased by as much as 50-fold within a 100 by 100 
µm area (122). These data suggest that within the physiological arterial niche, matrix 
stiffness “hotspots” may result in individual endothelial cells that have a hyper contractile 
profile from localized RhoA activation. It has already been reported that traction forces are 
non-uniformly distributed within endothelial monolayers, and that inter-endothelial gaps 
are more numerous in regions of high force fluctuation (275). Therefore, endothelial cells 
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with aberrant contractility profiles may further explain how the mechanical properties of 
the aged arterial intima contribute to atherogenesis. And because excess force across VE-
cadherin disrupts distant cell adhesions, the deleterious effects of localized hyper 
contractility may be propagated across a monolayer (189).  
 
Here, I used endothelial monolayers and microinjection as a minimal model to investigate 
how the effects of an individual cell with increased contractility is propagated into a 
monolayer response through force transmission across VE-cadherin junctions.  
 
Methods 
Cell Culture  
Bovine aortic endothelial cells (VEC Technologies, Rensselaer, NY) from passages 7−12 
were cultured in Medium 199 (Invitrogen, Carlsbad, CA) supplemented with 10% Fetal 
Clone III serum (HyClone, Logan, UT), 1% MEM amino acids (Invitrogen), 1% MEM 
vitamins (MedTech, Manassas, VA), and 1% penicillin−streptomycin (Invitrogen) at 37 
°C and 5% CO2. For microinjection studies, cells were seeded onto 0.1 mg/mL rat tail type 
I collagen coated coverglass and grown to confluence.  
 
Microinjection 
A FemtoJet injector equipped with an Injectman NI2 microinjector (Eppendorf, 
Hauppauge, NY) and mounted on a Zeiss LSM700 microscope with an environmental 
chamber was used to deliver sub-microliter volumes of material to endothelial cells without 
disrupting the internal cellular environment. Endothelial morphology was assessed 
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immediately after microinjection and also at 3 hours post-injection for signs of cell damage. 
Injection needles were fabricated from filamented glass capillaries with a 1.00 mm outer 
diameter and a 0.50 mm inner diameter (Sutter Instrument, Novato, CA) using a P-97 
micropipette puller (Sutter Instrument, Novato, CA). Cells were injected with Rho 
Activator II (Cytoskeleton, Denver, CO) at a final concentration of 100 µg/mL in PBS 
(Invitrogen). Cells were co-injected with a lysine fixable 10,000 MW Alexa Fluor 488 
dextran (Invitrogen) at a final concentration of 1 mg/mL for identification. Control cells 
were injected with the 488 dextran in PBS only. To account for the effects of RhoA 
activator that leaked out of the injection needles into the culture media while approaching 
the cell monolayer due to back pressure, after injecting control cells, a microinjection 
needle filled with RhoA activator at the treatment concentration was hovered over the 
injected control cells for ~30 seconds. After microinjection, samples were rinsed twice and 
placed in fresh culture media. All assays were conducted 3 hours post-injection. 
 
Actin Visualization 
Endothelial monolayers were fixed with 3.7 % formaldehyde (VWR) and permeabilized 
using 1% triton (J.T. Baker, Center Valley, PA), followed by incubation with Alexa Fluor 
phalloidin 568 (Invitrogen) to visualize actin structures. Samples were imaged using a 
Zeiss LSM700 microscope equipped with a 40x water immersion objective. 
 
Localized Permeability Assay 
Localized junction permeability was assessed as described by Dubrovskyi et al. (303). 
Briefly, biotinylated gelatin was synthesized by dissolving porcine gelatin (Sigma, St. 
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Louis, MO) at 10 mg/mL in 0.1 mol/L NaHCO3 (VWR), pH 8.3 in a 70 ºC water bath. The 
gelatin solution was then clarified by centrifugation at 10,000 x g for 5 minutes at room 
temperature. EZ-Link NHS-LC-LC-Biotin (Thermo Scientific, Rockford, IL) was 
dissolved in DMSO (VWR) at a final concentration of 0.57 mg/mL and added 1:10 to the 
clarified gelatin solution. The biotin-gelatin conjugation reaction was allowed to proceed 
at room temperature for 1 hour with constant stirring. The product was then aliquoted and 
stored at -20 ºC. For cell experiments, the biotinylated gelatin was diluted to 0.25 mg/mL 
in NaHCO3, pH 8.3 and activated coverglass was coated with the protein. To measure 
localized permeability, samples were incubated in culture media containing 25 µg/mL 
Alexa Fluor 568 streptavidin for 5 minutes, followed by two rinses with PBS (Invitrogen), 
and immediate fixation with 3.7 % formaldehyde in PBS. Samples were imaged using a 
Zeiss LSM700 microscope equipped with a 20x objective and permeability was evaluated 
by quantifying the Alexa Fluor 568 signal using ImageJ software.  
 
Cell-Cell Junction Size Quantification 
Cell-cell junction size was quantified by measuring the width of VE-cadherin signals in 
endothelial monolayers, as described previously (63, 258). Samples were fixed with 3.7 % 
formaldehyde (VWR) and permeabilized using 1% triton (J.T. Baker) in PBS (Invitrogen). 
VE-cadherin at cell junctions was visualized by incubating with a goat polyclonal VE-
cadherin primary antibody (Santa Cruz Biotechnology, Dallas, TX) followed by incubation 
with an Alexa Fluor 568 donkey antigoat secondary antibody (Invitrogen). Fluorescent 
images of the target cell and surrounding monolayer were acquired on a Zeiss Axio 
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Observer.Z1m microscope equipped with a Hamamatsu ORCA-ER camera using a 20x 
objective. 
 
Cells surrounding the microinjected cell were categorized on the basis on their proximity 
the target cell. Cells sharing a junction with the microinjected cell were categorized as 
“Layer 1” cells, cells sharing a junction with “Layer 1” cells were categorized as “Layer 
2,” and cells sharing a junction with “Layer 2” cells were categorized as “Layer 3” cells. 
The size of cell-cell junctions were quantified using ImageJ software and a custom MatLab 
code. All junctions for the cells in each layer were measured at their widest point by 
drawing a line perpendicular to the VE-cadherin junction signal and a pixel intensity profile 
was obtained in ImageJ (National Institutes of Health, Bethesda, MD). The pixel intensity 
profiles were fit to a two-Gaussian curve and the junction size was defined as the width of 
the curve 20% above the baseline intensity.  
 
Statistics 
All images are representative of 3 independent experiments and ANOVA statistical 
analysis with a Tukey’s Honestly Significant Difference (HSD) test was performed in 
GraphPad Prism version 6.0d (La Jolla, CA) were significance was considered with a p-
value <0.05. Data is presented as the mean ± standard error of the mean, 
 
Results 
To modulate single cell contractility within an endothelial monolayer, bovine aortic 
endothelial cells were cultured to confluence on 0.1 mg/mL collagen coated coverglass and 
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individual cells within the monolayer were co-microinjected with a recombinant protein 
RhoA activator and a fluorescent lysine fixable dextran in PBS. Control cells were injected 
with the lysine fixable dextran in PBS only, and successful injections were identified on 
the basis of the fluorescence signal of the injected cells. Increased stress fiber formation in 
cells microinjected with the RhoA activator compared to surrounding cells within the 
monolayer were indicative of an increased contractile state (Figure 4.11). 
 
Figure 4.11. Microinjection of a RhoA activator increased stress fiber formation in 
the target cell. Individual cells within endothelial monolayers were co-microinjected with 
a RhoA activator and an Alexa Fluor 488 dextran. (A) Microinjected cells were identified 
using the Alexa Fluor 488 signal and (B) actin stress fibers were visualized using 
phalloidin. The microinjected cell (white arrowhead) exhibited increased stress fiber 
formation compared to surrounding cells within the monolayer; scale bar = 50 µm. 
  
Force transmission across VE-cadherin has been shown to cause monolayer disruption 
distant from the applied force, and increased RhoA activation increases cell-cell junction 
tension; therefore, the effect of an individual cell exhibiting increased contractility on 
localized monolayer integrity was investigated. Local endothelial monolayer permeability 
was measured using a biotin-streptavidin permeability assay. Because of the strength and 
specificity of biotin-streptavidin interactions, fluorescently tagged streptavidin that 
diffuses across the monolayer binds nearly irreversibly to a biotinylated substrate below 
the monolayer, and the fluorescent signal in an indicator of local permeability. To validate 
the assay, endothelial monolayers were treated with thrombin, a well known endothelial 
A B ActinAlexa	Fluor	488
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barrier disruptive agonist that activates RhoA. Thrombin treatment monolayers had 
significantly higher fluorescent streptavidin signals compared to untreated control 
monolayers indicating increased permeability (Figure 4.12). No permeability signal was 
detected in negative controls cultured without a biotinylated substrate nor controls on a 
biotinylated substrate that were not incubated with streptavidin.  
 
Figure 4.12. Localized endothelial monolayer permeability was measured using 
streptavidin immobilization to biotin beneath the endothelial monolayer.  (A) Actin 
stress fiber formation was visualized in control and thrombin treated endothelial cells, and 
the signal from streptavidin that had diffused across the monolayer and bound to biotin was 
used to measure permeability. Monolayer permeability was increased in thrombin treated 
cells when the overall streptavidin area percentage (B) and the size of individual 
streptavidin signals (C) were compared between control and thrombin treated cells, 
**indicates p<0.01, **indicates p<0.001. Data are presented as means ± standard error of 
the mean; scale bar = 50 µm. 
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Individual cells within monolayers were then co-injected with RhoA activator and a green 
fluorescent dextran. Local monolayer permeability surrounding the hyper contractile 
(green) cell was measured (Figure 4.13A). Permeability was measured as a function of the 
radial distance from the contractile cell to determine if contractile force propagation across 
VE-cadherin was causing areas of increased monolayer permeability (Figure 4.13B).  
 
Figure 4.13. Local endothelial monolayer permeability surrounding microinjected 
cells was measured. (A) Isolated cells within endothelial monolayers were co-
microinjected with Alexa Fluor 488 and RhoA activator or Alexa Fluor 488 alone, and 
permeability was evaluated. (B) Monolayer permeability was analyzed as a function of 
radial distance from the microinjected cells where the diameter of the measurement circle 
increased by 25 µm in each increment. (C) There was no statistical difference in localized 
permeability in monolayers surrounding control and RhoA activator injected cells. Data 
are presented as means ± standard error of the mean; scale bar = 50 µm. 
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Permeability profiles between monolayers with RhoA activator and control injected cells 
were not significantly different, indicating that under the injection conditions and analysis 
metrics used, localized contractility did not increase endothelium permeability.  
 
To further investigate the effects of localized increased cell contractility and force 
propagation across VE-cadherin on endothelium integrity, cell-cell junctions between cells 
surrounding RhoA activator microinjected cells were measured. Previous studies have 
established that increased cell-cell junction size correlates with increased endothelium 
permeability (63, 258). Monolayers containing isolated microinjected cells were stained to 
visualize VE-cadherin and the width of the VE-cadherin signal between adjacent cells was 
quantified. Monolayer cells surrounding the microinjected cell were divided into groups 
on the basis of their relative distance from the cell with increased contractility to investigate 
the propagation of contractile effects. The cells that shared a junction with the 
microinjected cell were categorized as “Layer 1,” the cells that shared a junction with 
“Layer 1” cells were “Layer 2,” and cells that shared a junction with “Layer 2” cells were 
categorized as “Layer 3” cells (Figure 4.14).  
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Figure 4.14. Endothelial monolayers were microinjected and VE-cadherin was 
visualized to measure cell-cell junctions. (A) Endothelial monolayers were co-injected 
with Alexa Fluor 488 and RhoA activator or Alexa Fluor 488 alone, and cell nuclei and 
cell-cell junctions were visualized with DAPI and VE-cadherin, respectively. (B) 
Monolayer cells were divided into three cell layer categorizes on the basis of the proximity 
of their nearest junction to the microinjected cell. Data are presented as means ± standard 
error of the mean; scale bar = 50 µm. 
 
There was no statistical difference in junction size between the different cell layers (Figure 
4.15A). The distributions of cell-cell junction sizes between cell layers were also 
investigated to determine if there was an increased prevalence of larger junction sizes 
within a certain layer (Figure 4.15B). Consistent with the mean junction sizes, all groups 
had similar junction size distribution profiles.  
Alexa	Fluor	488 DAPI VE-Cadherin
1 2
3
Alexa	Fluor	488 DAPI VE-CadherinA
B
 127 
 
Figure 4.15. Endothelial cell-cell junction size was measured surrounding 
microinjected cells. (A) Cell-cell junction size was not statistically different in monolayers 
injected with RhoA activator or control. Cell-cell junction size was also not statistically 
different between cells adjacent to microinjected cells and those that did not directly share 
a cell border with the injected cell. (B) The distribution of cell-cell junction sizes was 
unchanged between monolayers with control and microinjected cells, and was also 
unchanged with respect to proximity to the microinjected cell. Larger junction sizes did 
not occur with greater frequency between the treatment and control monolayers, nor with 
respect to the proximity to the microinjected cell. Data are presented as means ± standard 
error of the mean. 
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Conclusion 
Direct force application to VE-cadherin and force transmission across endothelial junctions 
have been shown to cause global endothelial monolayer disruption (189). However, in the 
present study, using microinjection to locally increase cell contractility and tensional forces 
across cell-cell junctions, no change in monolayer integrity was measured. Differences in 
the approaches to apply a force across VE-cadherin may explain the incongruity among the 
two studies. Direct force application to VE-cadherin by Barry et al. was achieved using 
magnetic twisting cytometry to apply an oscillatory shear stress that increased from 0.036 
to 9 Pa. However, tension between cell-cell adhesions is not oscillatory under increased 
contractile conditions, as studied here, and the measured cell-cell force is on the order of 
nanonewtons for an entire adhesion when RhoA is constitutively active (188). The 
measured tension across an individual VE-cadherin molecule is 2.4 nN/molecule under 
basal conditions (300). In addition, force fluctuations are associated with increased inter-
endothelial gap formation, suggesting that both the magnitude of the applied force and the 
method of application may have attributed to the results reported by Barry and colleagues 
(275).  
 
The data discussed here indicate that an increase in cell contractility from the injected 
RhoA activator were insufficient to cause significant force changes across cell-cell 
junctions and elicit global monolayer effects.  A suggested future study to investigate the 
effects of an isolated hyper contractile cell within an endothelial monolayer, such as what 
could occur from a hotspot of increased extracellular matrix stiffness, is to directly measure 
VE-cadherin tension using a FRET sensor (300). Incorporating this technique into the 
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current microinjection approach would allow the investigator to verify that the level of 
microinjected RhoA activator significantly increased cell-cell junction forces. In addition, 
a quantitative assessment of force propagation could be analyzed in concert with localized 
permeability data.  
 
Another interesting future study is to investigate the effects of VE-cadherin force 
propagation on matrices of decreasing compliance. Because cells within a monolayer exert 
forces at both cell-cell and cell-ECM adhesions, this study would determine to what extent 
aberrant contractile forces are dissipated or strengthened at ECM and/or intercellular 
contacts. Forces exerted at focal adhesions could be measured with FRET based tension 
sensors developed for vinculin, talin, and integrin proteins (165, 304, 305). Although study 
complexity is increased with the introduction of matrix stiffness, physiological relevance 
it also increased. The effects of increased RhoA activation also have the potential to elicit 
a more robust response on compliant matrices because RhoA activation exists is in an 
elevated basal state on glass substrates (258). Important clinical insights into the underlying 
mechanisms and the role of cellular forces that contribute to endothelial permeability 
caused by the mechanical properties of the aged arterial intima would be gained from these 
studies. 
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CHAPTER 5 
       
THERAPEUTICALLY TARGETING INCREASED EXTRACELLULAR MATRIX 
MECHANICS TO ATTENUATE DISEASE: FROM MOLECULAR TARGETS TO 
CLINICAL TRIALS 
 
5.1 Abstract 
Tissue stiffening manifests during the pathological progression of cancer, fibrosis, and 
cardiovascular disease, and also during aging. Importantly, extracellular matrix stiffness is 
emerging as a prominent mechanical cue that precedes disease and drives it progression by 
altering cellular behaviors. As such, targeting mechanics, by preventing or reversing tissue 
stiffening, or interrupting the cellular response, is a novel therapeutic approach with 
important clinical potential. The contributions of phenotypically converted myofibroblasts, 
the growth factor TGFβ, and crosslinking to extracellular matrix stiffening are described. 
Potential pharmacological interventions to overcome extracellular matrix stiffening are 
then discussed with an emphasis on clinical translation. An alternative approach to mitigate 
the effects of increased matrix stiffness by identifying cellular targets to inhibit the 
deleterious response to matrix mechanical cues is also reviewed. Therapeutic interventions 
for each target are discussed in the context of their limitations, pre-clinical drug 
development efforts, and clinical trials.   
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5.2 Introduction  
Increased tissue stiffness is associated with a diverse array of pathologies including the two 
leading causes of death in the United States: cancer and cardiovascular disease (306, 307). 
Decreased extracellular matrix (ECM) compliance also occurs with fibrosis, advanced age, 
and diabetes (308, 309). With the expansion of the mechano-biology field over the past 
decade, integrating techniques and results across the engineering and biological 
landscapes, our understanding of the contributions of increased ECM stiffness on disease 
has vastly increased. Although it is well established that changes in tissue mechanics are 
hallmarks of specific pathological states, more recently, it has become apparent that tissue 
stiffening can precede disease development and that mechanical cues can drive its 
progression (249, 310). As such, mechano-medicine is an emerging field focused on 
therapeutically targeting mechanics, either by directly altering the mechanical cues 
presented to cells or disrupting the cellular response to mechanics.  
 
The extracellular matrix (ECM) is a cell secreted network that surrounds cells and is 
primarily composed of proteoglycans and fibrous proteins, the most abundant being 
collagen. In addition to providing structural support, the ECM imparts important 
biochemical and mechanical cues to maintain tissue homeostasis (311). The mechanical 
stiffness of healthy tissues is tightly controlled and exists on a continuum ranging from 200 
Pa within the breast to 20 GPa for cortical bone (292, 312). Importantly, tissue stiffness 
can regulate cell behavior and aberrant stiffening is associated with pathological states 
(313). Increased ECM stiffness elicits a diversity of adverse cellular responses by 
activating integrin-mediated signaling cascades (314).  
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Because aberrant ECM mechanical properties play a critical role in numerous pathologies, 
mechano-medicine, is a novel therapeutic approach to treat disease with important clinical 
implications. Mechanisms that cause ECM stiffening during natural aging and pathological 
progression are first discussed. Therapeutic approaches to prevent or reverse matrix 
stiffening, including their clinical relevance, are then reviewed. Potential cellular targets to 
disrupt the response to increased matrix mechanics are then identified, and their drug 
development efforts are described. Finally, translational potential is discussed in the 
context of available drugs, pre-clinical studies, and clinical trials.  
 
5.3 Targeting Tissue Stiffening to Limit Pathological Progression 
5.3.1 Extracellular matrix deposition 
Myofibroblasts 
A major cause of increased ECM stiffness during cancer and fibrotic diseases is the 
deposition of extracellular matrix by quiescent resident cells that have undergone epithelial 
to mesenchymal transition (EMT) to myofibroblasts (Figure 5.1). These dedifferentiated 
myofibroblast are proliferative, highly contractile, and secrete large amounts of matrix. 
Interestingly, myofibroblasts originate from different precursor cells depending on the 
pathology, and can be derived from multiple cell sources including bone marrow and 
immune cells (315). A significant shortfall in our knowledge is a comprehensive 
understanding of myofibroblast origins and the respective contributions of resident and  
 133 
 
Figure 5.1. Schematic of a cell within a stiffened ECM microenvironment. (A) Matrix 
crosslinking by LOX (squares) TG2 (diamonds) and AGEs (pentagons) in concert with 
increased matrix deposition (dashed lines) are major contributors of pathological matrix 
stiffening. Inside-out and outside-in ECM rigidity sensing is transmitted across cell 
adhesions composed of integrins and focal adhesion complexes. (B) Actomyosin cell 
contractility forces are increased in response to elevated matrix stiffness and traction forces 
are exerted against the ECM. Cellular force is also propagated across the cell cytoplasm to 
the nucleus. (C) Stiffness-mediated traction forces transmitted across integrins cause a 
conformational change in the TGFβ latency complex to release TGFβ ligand and activate 
positive feedback cycles of ECM synthesis and stiffening.  
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infiltrating cells during fibrosis. Although alpha smooth muscle actin (α-SMA) expression 
is commonly used as a myofibroblast molecular marker, not all cells expressing α-SMA 
are myofibroblasts, and α-SMA negative cells also exhibit myofibroblast behaviors (316). 
The diversity of myofibroblast precursor cells and a lack of a molecular identifier make 
them a difficult therapeutic target to prevent ECM deposition. 
 
Growth factors 
Common among myofibroblast driven pathologies is the prominent role of the growth 
factor TGFβ which is aberrantly overexpressed. TGFβ promotes myofibroblast 
differentiation, cell proliferation, and matrix production. Briefly, extracellular TGFβ ligand 
binds to its serine/threonine kinase receptor (TGFβR1) and activates canonical SMAD 
pathways that induce collagen and fibronectin gene expression (317). Simultaneously, 
TGFβ signaling inhibits matrix metalloproteinase (MMP) matrix degradation by inducing 
the expression of tissue inhibitors of matrix metalloproteinases (TIMPs) to drive 
microenvironment stiffening (318). Notably, cells exert increased contractile pulling forces 
against their matrix in response to elevated matrix stiffness which activates a vicious feed 
forward cycle of matrix production by releasing sequestered TGFβ from the matrix through 
mechanical force (319, 320). Both increased stiffness and TGFβ1 activity are found at the 
active front of invasive tumors, and TGFβ inhibition decreases fibrotic progression (321, 
322). 
 
Because of their dominant role stimulating proliferation and ECM production, growth 
factor therapies, especially those targeted against TGFβ, are a promising avenue to inhibit 
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pathological cycles of ECM synthesis. Targeting TGFβ is an active area of research for 
fibrosis and cancer applications, and therapeutics are in development stages ranging from 
in vitro pre-clinical studies to Phase III clinical trials (322). Disrupting the pathological 
role of TGFβ has been approached from multiple angles including inhibiting receptor-
ligand interactions, tyrosine kinase activity, and protein synthesis. These efforts have 
utilized peptides, antisense oligonucleotides, small molecule inhibitors, and monoclonal 
antibodies (322). Exploiting the off-target effects of tyrosine kinase inhibitors that have 
already been FDA approved for other applications has also been pursued to accelerate small 
molecule therapies for anti-fibrotic applications (323). (See Akhurst and Hata (322) for a 
review on TGFβ inhibitory drugs and their clinical translation.) Importantly, because of the 
central role of TGFβ in propagating fibrosis, once developed, therapeutics can have 
widespread applications across organ specific diseases. For example, the small molecule 
Pirfenidone is a breakthrough drug that inhibits TGFβ pathways and was FDA approved 
in 2014 to treat idiopathic lung fibrosis (324). Pirfenidone is now in clinical trials to 
improve patient outcomes in cancer (NCT00020631), kidney fibrosis (NCT02408744, 
NCT00001959), and systemic sclerosis (NCT01933334, NCT03068234). Fresolimumab 
(GC1008) is a monoclonal antibody against TGFβ that is also being actively pursued in 
numerous clinical trials for its anti-fibrotic effects in cancer (NCT01401062, 
NCT02581787), kidney sclerosis (NCT00464321), and systemic sclerosis 
(NCT01284322). 
 
Other growth factors such as PDGF and VEGF also contribute to fibrotic development, 
and similar to TGFβ, are potential therapeutic targets (325, 326). PDGF is of particular 
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interest because it stimulates vascular smooth muscle cell migration and proliferation 
during atherogenesis (325). A challenge with therapeutically targeting growth factor-
mediated ECM synthesis is that the ECM imparts tissue integrity, and regulating 
extracellular matrix turnover is one of many downstream growth factor signaling 
outcomes. Indeed, despite its identification as the key regulator of fibrosis, the pleiotropic 
effects of TGFβ impose significant challenges to its therapeutic targeting. During cancer, 
TGFβ can have both pro- and anti-tumorigenic effects, and TGFβ is important for 
inflammatory regulation (322). Paradoxical roles for growth factors underscore the 
challenges of using them as therapeutic targets and highlight a necessary role for spatial 
and temporal control in drug administration.  
 
Aptamers may represent the future for targeted therapeutics, including growth factor 
inhibition. Although conceptually similar to antibody approaches, as synthetic 
oligonucleotides, aptamers are advantageous because they are produced without animal 
intermediates, and can be designed to engage in distinct, location specific protein 
interactions with tailored pharmacokinetics (327). With continued contributions from next 
generation sequencing and bioinformatics, improved selection methods, and lower costs, 
it is anticipated that aptamers can fill a critical therapeutic niche (328). Currently, Macugen 
(Pfizer), which targets VEGF-165 to inhibit angiogenesis related to macular degeneration 
is the only aptamer on the market, but nevertheless, demonstrates the successful translation 
of aptamer technology to the clinic for effective, isoform specific, growth factor targeting 
(329).  
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Because cells respond to the mechanical cues of their microenvironment and a dense ECM 
inhibits the delivery of therapeutics, interventions that rely on disrupting fibrotic cascades 
are likely to be most effective during the earliest stages of disease before irreversible 
changes to ECM rigidity have occurred. Therefore, the success of these interventions will 
also rely on the development of new technologies that contribute to early disease detection.   
 
A unifying thread in the approaches to inhibit ECM deposition is that they target cells after 
they have undergone a pathological phenotypic switch. While the contribution of the ECM 
in promoting cancer malignancy, atherogenesis, and fibrosis is becoming increasingly 
appreciated, an ongoing area of investigation is understanding the mechanisms that drive 
quiescent cells to adopt a myofibroblast state. Genetic, gender, and age predispositions may 
cause the myofibroblast conversion (330). Notably, matrix stiffness may also contribute to 
myofibroblast phenotypes. Similar gene expression profiles are observed between cells 
originating from dense breast tissue and the tumor stroma (331). These data provide 
evidence that phenotypic modulation is more complex than cytokine and growth factor 
crosstalk. Further implicating mechanics as a driving factor in the development of 
myofibroblasts is evidence that stiffening precedes fibrosis and hypertension, that 
proliferation and migration increase with increased matrix stiffness, and that EMT and 
TGFβ stimulation are matrix stiffness dependent (140, 332–334). Denser tissues from 
genetic predisposition, aging, or diabetic complications may prime cells towards fibrotic 
phenotypes. If matrix stiffness is a driving factor that causes an even stiffer ECM, then 
what are the initial mechanisms contributing to pre-pathological increases in matrix 
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rigidity? As these pathways become unveiled, it is anticipated that new therapeutic targets 
will also be identified to interrupt matrix stiffening at earlier stages of disease development.   
 
5.3.2 Extracellular matrix crosslinking 
In concert with increased extracellular matrix deposition, increased crosslinking is also a 
major contributor to tissue stiffening. Collagen and elastin have low turnover rates, and 
covalent crosslinks by advanced glycation end products (AGEs) that occur from a reaction 
between reducing sugars and matrix proteins accumulate over the lifespan (200). 
Hyperglycemic diabetic individuals have increased susceptibility to glycation, and 
therefore, experience accelerated tissue crosslinking (308). Dysregulated enzymatic 
crosslinking of matrix components also contributes to stiffening. Lysyl oxidase and tissue 
transglutaminase (TG2) are implicated in these processes during cancer, fibrotic 
progression, and age-related arterial stiffening (335, 336). Importantly, covalent 
crosslinking induces irreversible changes in matrix stiffness and prevents tissue regression 
back to a compliant state (337).  
 
Breaking or preventing ECM crosslinks is an attractive therapeutic approach to stall, 
reverse, or even prevent pathologies that are in-part, driven by increased matrix stiffness, 
and appear promising on the basis of reports that hepatic stellate cells respond to both the 
mechanical stiffening and softening of their extracellular matrix in situ (170).  
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Advanced Glycation End Products (AGEs) 
Despite initial indications of clinical potential, there are no glycation-related therapeutics 
on the market. The pioneering AGE breaker alagebrium and the AGE inhibitor, 
aminoguanidine, had contradictory clinical trial results and ultimately, toxicity risks 
removed them from consideration for therapeutic use (338). Other therapeutics to break or 
inhibit glycation crosslinks have been investigated and are reviewed extensively elsewhere, 
but remarkably, despite a diverse range of candidate compounds, limited clinical success 
has been achieved (338). Repeatedly, in vitro results are not replicated in vivo. Progress is 
hindered by poorly defined mechanisms of target compounds and the widespread use of 
BSA as a model protein that does not capture the diversity of glycation crosslinks found in 
vivo. Synthetic AGE-BSA compounds produced in vitro behave differently than native 
AGEs and do not represent the varied kinetics between BSA, collagen, and elastin 
substrates (339, 340). Additionally, toxicity and low efficacy are common outcomes of 
clinical trials indicating that AGE therapeutics with increased specificity need to be 
designed.  
 
As previously highlighted, aptamers are an emerging therapeutic technology, and 
preliminary studies suggest they are also effective at ameliorating the deleterious effects of 
AGEs (341). Aptamer therapy prevented increases in serum AGE levels in an animal model 
of diabetes (342). Importantly, long term administration was well tolerated, suggesting that 
aptamer translation to clinical use will not be hindered by the same toxicological limitations 
of small molecule AGE inhibitors and breakers. In light of the challenges to develop drugs 
against glycation, diet adjustments that significantly reduce circulating AGE levels and 
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evidence that exercise reduces AGE crosslinking in tissues should also be emphasized for 
their therapeutic potential and ease of implementation (343, 344).  
 
Lysyl oxidase (LOX) 
Lysyl oxidase and TG2 are cell produced proteins; therefore, enzymatic crosslinking can 
be targeted at the transcriptional, post-translational, and catalytic levels. An ongoing 
pursuit is understanding the paradoxical outcomes of LOX activity, and the specific 
contexts in which it can be pro- or anti-pathogenic (345). Increasingly, LOX is considered 
as a therapeutic target because of its dual role in the formation of the tumor stroma and the 
pre-metastatic niche, in addition to its deleterious activity during fibrosis and 
atherosclerosis. The effectiveness of inhibiting LOX crosslinking to reduce extracellular 
matrix stiffness and improve pathological outcomes has been well established using the 
competitive inhibitor B-aminopropionitrile (BAPN). BAPN inhibition of LOX decreased 
aortic stiffness and atherosclerotic plaque burden, attenuated tumor stroma stiffness and 
reduced metastasis, inhibited liver fibrosis and promoted its reversal, decreased lung 
fibrosis, and prevented renal fibrosis (142, 346–348). Although BAPN is a valuable 
research tool and validates LOX as a clinical target to prevent pathological progression 
caused by matrix crosslinking, high toxicity during clinical trials preclude its clinical use 
(349). 
 
Monoclonal antibody inhibition of lysyl oxidase-like 2 (LOXL2) was pursued by Gilead 
Sciences with Simtuzumab, but the culmination of Phase II clinical trials during late 2016 
revealed no benefit for cancer and fibrotic disease patients (350, 351). A sizeable challenge 
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in the race to create effective LOX inhibitors is that the complete crystal structure, which 
is typically used to guide small molecule development pipelines, remains unknown for 
mammalian LOX (352). Therefore, alternative approaches that include inhibiting the LOX 
transcription factor or preventing post-translational cleavage of the precursor peptide by 
BMP-1 have been proposed (353). Notably, unparalleled clinical success in cancer has 
been achieved with the  non-specific copper chelator tetrathiomolybdate which depletes 
the LOX catalytic site of the metal and lowered serum LOXL2 levels in Phase II clinical 
trials (NCT00195091) (354). Corresponding murine models demonstrated that copper 
depletion reduced LOX, collagen deposition, and collagen fiber length in pre-metastatic 
lungs (354). Tetrathiomolybdate treatment is favorable because of its simple oral 
administration route, excellent tolerability, and greater LOX inhibition when compared to 
BAPN (354).  
 
Tissue Transglutaminase (TG2) 
Pharmacological inhibition of TG2 is in pre-clinical stages with classical small molecule 
competitive, reversible, and irreversible inhibitors (355). Reportedly, a TG2 inhibitor was 
investigated in Canadian clinical trials where poor efficacy was demonstrated, and an 
irreversible TG2 inhibitor is in Phase 1b clinical trials in Europe, but limited information 
is available about these efforts (355, 356).  Interestingly, TG2 is found in almost all tissues 
where it exists as a cytosolic protein with catalytic, G-protein, kinase, cell survival, and 
transcription regulating roles (336). The ubiquitous nature of TG2 and its multi-faceted 
impact on cell behaviors beyond ECM crosslinking make it a difficult therapeutic target. 
The challenge of developing effective small molecule inhibitors is exacerbated by evidence 
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that TG2 exists in multiple conformational states and has several structural domains (336). 
Therefore, less conventional methods that abolish TG2 activity by limiting its expression 
are also being pursued.  Upstream inhibitors of the ERK pathway that downregulate TG2 
expression and siRNA have successfully demonstrated fibrotic reduction in animal models 
(357, 358). Notably, TG2 siRNA coupled with liposome delivery yielded effective organ 
specific targeting to the liver and lungs (358).  
 
5.3.3 Proteolytic matrix degradation 
Paradoxically, despite mounting evidence that increased stiffness contributes to poor 
patient outcomes, the proteolytic activity of MMPs also contributes to disease progression. 
Notably, cancer, fibrosis, and cardiovascular disease are all associated with dysregulated 
MMP activity (359). Although MMPs are commonly affiliated with extracellular matrix 
proteolytic activity, matrix components only account for 20% of MMP substrates and their 
ability to cleave and activate growth factors, chemokines, cytokines, and receptors are 
associated with conflicting cell processes that promote and inhibit stiffness mediated 
pathologies (360). For example, MMPs can release matrix-bound latent TGFβ, but their 
expression can also have anti-fibrotic effects, and MMPs have a critical role in fibrotic 
resolution (361–363). There is also evidence indicating that MMP activity is mediated by 
substrate stiffness, suggesting that MMPs can have an evolving role during disease 
progression (364). Because of the varied, context specific effects of MMPs, and the major 
clinical failure of MMP targeting for cancer treatment, strategies that rely on altering MMP 
activity to overcome ECM stiffness should be pursued with caution (365). Therapeutics 
with high specificity must be developed, but present a significant challenge because of 
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similarities between catalytic sites and functional redundancy among the 24 mammalian 
MMP family members (365). The success of MMP therapeutic strategies will also rely on 
correctly identifying the appropriate pathological stage during which to administer the 
drugs to avoid amplifying MMP disease-promoting effects. 
 
Hyaluronidase 
Despite significant hurdles to controlling MMP activity, enzymatic matrix degradation 
with hyaluronidase that improved prognostic outcomes has been achieved in pre-clinical 
models of cancer. Intravenous injection of hyaluronidase decreased tumor size by 50% 
within 4 days in mice, and co-administration of hyaluronidase is an ongoing effort to 
improve drug delivery to the tumor stroma (366). Hyaluronidase has exceptionally high 
tolerability and pegylated hyaluronidase (PEGPH20) is in several late stage clinical trials 
as a combination cancer therapy to improve drug penetration (NCT02753595, 
NCT02921022, NCT02715804) (367, 368). The success of hyaluronidase in the cancer 
sphere could crossover to other stiffness pathologies to aid drug delivery efforts. 
 
Although targeting the ECM presents a significant challenge and is confounded by 
crosstalk between disparate mechanisms that contribute to stiffening, it will remain an 
active area of investigation as the contribution of ECM mechanics in disease progression 
is increasingly elucidated. Advances in mitigating matrix stiffness directly will likely draw 
on clinical successes from other settings such as scar and wound healing where matrix 
turnover is critical (356).  
 
 
 144 
5.4 Interrupting Cellular Responses to Increased Extracellular Matrix Stiffness 
Instead of preventing ECM stiffening which occurs with advanced age and can precede 
disease, an alternative approach to overcome the adverse effects of microenvironment 
stiffening is to inhibit the cellular response to increased matrix mechanics. The 
extracellular matrix activates integrin-mediated signaling pathways to elicit cellular 
outcomes; therefore, mechanotransduction can be disrupted at the cell-ECM level as well 
as with downstream signaling targets.  
 
5.4.1 Integrins 
A logical first choice to interrupt ECM mechano-sensing is integrin targeting because the 
transmembrane adhesion proteins are conduits of bidirectional signaling directly 
connecting extracellular inputs to intracellular outputs. Interestingly, integrin expression 
alone does not drive the cellular response to increased substrate mechanics (369). The 
judicious selection of which integrins to antagonize to specifically ameliorate matrix 
stiffness sensing is not straightforward and the regulation of diverse cellular events that 
result from integrin binding is an active area of investigation. The β integrin subunit recruits 
focal adhesion kinase (FAK) to initiate downstream signaling cascades that include Rho 
and Src, and therefore, is a potential target to mediate matrix stiffness responses (370, 371). 
Already, antagonizing integrins is being pursued in clinical trials for cancer (372). On 
fibronectin, rigidity sensing through α5β1stimulates Rho-mediated contractility and αv 
integrins activate the GEF-H1 Rho pathway, suggesting other potential targets (373).  
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The current understanding of force sensing across focal adhesions is centered around a 
shared sequence of events among autonomous adhesions that begins when integrin dimers 
bind their ECM ligands (174).  Extracellular integrin deformation from cytoskeletal forces 
is dependent on substrate compliance which then drives the intracellular recruitment of 
scaffolding proteins, actin binding reinforcement, and finally, the activation of downstream 
effectors (174). A stiffened ECM is well established to increase Rho-mediated cellular 
contractile forces that are necessary for protein conformational changes contributing to 
focal adhesion maturation, and cell-ECM adhesions are stronger on rigid matrices (174, 
246). However, the individual contributions of specific integrin dimer pairs to stiffness 
sensing and mechanotrasduction in a multi-component ECM has not been fully delineated 
(174, 314). Fibronectin and collagen are often used interchangeably as ECM proteins 
during in vitro experiments studying cellular forces despite groundwork that ECM ligand 
biochemistry and thus, integrin engagement, influences cellular mechano-responses (187). 
Further confounding efforts to target specific integrin mechanosensors is the intersection 
of integrin cascades with inputs from other microenvironment mechanical stimuli that are 
also affected by pathological stiffening, for example hemodynamic forces in the artery 
wall, elevated interstitial pressure in the tumor stroma, or lung parenchyma stretching 
during respiration (374–376).  
 
Among integrins, the αv family has been identified as a possible therapeutic target for 
fibrotic pathologies, not for their mechanosensitive signaling, but rather facilitating ECM 
deposition. Engagement of the arginine-glycine-aspartic acid (RGD) sequence on the 
latency associated peptide of TGFβ1 by the integrins αvβ1, αvβ3, αvβ5, αvβ6, or αvβ8 
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coupled with traction forces releases TGFβ1 from a latency complex (377, 378). Function 
blocking antibodies and small molecule inhibitors that antagonized αvβ1, αvβ6, or αvβ8  
to inhibit TGFβ1 activity demonstrated decreased xenograft tumor growth and fibrotic 
progression in pre-clinical models (378–380). With these encouraging results, a Phase 2 
clinical trial is currently active to evaluate the safety and tolerability of BG00011, a 
humanized monoclonal antibody against αvβ6 for idiopathic lung fibrosis 
(NCT01371305). Whether αv integrin inhibitors in development for other applications, 
such as Cilengitide for glioblastoma, also have efficacy against TGFβ1 remains to be 
established (381). Integrin inhibition is championed when compared to other strategies that 
target TGFβ1 because it inhibits a population of TGFβ1 that becomes active as an outcome 
of pathological stiffening, and circumvents the inflammatory reactions that plague 
systemic inhibition (377).     
 
5.4.2 Cell contractility  
Rho GTPase Targeting 
Elevated Rho GTPase signaling and contractile traction forces activated by integrin 
engagement with the ECM is one of the most widely documented downstream 
consequences of increased ECM stiffness (Figure 5.2) (173). As a critical regulator of 
cytoskeletal dynamics and cellular force through the formation of actin stress fibers, Rho 
signaling has been causally attributed to pathological cell contractility, motility, gene 
expression, cell cycle progression, and survival (183, 382, 383). However, Rho is 
considered “un-druggable” from the standpoint of traditional small molecule inhibitors that 
directly bind their protein targets because of its globular structure.  Classical small 
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molecule drugs are designed to fit into hydrophobic pockets, which Rho lacks (384). As an 
intracellular protein, Rho is also inaccessible to protein biologics that do not require a 
defined binding pocket, but are too large to cross the plasma membrane (384). Bacterial 
toxins that block Rho activity are used in academic research, but are not suitable for the 
clinic because they are non-specific and irreversible (385). Therefore, with these 
limitations, the Rho pathway has been targeted upstream or downstream of the mature 
GTPase. The primary strategies are focused on inhibiting Rho localization, preventing Rho 
activation by guanine nucleotide exchange factors (GEFs), and targeting downstream 
effectors.  
 
Figure 5.2. Increased ECM stiffness activates the Rho-mediated cell contractility 
pathway. Mechanical force on integrins activates the Rho GEFs, GEF-H1 and LARG to 
catalyze the exchange of GDP for GTP.  The major Rho effector Rho-associated coiled- 
coil kinase (ROCK) induces actomyosin cell contractility by phosphorylating myosin light 
chain (MLC) and myosin light chain phosphatase (MLCP). Downstream of Rho activation, 
nuclear localization of MRTF-A and YAP/TAZ regulate gene expression, and Rho activity 
has pathological implications on cell survival, proliferation, and migration.  
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Statins 
Rho localization is important to its activation and is regulated by the post-translational 
addition of a geranylgeranyl pyrophosphate moiety (146). The lipid anchor targets Rho to 
the plasma membrane where it maintains close proximity to GEFs that catalyze the 
exchange of GDP for GTP to transform Rho from an inactive to an active state in a rapid, 
switch-like manner (146). Intriguingly, statins, which are widely prescribed to lower serum 
cholesterol levels by competitive inhibition with the enzyme HMG-CoA reductase during 
cholesterol synthesis have been pursued to inhibit Rho (386). Because statins block 
cholesterol synthesis, they also inhibit the synthesis of prenylated protein intermediates 
including geranylgeranyl pyrophosphate, thereby interfering with Rho localization and 
activation (386). Notably, the therapeutic benefits of statins in cardiovascular disease 
exceed what can be attributed to their cholesterol lowering abilities (214). Re-purposing 
statins for clinical use beyond cholesterol lowering is a potential clinical tool to overcome 
the effects of matrix stiffening that occurs with age or pathology. The statin simvastatin 
attenuated elevated Rho activity caused by increased matrix stiffness in endothelial cells 
to reduce cell contractility and improved endothelial barrier function (258). In fibroblasts 
derived from fibrotic lungs, simvastatin attenuated the myofibroblast phenotype and 
reduced growth factor expression (387). Despite common deleterious roles for increased 
matrix stiffness and elevated Rho, the benefits of statins in cancer are less clear, and even 
conflicting. Pharmacokinetic differences between lipophilic and hydrophilic statins, 
heterogeneity between patient cancer, and data extracted from clinical trials designed with 
cardiovascular endpoints rather than as cancer studies have all been cited as causes of  the 
inconsistencies (388). Nevertheless, because the off-target effects of statins extend beyond 
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Rho, and noting that matrix stiffness is one of many factors that compound to drive disease 
progression, the success or failure of statin re-purposing cannot be attributed to altered Rho 
activity alone.   
 
Rho GEF Targeting 
GEFs are a therapeutic target to control Rho activity because of their direct role in 
activating Rho signaling. In addition, because of the diversity of cellular behaviors that 
result from intricate upstream signaling pathways that converge at Rho, and the 
identification of more than 80 GEFs, GEF targeting has the potential to impart an elevated 
degree of specificity on Rho inhibition (389).  
 
GEF inhibitors can be designed to block GEF-Rho interactions or target the GEF catalytic 
site, both of which terminate forward movement of the signal cascade. For example, the 
compound Rhosin blocks a GEF docking site on RhoA and a class of compounds named 
Y16 bind to the GEF catalytic site (390, 391). Importantly, within the Rho family of 
GTPases, Rhosin only inhibits RhoA activity without interrupting the function of other 
Rho GTPase family members, and Y16 binds to just three RhoA GEFs: LARG, p115, and 
PDZ demonstrating high specificity with GEF targeting approaches (391). In silico 
methods were used to discover these two Rho GEF inhibitors, and are becoming powerful 
tools for rational drug discovery. Because the siRNA techniques used to study GEFs in 
experimental settings are not applicable for clinical translation, there is a need to develop 
small molecule inhibitors. However, similar to Rho, GEFs engage in protein-protein 
interactions and lack large structural pockets which make them poor candidates for 
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traditional small molecule inhibitors. The combination of computational methods with data 
driven structural knowledge is identifying novel surface sites that are energetically 
favorable on proteins that were previously deemed un-druggable, and due to the high 
clinical need, it is anticipated these methods will yield additional sites to target Rho 
signaling and the associated GEFs (392). The Rho GEFs LARG and GEF-H1 have been 
identified as critical mediators of the cellular response to integrin force; and therefore, are 
ideal GEF targets for dampening cell-ECM mechanotransduction (393). As the ability to 
target Rho signaling expands, a more complete understanding of the expression, function, 
regulation, and activation of individual GEFs in specific cell types will be necessary.  
 
Rho-associated coil-coiled kinase (ROCK)  
Rho-associated coil-coiled kinase (ROCK) is the major downstream effector of Rho that 
drives cell contractility and is a mediator of fibrotic pathologies (394). ROCK 
phosphorylates myosin light chain and myosin light chain phosphatase to induce the 
generation of cellular force from actomyosin filament contraction. Recently, a stiffness 
dependent role for ROCK in driving fibroblast to myofibroblast conversion in pulmonary 
fibrosis was identified, and ROCK inhibition attenuated increased endothelial permeability 
caused by age-related increased intima stiffness (63, 395).  
 
As a kinase, ROCK inhibition can be readily pursued using traditional small molecule 
discovery efforts but is also plagued by non-specificity. Indeed, the two most prominent 
small molecule ROCK inhibitors, Fasudil and Y27632 target the ATP-dependent ROCK 
kinase domain, but also show non-specific interactions with other kinases (396).  It is 
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hypothesized that Fasudil and Y27632 effectiveness is partially due to their off-target 
effects with other kinases (397). To overcome off-target interactions, high inhibitor 
concentrations in the nanomolar range are required for in vivo efficacy, which limits 
clinical translation.  In addition to its pathological role, ROCK has an important function 
maintaining vascular tone via vascular smooth muscle cell contraction (397). Thus, ROCK 
inhibitors, such as Fasudil, can be designed and employed with this motivation. However, 
drugs that are successful in vitro for different clinical applications of ROCK inhibition can 
also induce unwanted decreases in blood pressure when transferred to animal models or 
humans, creating a barrier to their clinical adaptation. Nevertheless, the ROCK inhibitor 
Fasudil has been used in Japan since 1995 for the treatment of cerebral vasospasms, and 
ROCK inhibitors have been widely investigated to treat a variety of pathologies either 
alone or as a combination treatment (397). Fasudil has demonstrated an impressive record 
of safety and efficacy, but interestingly to date, has not been commercially marketed in the 
United States. The pharmaceutical company contracted to manage Fasudil in the United 
States was acquired by a competitor, ultimately resulting in an international lawsuit that 
reached the California Supreme Court (Asahi Kasei Pharma Corporation v. Actelion Ltd., 
No. S216123 (Cal)) and stalled Fasudil development. The composition of matter patent on 
Fasudil expired in early 2016, and while its commercial future is unknown, it continues to 
be evaluated in pre-clinical and clinical studies (U.S. Patent 5,942,505). A timely pre-
clinical investigation recently reported that priming with Fasudil to inhibit Rho-pathway 
mediated ECM remodeling markedly improves the efficacy of the current standard-of-care 
pancreatic chemotherapies gemcitabine and Abraxane at both the primary tumor and 
metastatic sites (398).  
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New ROCK inhibitors have emerged from the clinical need to lower ocular pressure in 
glaucoma (399). Ripasudil, a Fasudil derivative is already approved for use in Japan for 
glaucoma patients (400). One approach to mitigate the off-target effects of ROCK 
inhibitors is the development of “soft inhibitors”  which are designed to degrade into 
inactive metabolites when not at their target site for improved patient tolerability (401). 
For example,  the soft inhibitor AMA0076 which completed Phase 2 clinical trials 
(NCT02136940, NCT01693315) is structurally based on Y27632, but exhibits tissue-
specific hydrolysis rates in the eye (401). Pharmacological efforts distinguishing the 
distinct roles of the two ROCK isoforms, ROCK1 and ROCK2 are also in progress (396). 
The development of small molecule inhibitors that exhibit greater specificity towards the 
ROCK family kinases or its specific isoforms are using high throughput screening and 
fragment based approaches (397). New patents for clinical siRNA inhibition of ROCK 
have also been filed (397).  
 
Focal adhesion kinase (FAK) 
Focal adhesion kinase (FAK) is a cytosolic non-receptor tyrosine kinase that is activated 
by integrin clustering and is a regulator of focal adhesion dynamics and Rho activity (402). 
FAK integrates extracellular matrix signals from integrins to activate downstream 
pathways that control adhesion, proliferation, motility and survival  (402). In addition, 
focal adhesions are sites of actomyosin force transmission to the extracellular matrix; 
therefore, FAK is a potential upstream target to inhibit cellular responses to matrix 
mechanical cues. Moreover, phosphorylation of FAK at Tyrosine 397 (Tyr-397) which is 
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necessary for Src binding followed by complete FAK activation through additional 
phosphorylation, is increased with increased matrix stiffness (167, 402).  Dysregulated 
FAK-Src signaling is widely appreciated for a role in cancer invasion and metastasis, and 
consequently, the development of FAK inhibitors is co-currently being pursued by 
GlaxoSmithKline, Novartis, Merck, Takeda, and Pfizer, in addition to efforts by smaller 
pharmaceutical companies (403, 404). These inhibitors primarily target the FAK catalytic 
site, and several have reached clinical trials, either alone or as combination therapies (403, 
404). However, stiffness induced upregulated FAK activation is also deleterious in 
pathologies other than cancer. Constitutive phosphorylation of the kinase is found in 
fibrotic fibroblasts (405). FAK signaling also potentiates growth factor signaling and the 
myofibroblast phenotype (405, 406). In addition, mechanically driven FAK-ERK pathways 
activate the Rho GEF, GEF-H1 (393). 
 
As a druggable protein, FAK suffers from the same limitations as other kinases, namely 
similarity in the catalytic domain that imparts non-specific cross reactivity of small 
molecule inhibitors. Among a subset of kinases, improved selectivity has been 
demonstrated with allosteric inhibitors directed to a flexible Aps-Phe-Gly (DFG) amino 
acid trio at the N-terminus of the activation loop (407). In these kinases, the DFG portion 
undergoes dramatic conformational changes as it switches between active and inactive 
states, and has been identified as a domain that imparts selectivity when targeted in the 
inactive state (407). Importantly, inhibitors stabilizing a unique alpha helix conformation 
of the FAK DFG-domain have exhibited robust selectivity and efficacy in vivo (408). Other 
recent efforts to target FAK signaling are designed to inhibit scaffolding interactions with 
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downstream effectors (403). These approaches are advantageous because they target 
specific lineages of FAK signaling (403). Another current approach to targeted FAK 
inhibition is preventing autophosphorylation at Tyr-397 which is particularly relevant to 
attenuating aberrant FAK activation caused by increased extracellular matrix stiffness 
(409). For detailed discussions on FAK pharmacological development the reader is 
directed to reviews by Lee et al. and Golubovskaya (403, 404). 
 
5.4.3 Gene expression 
YAP/TAZ 
In addition to protein activation, the cellular response to increased extracellular matrix 
stiffness also occurs at the transcriptional level. Most prominently, the downstream 
effectors of the Hippo pathway yes-associated protein (YAP) and transcriptional 
coactivator with PDZ-binding motif (TAZ) that are known for mediating transcriptional 
regulation of apoptosis and proliferation, are also activated by increased matrix rigidity 
independent of the canonical Hippo cascade (410). YAP/TAZ activation by matrix stiffness 
contributes to fibroblast phenotypic conversion, increased collagen deposition, and cell 
proliferation where feed-forward cycles that enhance microenvironment stiffening are 
augmented (411, 412). YAP/TAZ also potentiates TGFβ signaling (413). Interestingly, 
actomyosin contractility is necessary for stiffness-induced YAP activation, and inhibition 
of intercellular tension by abrogating Rho activation attenuates YAP/TAZ nuclear 
localization (410). The ongoing efforts to develop therapeutic Rho antagonists therefore 
represent an indirect mechanism to inhibit stiffness mediated YAP/TAZ activation. 
Already, statins have been identified as strong inhibitors of YAP/TAZ nuclear localization 
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due to the crossover between the synthesis of cholesterol intermediates and the synthesis 
of geranygeranyl pyrophosphate for Rho post-translational modification (414). Direct 
inhibition of YAP/TAZ has been pursued using small molecule inhibitors that prevent 
YAP/TAZ from associating with their target TEAD transcription factors in the nucleus 
(415). The results of a small molecule screen revealed the Novartis photosensitizer 
Visudyne administered for macular degeneration treatment prevented YAP from 
interacting with TEAD, and Visudyne was confirmed to attenuate YAP mediated events in 
vivo (415). Inhibition of YAP has also been demonstrated with a peptide designed to mimic 
the native inhibition of YAP-TEAD association by vestigial like family member 4 
(VGLL4) (416). Regulation of YAP/TAZ in both normal and pathological settings is an 
intense area of investigation, and undoubtedly as our understanding of the crosstalk 
between the Hippo and mechanotransduction pathways expands, new therapeutic 
approaches will build upon the proof-of-concept studies that have validated YAP/TAZ as 
a druggable target. Notably, YAP inhibition in hepatic stellate cells impeded the activated 
cell phenotype in vitro and prevented fibrosis, indicating that transcriptional regulation 
may be a method to inhibit tissue stiffening (417). Screens of available drugs have already 
yielded strong candidates that can be re-purposed to inhibit YAP/TAZ which suggest that 
an accelerated track for druggable efforts may exist.  
 
MRTF-A 
Another transcriptional co-activator, myocardin related transcription factor-A (MRTF-A) 
also undergoes nuclear localization with increasing matrix stiffness. Through the 
generation of cellular force by Rho activation and actin polymerization, MRTF-A promotes 
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myofibroblast differentiation (418). Nuclear MRTF-A activates the serum response factor 
(SRF) transcription factor to induce α-SMA and collagen-I expression, thereby inducing 
fibrogenesis (419). In addition to activation by cellular tension, TGFβ intersects with 
MRTF-A activation and also induces its nuclear translocation, further linking matrix 
stiffness and TGFβ in a self-propagating cycle (420). High throughput screening of 2000 
compounds from the Maybridge Diverse Chemical Library led to the identification of the 
compound CCG-1423 that inhibited transcription along the Rho/MRTF/SRF pathway, 
downstream of Rho activation by binding to the MRTF-A nuclear localization sequence 
(421, 422). Although CCG-1423 suffered from high toxicity, structural insights into the 
rational design of Rho-mediated transcription inhibitors were gained, and new compounds 
with improved cytocompatibility were subsequently developed. Attenuated matrix 
stiffness and TGFβ fibrosis were achieved with the second generation MRTF-A inhibitors 
CCG-100602 and CCG-20397, justifying stiffness-mediated Rho transcription as a 
therapeutic target (419). 
 
Alternative splicing 
Variations in gene expression by alternative splicing were recently found to be regulated 
by extracellular matrix mechanics. Bordeleau and colleagues reported that expression of 
the splice variant of fibronectin including the extra domain-B (EDB) type III repeat (EDB-
FN), commonly found in tumors and believed to contribute to tumorigenesis, is regulated 
by increased matrix stiffness (423). Interestingly, the splicing event depends on Rho-
mediated cell contractility. The authors also identified alternative splicing of PKC BII and 
VEGF 165b to be matrix-stiffness dependent. Notably, the phosphorylation of serine-
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arginine rich (SR) proteins that mediate splicing increased with matrix stiffness via a 
PI3/AKT pathway. These data suggest that other splice variant proteins that aberrantly 
appear in the extracellular matrix milieu of stiffened tissues, may also be mediated by 
matrix mechanics through a similar pathway. For example, the extra domain-A (EDA) type 
III repeat fibronectin (EDA-FN) variant is found in the abnormal matrix of atherosclerotic 
plaques (424). Furthermore, TGFβ is often upregulated in pathologically stiff 
microenvironments, and contributes to splicing events, suggesting that alternative splicing 
may involve synergistic contributions between mechanical cues and ECM components 
(425). SR proteins or the PI3/AKT pathways are potential therapeutic targets to control 
stiffness-mediated splicing events, in addition to current approaches using oligonucleotides 
and small molecules (426).   
 
Nuclear mechanics 
The cell nucleus is mechanically coupled to the actin cytoskeleton by an assembly of 
proteins that comprise the linker of nucleoskeleton and cytoskeleton (LINC) complex, and 
by extension to integrins and the extracellular matrix (427). Thus, as first described by the 
cellular tensegrity model, externally applied force, as well as cell-generated intercellular 
tension is propagated to the nucleus, which itself is a mechanotransducer (427, 428). Force 
propagation across the cytoskeleton occurs orders of magnitude faster than biochemical 
signaling and the nucleus is involved in the integration and response to these mechanical 
inputs (427). Because cellular DNA is stored in the nucleus, transmitted forces that induce 
changes in protein conformation, protein association, or deform chromatin may have 
transcriptional implications (429).  
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Lamins are nuclear intermediate filaments that create a structured protein network 
associated with the interior nuclear membrane and are implicated in both nuclear 
mechanotransduction and matrix stiffening responses (429). Of interest, lamin-A 
expression increases with matrix stiffness altering the structure and stiffness of the nuclear 
envelope (430). In addition to transducing force, lamins are scaffolding proteins that 
interact with transcription factors and bind chromatin (429). Lamin-dependent regulation 
of the MRTF-A/SRF and YAP/TAZ pathways may explain the excessive ECM production 
in many laminopathies, and demonstrate another mechanism by which ECM protein 
transcription is regulated by matrix stiffness (431). Therapeutic targets for nuclear 
mechanotranduction are likely to be discovered in parallel with the development of 
improved technologies to study subcellular processes. However, the complexity and 
delicacy of the nucleus, coupled with our current understanding of mechanotransduction, 
suggest that the best therapeutic options to intervene lie within already discussed 
mechanotransduction sensing components. Force transmission to the nucleus requires cells 
under pre-stress which can be modulated by Rho contractility (427). Additionally, MRTF-
A and YAP/TAZ pathways can be targeted independent of lamin regulation as already 
described.  
 
5.5 Conclusion  
Two key players emerge from the discussion about potential therapeutic targets to 
overcome pathological extracellular matrix stiffening: TGFβ and Rho. Not surprisingly, 
their pleiotropic effects converge as they function in concert to promote feed forward 
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cycles that amplify extracellular matrix production and stiffening. However, they also 
represent elusive therapeutic targets because of their ubiquitous expression and important 
functions in healthy tissues. Indeed, a common underlying theme is a need for high potency 
and specificity among druggable efforts. Off-target interactions are a major hurdle for 
developing kinase inhibitors, and high toxicities have been crippling to the development of 
small molecules to prevent or disrupt matrix crosslinking. Moreover, these interventions 
need to be localized to the organs of interest to further minimize deleterious side-effects. 
Improved specificity is anticipated with aptamer technologies and new approaches to small 
molecule drug development that employ multi-faceted approaches combining 
thermodynamics, structural biology, and mathematical computation to identify novel sites 
for small molecule-protein interactions (392). The identification of inhibitor sites on 
previously undruggable proteins, including Rho, should vastly expand the available 
therapeutic library.  
 
With the recognition of ECM stiffness as a contributing factor to multiple pathologies 
across diverse organs, the advancement of clinical technologies to non-invasively measure 
local tissue mechanics are necessary to achieve earlier diagnoses and better patient 
outcomes. From an academic perspective, these modalities will contribute to an increased 
understanding of pathological stiffening in its earliest stages, and drive research efforts to 
identify novel clinical targets, perhaps even preventing full disease manifestation. An 
example of one such platform, is non-invasive tissue stiffness quantification by measuring 
the propagation of shear waves using high speed ultrasound imaging. Less shear is 
generated in stiff tissues, allowing for healthy and pathological tissues to be distinguished. 
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Over the past two decades, this technology has rapidly expanded from a 1-D measurement 
to 3D supersonic shear wave elastography with improved resolution and accuracy, and has 
been validated for clinical implementation (432). The recently NIH funded total body 
positron emission (TB-PET) scanner is also expected to expand the understanding of ECM 
in disease. The technology is projected to identify micro-metastases beyond the current 
clinical resolution limit to gain new insights into the pre-metastatic niche (433).  
 
With the strong foundation of the mechanotransduction field and the importance of 
microenvironment stiffness built up over the past two decades, we can now work towards 
applying our knowledge to mitigating the effects of increased substrate mechanics in the 
emerging field of mechano-medicine. As has already been discovered for other 
pathologies, the most successful mechano-based therapeutic interventions will likely 
include drug cocktails to reach more than one target and overcome cellular redundancies.   
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CHAPTER 6 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Conclusions 
Biochemical and mechanical cues from the extracellular matrix (ECM) are increasingly 
being appreciated for their role in regulating cell behaviors, both during development and 
disease progression. Notably, increased extracellular matrix stiffness is a hallmark of 
diverse pathologies, including atherosclerosis. Evidence now suggests that elevated matrix 
rigidity is not a passive outcome of disease, but instead, a cue that drives pathological 
progression. Thus, both the identification of cellular targets to overcome the cellular 
response to stiffness and an increased understanding of extracellular matrix mechanical 
cues on pathological cell behaviors are of high clinical importance. This dissertation 
investigates the role of the altered mechanical properties of the aged arterial intima on 
endothelial cells behaviors that contribute to atherosclerosis, a leading cause of death in 
the Western world. Using in vitro gel systems to modulate ECM stiffness and mimic the 
young and aged arterial intima mechanics, this work demonstrates that the endothelial cell 
response to increased matrix stiffness can be pharmacologically interrupted. Moreover, the 
heterogeneous spatial presentation of matrix stiffness cues in addition to an overall increase 
in elastic modulus are deleterious to endothelial monolayer integrity. This work also 
explores the emerging field of mechano-medicine with a detailed discussion of pre-clinical 
and clinical approaches to attenuate the effects of increased ECM stiffness on disease.  
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In Chapter 2, I investigated re-purposing the commercially available pharmaceutical 
simvastatin to ameliorate the effects of increased ECM stiffness on endothelial cell 
behaviors that are associated with poor endothelium barrier integrity, an initial step in 
atherogenesis. Because elevated RhoA activity scales with matrix stiffness and disrupts the 
endothelium, I hypothesized that statin treatment to prevent RhoA post-translational 
prenylation and membrane localization near activating guanine nucleotide exchange 
factors (GEFs) would attenuate the deleterious cellular response to increased matrix 
mechanics. Polyacrylamide gels with compliances between 2.5 and 10 kPa were fabricated 
to mimic the compliance of the young and aged arterial intima, respectively, and 
endothelial cells were treated with simvastatin. The data demonstrated that GTP-bound 
RhoA was decreased while GTP-bound Rac1 increased in endothelial monolayers 
following the statin treatment. Importantly, the altered GTPase signaling occurred in 
concert with protein recruitment to cell-cell adhesions that is associated with enhanced 
endothelium integrity. Moreover, focal adhesion size was decreased with simvastatin 
treatment demonstrating that disrupting RhoA and Rac1 activation interrupts matrix 
stiffness sensing at cell-ECM adhesions that are critical sites of outside-in and inside-out 
signaling.   
 
The cardiovascular protective effects of statins are known to exceed their cholesterol 
lowering outcomes, and my data indicates that improved endothelium integrity from 
attenuated RhoA activity may be one underlying mechanism, especially in aged individuals 
where elevated artery stiffness is prevalent (212, 434).  These data complement in vivo 
models that implicate arterial stiffness as a contributor to atherogenesis, and notably, 
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indicate the validity of a pharmacological approach to overcome the cellular response to 
matrix mechanical cues. Prior in vivo work from our group demonstrated that inhibiting 
Rho-associated coiled-coil kinase (ROCK), the major downstream effector of RhoA in the 
cell contractility pathway decreased permeability in stiffer, aged arteries. However, the 
inhibitor employed in these studies, Fasudil, is not FDA approved in the United States and 
has off-target effects with the catalytic sites of other serine/threonine kinases. Kothapalli 
and colleagues used the lysyl oxidase inhibitor B-aminopropionitrile (BAPN) to prevent 
collagen crosslinking in a mouse model of atherosclerosis and reported more compliant 
arteries exhibited a reduced atherosclerotic burden. Furthermore, they identified a 
pathological feed-forward cycle of collagen, fibronectin, and lysyl oxidase expression in 
response to increased matrix mechanics that was attenuated in compliant arteries, and was 
later attributed to RhoA activation (142, 435). However, these encouraging data are not 
transferrable to the clinic because BAPN toxicity precludes its use in patients. Therefore, 
the data presented in this dissertation identify that as an FDA approved drug, simvastatin 
could fill an unmet clinical need and mitigate the contributions of arterial stiffness to 
atherogenesis.   
 
I further explored the effects of age-related arterial stiffness on endothelial cell behaviors 
that contribute to atherogenesis in Chapter 3 by developing an in vitro model to modulate 
the spatial presentation of matrix mechanical cues. Characterization of the subendothelial 
matrix by atomic force microscopy indicated that both mean intima stiffness and spatial 
stiffness heterogeneity increase with age (122). Motivated by age-related stiffness 
heterogeneity in the arterial intima and evidence of crosstalk between integrin and cadherin 
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adhesions, I hypothesized that subcellular matrix stiffness cues could disrupt endothelial 
cell-cell junction integrity (197).  
 
A methacrylated hyaluronic acid (MeHA) hydrogel that sequentially crosslinks first by 
Michael-type addition followed by photo crosslinking, developed by the Burdick Lab at 
the University of Pennsylvania, was adapted to create a physiologically relevant platform 
to vary the spatial presentation of matrix stiffness. The hydrogel substrate had a 
checkerboard grid of high and low stiffness regions, and was characterized with respect to 
the elastic modulus, swelling, and stiffness pattern fidelity. The stiffness patterned 
hydrogel platform was then applied to investigate the endothelial cell response to 
subcellular increases in matrix stiffness, and the data revealed that cell-ECM adhesions 
corresponded to the local stiffness of the underlying matrix. Additionally, integrity of 
endothelial monolayers decreased with increased stiffness heterogeneity (50 by 50 µm vs. 
100 by 100 µm features). Importantly, this study identified the spatial presentation of ECM 
stiffness as a mechanical cue that disrupts endothelial cell-cell junction integrity. 
 
Because atherosclerotic plaques preferentially develop at distinct locations within the 
artery wall, and endothelium permeability within a monolayer is non-uniform, identifying 
physiological causes of local permeability is clinically relevant. A central dogma is that 
increased matrix stiffness causes increased RhoA-mediated cell contractility resulting in 
cell-cell junction disruption and permeability (63, 185, 210). However, it is now emerging 
that the regulation of endothelial permeability is more complex than mean monolayer 
traction forces. Cellular forces within a monolayer are highly dynamic and exhibit spatial 
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variation. High traction force fluctuations rather than absolute force magnitudes predict 
intercellular gap formation (275). Additionally, the effects of RhoA are dependent on 
spatio-temporal localization. Cytoplasmic RhoA localization near actin bundles is barrier 
disrupting (242). At the cell periphery, hotspots of RhoA activity have been associated with 
adhesion formation and repair (242). The MeHA hydrogel platform validated in Chapter 3 
expands beyond prior studies investigating the deleterious effects of elevated matrix 
stiffness on endothelial cell behavior by incorporating matrix stiffness heterogeneity, a 
distinct characteristic of the aged arterial intima (122).  Intriguingly, RhoA activation, 
subcellular traction forces, and cell-cell junction tension scale with local ECM stiffness 
(175, 187, 210, 258). And cytoplasmic coherence indicates that traction forces must be 
balanced even though local matrix stiffness cues can elicit different subcellular forces (175, 
277).  In this context, my data suggests that spatial variations in age-related matrix 
stiffening may contribute to enhanced endothelial permeability and atherosclerosis by 
stimulating unstable cellular force generation.  
 
Although vascular stiffening is a hallmark of atherosclerosis, other pathologies including 
cancer, fibrosis, and diabetes are also characterized by increased ECM stiffness that alters 
cell behaviors and promotes disease progression. In Chapter 5, I performed a literature 
review that investigated the emerging field of mechano-medicine. I discussed 
pharmacological interventions ranging from novel pre-clinical in vitro approaches to 
clinical trials aimed to overcome either matrix stiffening or the cellular response to 
increased matrix mechanics. The feasibility and challenges associated with each ECM or 
cellular target were highlighted. Because matrix stiffening is increasingly being identified 
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as a driving force in disease development, the advancement of mechano-based therapeutic 
approaches to the clinic has important patient implications across diverse pathologies.  
 
Collectively, this dissertation investigated the role of age-related stiffness changes in the 
arterial intima on endothelial cell behaviors that contribute to atherosclerosis with an 
emphasis on clinical translation. I demonstrated the off-target effects of the available statin, 
simvastatin interrupt RhoA and Rac1 pathways to attenuate the endothelial cell response 
to increased matrix stiffness and enhance cell-cell adhesions. I next identified increased 
stiffness heterogeneity as a physiologically relevant ECM mechanical cue that disrupts 
endothelial monolayer integrity. Finally, I discussed clinical targets and therapeutic 
interventions to overcome pathologies driven by the cellular response to ECM stiffening. 
Cardiovascular pathologies initiated by atherosclerosis continue to be a leading cause of 
death in the Western world; therefore, the identification of novel therapeutic strategies, 
such as age-related matrix stiffness targeting, are of high clinical importance.   
 
6.2 Future Directions 
The research presented in this dissertation identified a method to pharmacologically 
overcome the cellular response to increased matrix stiffness and developed a novel 
hydrogel platform to determine that matrix stiffness heterogeneity disrupts endothelial 
monolayer integrity. These studies contribute to our understanding of the effects of altered 
matrix mechanics associated with aging on atherogenesis, and future studies will build 
upon these findings. 
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In Chapter 2, my data revealed that the pleiotropic effects of statins can be used overcome 
the cellular response to matrix stiffness by attenuating RhoA activation and reducing 
intercellular junction tension. However, statins have other reported atheroprotective effects 
and investigating their benefits in the context of age-related intima stiffening is of interest. 
Nitric oxide (NO) production by endothelial cells is critical to the regulation of vascular 
tone and is used as a marker of endothelial dysfunction. Intriguingly, the inhibition of 
RhoA by statins increases NO through stabilization of endothelial nitric oxide synthase 
(eNOS) mRNA and phosphorylation of mature eNOS (436, 437). The activation of eNOS 
and NO production by shear stress have also been demonstrated to be matrix stiffness- 
dependent with reduced early signaling on rigid matrices (287). These data lead to the 
hypothesis that statins would enhance NO bioavailability on stiff substrates to reduce 
endothelial dysfunction.  
 
This dissertation focused on endothelium integrity as a gatekeeper to prevent cholesterol 
entry into the arterial wall and the initiation of atherogenic cascades. However, once 
initiated, atherosclerosis is largely recognized as a prolonged inflammatory pathology (2). 
In vivo, atherosclerosis development is a complex process with contributions from multiple 
cell types; therefore, investigating the dual effects of ECM stiffness and statins on other 
cell types within the atherosclerotic plaque milieu is necessary for a comprehensive 
understanding of statins as a mechano-based therapeutic approach. Notably, immune cell 
transmigration is regulated via the Rho/ROCK/pMLC pathway, suggesting that statin 
inhibition of RhoA would interrupt this behavior and attenuate an inflammatory response 
(438, 439).   Moreover, because immune cell transmigration events across the endothelium 
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are substrate stiffness-dependent and are attributed to increased cell contractility that 
reduces endothelium barrier resistance (63, 185); statins could have synergistic effects 
when acting on multiple cell types by combining enhanced endothelial integrity with 
reduced immune cell migration behaviors. Statins could also attenuate the mechanically 
driven pathological behavior of vascular smooth muscle cells that migrate to the arterial 
intima and contribute to atherosclerotic plaque progression. ECM stiffness-mediated MLC 
phosphorylation and cell contractility promoted the formation of migration associated 
circular dorsal ruffles in VSMC (440). My data demonstrated that statins attenuated 
RhoA/pMLC activation caused by matrix mechanics, suggesting that VSMC migration 
would be suppressed by statins. VSMC proliferation also increases with matrix stiffness 
and proliferation caused by matrix stiffness is a RhoA-dependent process, implying another 
potential atheroprotective benefit of statin treatment in stiff, aged arteries (441, 442).    
 
In chapter 3, I developed and characterized a photocrosslinked hydrogel platform that was 
used to study endothelial single cell and monolayer responses to subcellular matrix 
stiffness cues. From the conclusion that spatial stiffness heterogeneity observed in vivo 
with advanced age is a monolayer disrupting cue when modeled in vitro, new questions 
arise to discern the underlying mechanistic processes.  
 
An advantage of employing a photocrosslinking approach to create a stiffness patterned 
substrate is that feature size and presentation are easily tunable with new photomasks. My 
data demonstrated that decreasing the feature size to 50 by 50 µm squares to increase 
stiffness heterogeneity caused increased monolayer disruption. Future studies should 
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further reduce the feature size to determine a biophysical resolution of monolayer stiffness 
sensing heterogeneity. Data from single cell studies suggest that subcellular matrix 
mechano-sensing occurs at multiple length scales ranging from sub-focal adhesion 
nanometer sensing to cell-scale global responses (443, 444). At cell-ECM adhesions a 58-
73 nm separation is proposed as a universal length scale for integrin clustering and 
signaling, which suggests that much smaller subcellular mechanical features  than 
investigated in this dissertation, can be discerned by monolayer cells (445). At the same 
time, cytoplasmic coherence proposes a global mechano-sensitive contractile cellular 
response (276, 277). Modulating stiffness pattern feature size across length scales could 
determine at which threshold subcellular and cellular scale sensing mechanisms dominate 
the monolayer response. The stiffness dependent nuclear localization of the transcriptional 
activators YAP/TAZ, which are also associated with a pro-atherogeneic mechanically 
stimulated inflammatory response, could be used as indicators of overall cell sensing of a 
compliant or rigid substrate (410, 446).  
 
In addition to changing the size of stiffness pattern features in the ECM, changing their 
spatial presentation is also interesting for future studies. Because arterial stiffening is a 
progressive and dynamic process, this data would provide insight into the degree of 
localized ECM stiffening that is necessary for monolayer disruption. Instead of creating a 
photomask of repeating stiffness patterns, stiffness islands of different sizes could be 
patterned. Matrix stiffness cues that cause cell contractile forces are transmitted into cell-
cell junction tension, and Barry et al. have demonstrated that force transmission across VE-
cadherin results in long range monolayer disruption (187, 189). Thus, with stiffness islands 
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the dissipation of localized stiffness effects could also be evaluated.  Finally, recognizing 
that more than two compliance levels exist in vivo, heterogeneity of stiffness levels within 
the substrate could be investigated by creating patterned gradient photomasks. For greater 
in vivo relevance, the stiffness profile of representative intimas from young and aged 
animals could be mapped using atomic force microscopy and recapitulated in vitro using a 
photomask with different opacities to match the magnitude and spatial presentation of the 
ex vivo measurements.  
 
Studies to determine the underlying cellular mechanisms contributing to monolayer 
disruption caused by endothelial matrix stiffness heterogeneity would nicely extend the 
work presented in this dissertation. Mechanistic parallels between adhesion complexes at 
cell-matrix and cell-cell interfaces, and conserved scaffolding proteins used at both sites 
lead to questions related to the spatial regulation that governs adhesion integrity (177, 191, 
197). Interestingly, vinculin is paradoxically associated with both focal adhesion 
strengthening and cell-cell adhesion reinforcement, and its phosphorylation is adhesion 
specific (197). In endothelial cells pharmacologically treated to enhance or disrupt 
monolayer integrity, vinculin localized to either cell-cell junctions or focal adhesions, 
respectively (195).  VASP, zyxin, and TES are also traditional focal adhesion proteins that 
are recruited in a tension dependent manner to adherens junctions, and together with 
vinculin, represent initial candidate proteins to investigate adhesion regulation (196). A 
body of work has demonstrated that matrix stiffness promotes focal adhesion maturation 
and reinforcement (173); therefore, it is hypothesized that stiff matrix regions would recruit 
shared adhesion strengthening proteins to the cell-ECM interface and destabilize cell-cell 
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contacts. Modulating the stiffness pattern feature size and compliance would elucidate at 
what threshold shared proteins are recruited to each adhesion type. 
 
In concert with adhesion protein localization studies, quantitative measurements of force 
would contribute to an increased understanding of crosstalk between cell-ECM and cell-
cell adhesions that contribute to matrix stiffness-mediated junction disruption. The FRET 
based tension sensors developed by the Schwartz group for vinculin and VE-cadherin could 
be used to simultaneously measure forces at focal adhesions and cell-cell junctions, 
respectively (300, 304). These studies would elucidate how adhesion tensional force 
patterns within monolayers change with both uniform and heterogeneous matrix 
mechanics, and could be correlated with monolayer integrity. Additionally, because 
tension-dependent conformational changes in protein structure recruits scaffolding 
proteins, the recruitment of adhesion strengthening proteins could be quantitatively 
assessed with respect to adhesion tension and matrix rigidity (177, 191). Monolayer 
traction force studies on mechanically heterogeneous substrates are also of interest to 
investigate the physiologically relevant multi-cell response that includes cell-cell force 
transmission through both the ECM and cell-cell junctions (189, 275, 447).  
 
The data presented in this dissertation identified a pharmacological approach to mitigate 
the cellular response to age-related arterial stiffening and determined that matrix stiffness 
heterogeneity in addition to a bulk increase in rigidity alters endothelial behaviors towards 
an atherogenic phenotype. Because cardiovascular diseases initiated by atherosclerosis 
continue to be prevalent and deadly, novel therapeutic methods beyond lipid lowering 
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strategies are needed. The experiments described in the future directions will provide useful 
insight into the clinical utility of targeting the age-related mechanical properties of the 
intima from a biophysical perspective.   
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APPENDIX A  
  
PROTOCOL FOR METHACRYLATED  
HYALURONIC ACID POLYMER SYNTHESIS 
 
 
Materials: 
Sodium hyaluronate (HA) (Lifecore Biomedical, 59 kDa) 
50 mL conical tubes 
Methacrylic anhydride 
5 N NaOH 
Three neck round bottom flask 
Ice bucket 
Ice 
Stir plate and stir bar 
pH meter 
Parafilm 
Cell strainers (70µm) 
 
4 L Glass beaker 
 
Dialysis tubing (6-8 kDa MWCO) 
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Protocol for Methacrylated Hyaluronic Acid Polymer Synthesis: 
Day 1: 
1. Weigh out 0.5 g HA in 6- 50 mL conical tubes (total 3 g HA). 
2. Add 50 mL of DI water to each conical tube (300 mL total). 
3. Vortex to dissolve the HA. 
4. Place the round bottom flask in a container of ice and place the set-up on a stir 
plate.  
5. Pour the dissolved 1 wt% HA solution from the conical tubes into the round 
bottom flask on ice. 
6. Insert the pH probe into one of the round bottom flask openings and secure it with 
a clamp. 
7. Turn on the stir plate and set it to a fast stir rate to create a vortex. 
8. Slowly dissolve 7.66 mL methacrylic anhydride drop-wise into the HA solution. 
Adjust the pH with 5 N NaOH to maintain a reaction pH of ~8-9.  
9. Continue the polymerization reaction for 8 hours monitoring the pH and adding  
5 N NaOH dropwise as necessary to maintain a pH of ~8-9.  
10. Remove the pH probe and seal the openings of the round bottom flask with 
Parafilm. 
11. Store the polymer reaction solution at 4 °C overnight. 
 
Day 2: 
12. Set-up the round bottom flask on ice with the pH probe and stir plate as was done 
the previous day. 
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13. Add 3.6 mL methacrylic anhydride (1.2 mL/g HA), drop-wise. Adjust the pH with 
5 N NaOH to maintain a reaction pH of ~8-9.  
14. Continue the polymerization reaction for 4 hours monitoring the pH and adding  
5 N NaOH drop-wise as necessary to maintain a pH of ~8-9. Note: Goal is ~100 
mol% HA modification with methacrylates. 
15. Soak dialysis tubing in DI water. 
16. Filter the reaction product solution through cell strainers into the dialysis tubing. 
17. Fill a 4 L beaker with DI water and dialyze the polymer solution against water at 
room temperature. 
 
Days 3-9: 
18. Change the dialysis DI water at least 1x per day. Continue the dialysis at least 1 
week at room temperature. 
 
Day 10: 
19. Remove the MeHA polymer solution from the dialysis tubing and place it in 50 
mL conical tubes 
20. Freeze the polymer solution at -20 ºC. 
 
Day 11 
21. Lyophilize the polymer product.  
22. Store the final product in desiccant protected from light.   
23. Perform NMR characterization to confirm MeHA synthesis and modification %. 
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APPENDIX B 
 
PROTOCOL FOR METHACRYLATED HYALURONIC  
ACID HYDROGEL FABRICATION 
 
 
 
Materials: 
22 x 22 mm activated coverglass 
22 x 22 mm non-activated coverglass  
50 mL conical tubes 
15 mL conical tube caps 
RGD peptide (GCGYGRGDSPG, Custom Synthesis, Genscript), aliquoted to 50 mg/mL  
in PBS and frozen 
0.2 M triethanolamine (TE) buffer in PBS, pH 10.25 
MeHA DTT
0.2 M triethanolamine
pH 10.25
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Synthesized methacrylated hyaluronic acid (MeHA)  
Dithiothreitol (DTT)  
 
Reagents per 50 mL conical tube reaction: 
 
 
 
 
 
 
Protocol for Methacrylated Hyaluronic Acid Hydrogel Fabrication: 
1. Remove DTT from the freezer. 
2. Weigh out MeHA and place it in a 50 mL conical tube. 
3. Dissolve MeHa in the TE buffer using the vortexer to create a 3 wt% solution.  
4. Add the RGD peptide (sterile aliquots – 50 mg/mL in PBS) at a final 
concentration of 1 mM. 
5. Vortex the mixture. 
6. Change the vortex platform to the conical tube foam inserts.   
7. Vortex the mixture 45 minutes on medium. The Michael-type addition reaction of 
the RGD peptide is pH controlled – pH≥8. 
8. Prepare a 25 mg/mL DTT solution in TE buffer and vortex ~45 seconds. Make 
this fresh every time and use it immediately because it is reactive with air. Note: 
MeHA 22.0 mg 
TE buffer, pH 10.25 687 µL 
RGD, 50 mg/mL in PBS 15 µL 
DTT, 25 mg/mL 31 µL 
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Initial gel stiffness can be modulated by varying the DTT concentration to 
increase or decrease crosslinking.  
9. Place an activated 22 x 22 mm coverslip with the activated side facing up on top 
of a 15 mL falcon tube lid to create a “pedestal” to polymerize the gel.  
10. Change the vortex platform back to the standard cup fitting.  
11. Add DTT to the gel solution and vortex to mix. Use immediately. Note: 
Polymerization starts immediately and is controlled by the % DTT and reaction 
pH. 
12. Make gels by pipetting 80 µL of the gel solution directly onto the activated 
coverslip.  
13. Carefully slide a clean (non-activated) coverslip over the gel drop. The gel will 
polymerize between the two coverslips. 
14. Protect the gels from light during polymerization by covering with an upside-
down tray or tented foil.  
15. Polymerize gels 2 hours. 
16. Peel off the top coverslip using a razor blade. 
17. Place gels in a 6 well-plate and swell in 3-4 mL of sterile PBS overnight before use. 
Can be stored up to 2 days if necessary.  
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APPENDIX C 
 
PROTOCOL FOR METHACRYLTED HYALURONIC ACID  
HYDROGEL PHOTOCROSSLINKING 
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Materials: 
Polymerized methacrylated hyaluronic acid (MeHA) hydrogels  
Irgacure 2959 (I2959) photoinitiator 
1x PBS  
Warm 1x PBS buffer for rinses (4 mL per sample) 
Cell culture media 
UV lamp (320-500 nm, 100 watt mercury bulb) 
UV light meter 
 
Protocol for Methacrylated Hyaluronic Acid Hydrogel Photocrosslinking: 
Day 0 
1. Prepare a 0.5 wt% I2959 stock solution in 1x PBS. Vortex overnight to fully 
dissolve, sterile filter, and store protected from light in foil at 4 ºC. 
 
Day 1 
2. Dilute the 0.5 wt% I2959 stock solution 1:10 to 0.05 wt% in media or sterile PBS 
for cell or mechanical testing studies, respectively.  
3. Transfer gels to sterile 35 mm Petri dishes. 
4. Add 2 mL of the 0.05 wt% photoinitiator solution to each dish. 
5. Incubate the gels with the photoinitiator for 30 minutes at 37 ºC and 5% CO2. 
6. Turn on the UV lamp and allow it to warm-up.  
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7. Adjust the vertical height of the light guide so the light intensity at the gel surface 
is 10 mW/cm2.  Note: Make sure the UV light meter probe is calibrated at the 
same vertical height as the gels in the Petri dish. 
8. Expose an individual hydrogel to the desired amount (time) of UV light. The 
media color will turn purple in the presence of free radicals. 
9. Immediately rinse the gel 2x with warm PBS, and add fresh media. 
10. Return the gel to the cell incubator.  
11. Repeat steps 8 and 9 for all remaining gels. 
12. Refresh the cell culture media after UV crosslinking has been completed for all 
the samples. 
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APPENDIX D  
 
PROTOCOL FOR MICROINJECTION OF ADHERENT CELLS 
 
Materials: 
Eppendorf FemtoJet injector  
Eppendorf Injectman NI2 microinjector 
Femtotips injection tips (Eppendorf Cat #930000035) or custom pulled tips 
Microloader tips (Eppendorf Cat #930001007) 
Cells to inject in a traction chamber 
Lysine fixable 10,000 MW Alexa Fluor 488 dextran 
Microcentrifuge or 0.22 µm syringe filter 
Solution for microinjection—Should be 10-20x the optimal in vitro concentration 
 
Parameters to adjust for microinjection 
These parameters can be adjusted using the knobs on the FemtoJet injector unit. The 
volume delivered to the cells is a product of the (injection pressure) x (injection time). 
• Pc (Compensating pressure): The constant back pressure to prevent capillary 
action from pulling media from the sample dish into the injection needle. If Pc is 
not stable your needle is broken or a gasket needs replacement.  
• Pi (Injection pressure): The pressure used to inject your solution.  
• Ti (Injection time): The amount of time the injection needle is inside a cell at the 
set injection pressure delivering your solution. 
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Good starting parameters are: Pc: 30 hPa, Pi: 170 hPa, and Ti: 0.1-0.3 s, but can be 
empirically determined for each system based on the literature for specific cells, 
reagents, and needle geometry combinations.  
 
Protocol for Microinjection of Adherent Cells: 
1. Turn on the LSM microscope, fluorescent bulb, CO2, and heat, and allow the 
environmental chamber to stabilize at 37 °C and 5% CO2. 
2. Place the cell sample in an assembled traction chamber on the microscope and 
bring the cells into focus using the 20x objective and the TPMT LSM mode.  
3. Turn on the FemtoJet injector unit using the switch on the back of the module and 
allow it to warm-up and complete a self-check. Make sure the pressure tubing is 
detached at this point. 
4. Press the menu button on the FemtoJet injector unit to temporarily turn off the 
pressure and wait until a message prompting you to change the capillary appears. 
5. Attach the pressure tubing to the injector unit on one end and the metal shaft of 
the injection needle holder on the other end. 
6. Press the menu button. Note: The Cp pressure will not stabilize unless the 
injection capillary is attached.  
7. Prepare the microinjection sample: 
Note: The sample will dry out quickly and clog the injection needle tip if 
you let it sit for a long period of time, so have your cells ready to go on the 
microscope and the microinjection unit set-up before loading the tips.  
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a. Prepare the injection solution in PBS or other physiological buffer at 10-
20x the optimal in vitro concentration.  
b. Add a co-injection fluorescent marker at a 1-10 mg/mL final 
concentration. The lysine fixable Alexa Fluor 488 dextran works well at 
10 mg/mL. If you want to fix, permeabilize and stain your cells after 
microinjection, make sure you use a fixable fluorescent dextran. Normal 
FITC will wash out of the cells during permeabilization and washing.  
c. Filter the final microinjection solution through a 0.22 µm syringe filter or 
centrifuge it for 15 minutes at the highest speed and remove the 
supernatant.  
d. Using a microloader tip, pick up 3 µL of the solution to be injected, and 
thread the microloader into the top of a glass injection needle all the way 
to the bottom. 
e.  Release the injection solution at the bottom of the capillary as you are 
removing the pipette. 
f. If air bubbles are present, vigorously flick your wrist repeatedly to remove 
the bubbles and force the liquid solution to the bottom of the 
microinjection capillary.  
8. Press the menu button on the FemtoJet injector unit and wait until a message 
prompting you to change the capillary appears. 
9. Attach the loaded glass capillary needle to the free end of the injection needle 
holder. 
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10. Press the menu button on the FemtoJet injector unit to resume pressure through 
the tubing. The Cp (compensating pressure) on the FemtoJet injector screen 
should be constant. An unstable Cp indicates that a gasket should be changed or 
your needle is broken. Note: If there is no back pressure in your needle as you 
lower it into the cell media to inject, capillary action can pull media into the 
needle tip and will dilute your injection solution. 
11. Press the clean button on the FemtoJet injector unit to push a high pressure burst 
through your needle tip to clear it. 
12. Tilt the injection motor unit (black casing attached to the microscope) downwards 
into the load position. 
13. Wake-up the Injectman NI2 microinjector joystick unit by pushing the standby 
button. 
14. Press the coarse adjustment button on the joystick unit and lower the 
microinjection tip into your sample by rotating the joystick until you can visually 
see that it is beneath the liquid surface.  
15. Turn on the appropriate fluorescent channel for your co-injection marker and 
visually move the tip in the x-y plane using the joystick to the general vicinity of 
the objective center. 
16. Press the fine adjustment button to slow the speed of the needle movement.  
17. Using the oculars, slowly lower the injection needle until it comes into a sharp 
focus. The solution inside the needle will have a bright fluorescent signal. The 
needle will appear rounded if you are centered away from the tip on the body of 
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the glass capillary, but will focus as you lower the needle and translate it 
horizontally to focus on the tip.  
18. Switch to the LSM imaging mode, and using the TPMT make sure both your cells 
and injection needle are in focus. If you need to change the z-plane of the stage to 
bring your cells into focus, significantly raise up the needle first, focus the cells, 
and then slowly lower the needle back down.  
19. To perform an injection, lower the microinjection needle until you visually see the 
cell membrane of the target cell slightly deform and that the needle has entered 
the cell. 
20. Press the limit button on the Injectman joystick unit. This sets the z-limit where 
the needle is currently located as the location where the injection will occur. You 
will not be able to manually move the joystick lower than this z-position unless 
you push the limit button again to remove the current set z-limit.  
21. Raise the needle and move it to a new cell. Lower the needle until it hovers just 
over the top of the new target cell membrane. 
22. Push the inject button or the button on the top of the joystick to inject the target 
cell using the current injection pressure and time settings. The injection needle 
will raise up and move backwards at a 45° angle, and then lower down at the 
same angle to pierce the cell. 
23. Use your co-injection signal to verify that material was successfully delivered to 
the target cell.  
24. Continue moving around your cell sample injecting cells. Raise the needle up 
before any large movements of the sample. Because your sample is likely not 
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completely flat due to variations in the coverglass thickness and the amount of 
vacuum grease used to attach the coverglass to the traction chamber, it may be 
necessary to reset the injection z-limit for different regions of your sample. 
25. If the injection needle becomes clogged, use the home button to retract the needle 
out of the solution and press the clean button to push through a high burst of 
pressurized air. Use the home button to return the needle back to your sample. 
Note: If you move the needle with the joystick unit after retracting it, the home 
function will not work to return the needle. Repeatedly using the home feature to 
retract and lower the needle can also be used to remove debris that are stuck to the 
needle exterior.  
26. If your needle breaks or becomes clogged and needs replacement: 
a. Use the home button to retract the needle out of the solution. 
b. Tilt the injection motor unit attached to the microscope backwards. 
c. Press the menu button until it prompts you to change the capillary. 
d. Remove the old injection needle. 
e. Fill a new injection needle with solution. 
f. Return to step 8, and proceed through the protocol.  
27. To turn off the microinjection unit: 
a. Use the home button to retract the needle out of the solution. 
b. Tilt the injection motor unit attached to the microscope backwards. 
c. Press the menu button until it prompts you to change the capillary. 
d. Remove the injection needle. 
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e. Firmly press and hold the standby button for 3 seconds on the FemtoJet 
injector unit until you hear a loud exhaust as the pressure is bled out of the 
diaphragm. The FemtoJet inject unit will prompt you to wait, and then 
enter standby mode.  
f. Turn off the FemtoJect inject unit using the switch on the back. 
g. Disconnect the pressure tubing.  
h. Press the standby button on the Injectman microinjector unit until the 
display dims. 
 
Other Notes: 
• The FemtoJet injector unit will record the number of injections you have 
performed. It is the “n” number on the screen.  
• The menu button on the FemtoJet injector unit can be used to enter into various 
menus and change advanced settings. Use the knobs on the front of the unit to 
cycle through menu options. 
• The Pos 1/Pos 2 buttons on the Injectman Unit are memory keys that can be used 
to save positions. Pushing the button saves the position. Pushing the button at the 
saved position removes it.  
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APPENDIX E 
 
PROTOCOL FOR LOCAL SUBCELLULAR PERMEABILITY ASSAY 
Adapted from Dubrovskyi et al., 2013. 
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A. Biotinylated Gelatin Synthesis:
B. Biotin-Streptavidin Interaction:
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Materials: 
Type A porcine gelatin  
0.1 mol/L NaHCO3, pH 8.3 buffer 
EZ-Link NHS-LC-LC-Biotin (Cat. #21343, Thermo Scientific) 
 
DMSO 
Hot/stir plate and stir bar 
Water bath 
Centrifuge 
 
Protocol for Synthesis of Biotinylated Gelatin: 
1. Allow the NHS-biotin to warm to room temperature. 
2. Prepare a 70 ºC water bath. 
3. Prepare a 10 mg/mL gelatin solution in 0.1 mol/L NaHCO3, pH 8.3 and dissolve 
the gelatin by heating the solution in the water bath with continuous stirring. 
a. Example:  600 mg gelatin in 60 mL of NaHCO3, buffer 
4. Centrifuge the gelatin solution for 5 min at 10,000 x g at room temperature to 
clarify. 
5. Dissolve the EZ-link biotin in DMSO at 5.7 mg/mL and mix by pipetting up and 
down. 
a. Example: 28.5 mg EZ-link biotin in 5 mL DMSO 
6. Combine the biotin and gelatin solutions in a 1:10 ratio for a final biotin 
concentration of 0.57 mg/mL biotin.  
a. Example: 45 mL of gelatin from #4 and 5 mL of biotin from #6 
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7. React for 1 hour at room temperature to conjugate the biotin to the gelatin. 
8. Prepare 3 mL aliquots of the biotinylated gelatin and store at -20 ºC. 
 
 
Materials: 
0.57 mg/mL biotinylated gelatin aliquots, stored at -20 ºC 
0.1 mol/L NaHCO3, pH 8.3 buffer 
Parafilm 
Activated 22 x 22 coverglass or PA gels on 22 x 22 coverglass 
6 well plate 
PBS 
 
Protocol for Coating Coverglass with Biotinylated Gelatin for Cell Studies: 
1. Thaw biotinylated gelatin aliquots in a 37 ºC water bath for 10 minutes. 
2. Add 0.1 mol/L NaHCO3 buffer for a final protein concentration of 0.25 mg/mL.  
a. Example: 3.35 mL buffer per 3 mL aliquot. 
3. Create 200 µL drops of the protein solution on Parafilm. 
4. Invert coverlass onto the liquid drop with the activated side (or PA gel) touching 
the protein solution and incubate for 30 minutes at room temperature. 
5. Place coverglass in a 6 well plate and rinse with PBS. 
6. Proceed to cell culture. 
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Materials: 
Confluent cell monolayers cultured on a biotinylated gelatin substrate 
Alexa Fluor 568 streptavidin 
Cell culture media, warmed to 37 ºC 
PBS 
3.7 % formaldehyde in PBS 
 
Protocol for Localized Subcellular Permeability Assay: 
1. Prepare a 25 µg/mL solution of Alexa Fluor 568 streptavidin in warm cell culture 
media.  
2. Remove the culture media from samples and add 2 mL of the streptavidin 
containing media. 
3. Incubate 5 minutes. 
4. Wash samples 2x with 3 mL PBS. 
5. Fix samples with 3.7% PFA. 
6. Proceed to cell staining 
7. Visualize stained cellular structures and the fluorescent biotin-streptavidin signal. 
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APPENDIX F 
 
PROTOCOLS FOR PLASMID AND LENTIVIRUS MOLECULR BIOLOGY 
 
Contents: 
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F.1 Process Flow 
 
1. Pick gene of interest. 
2. Choose plasmid source.  
a. Addgene (Type of vector dictates where in the process flow you begin) 
b. cDNA 
3. Primer design 
4. Convert mRNA to cDNA 
5. Generate the plasmid (i.e. with overlapping PCR) 
a. Sample 1: Overlapping PCR to create construct of interest 
i. Overlapping PCR for fusion constructs  
ii. Amplification PCR  
iii. PCR cleanup 
iv. Restriction digest 
v. Agarose gel electrophoresis 
vi. Agarose gel extraction 
vii. Preparation of LB + Ampicillin agar plates 
viii. Ligation 
ix. Transformation 
x. Sequencing 
b. Sample 2: Modify an existing plasmid (i.e. replace a fluorescent tag) 
i. Amplification PCR for replacement sequence  
ii. PCR cleanup 
iii. Restriction digest 
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iv. Agarose gel electrophoresis 
v. Agarose gel extraction 
vi. Ligation 
vii. Transformation 
viii. Sequencing 
6. Preparation of LB + Ampicillin broth 
7. Inoculation 
8. Midiprep 
9. Transfection 
10. Lentiviral concentration 
11. Transduction 
  
 196 
F.2 Primer Design 
1. Find the reference sequence for the gene of interest. 
a. NCBI has reference sequences for many genes: 
http://www.ncbi.nlm.nih.gov/gene 
b. Under NCBI Reference Sequences: 
i. NM = DNA sequence referring to mRNA 
ii. NP = DNA sequence referring to polypeptide (final protein) 
c. Many proteins undergo processing. Click on NM to view the mRNA. 
i. CDS = Coding sequence (ORFs), excluding introns and 5’/3’ UTR 
(click to highlight in the sequence) 
ii. Sig_peptide = DNA sequence referring to the signaling portion of 
the peptide 
1. If you want to change the N-terminus region, this could 
interfere with the signaling peptide function (i.e. secretion). 
iii. Mat_peptide = DNA sequence referring to the mature peptide 
d. To find the protein structure: 
i. UniProt (http://www.uniprot.org/) provides information on protein 
structure.  
e. Efficiency of transfection is inversely related to the plasmid size. 
2. Manipulate the mRNA gene sequence in ApE plasmid editing software. 
a.  http://biologylabs.utah.edu/jorgensen/wayned/ape/ 
b. Example: Adding GFP to the C-terminus 
c. Copy the desired mRNA into a new file in ApE.  
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i. Annotate features with “Features” à “New Feature” 
ii. Highlight restriction sites with “Enzymes” à “Highlight” 
d. [if needed] Delete unnecessary stop codons (TAA, TAG, TGA).  
e. [if adding a GFP reporter] Open the eGFP sequence (brighter than GFP) 
and copy the sequence at end of the mRNA sequence. 
i. Do not include the “ATG” sequence because the gene already has 
a start codon from the fusion protein mRNA. Keep the stop codon 
after the eGFP sequence. 
f. Check existing restriction sites within your plasmid and the desired 
mRNA insert using the enzyme tab. 
i. Open the graphic maps and highlight unique restriction sites. 
1. You need 1 unique restriction site before and after the 
inserted sequence. 
ii. Only use restriction enzymes that have 1 restriction site within the 
polyclonal site. 
g. Copy the entire [fusion] gene sequence into your plasmid between your 
two unique restriction sites that are also not present within your [fusion] 
sequence. 
h. It is good practice to check the amino acid sequence of your construct. 
Select the sequence you would like to translate, and click “ORFs” and 
“Translate” to view the amino acid sequence. 
i. Adding a Kozak sequence can improve protein expression if placed directly 
before the start codon: GCCGCC (ATG). 
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3. Designing primers for amplification. 
a. The melting temperature of the primers is an important parameter.  
i. Increasing the length of the DNA increases the melting temperature: 
generally want ~20 nucleotides. 
ii. Increasing the GC content of the DNA increases the melting 
temperature: generally want ~50%. 
iii. The melting temperature of the primers should be similar: generally 
around ~60 °C is optimal. 
b. Also avoid three CG nucleotides at the beginning or end of a primer because 
it reduces the binding specificity. 
c. Add a kozak sequence before the annealing sequence on the forward primer 
(if desired). 
d. Add restriction sites for future digestion with restriction enzymes.  
e. Add additional overhang 4-6 base pairs (length required depends on the 
specific restriction enzyme) of random A,T nucleotides (decreases the Tm). 
f. Example forward primer: 
i. Overhang – XbaI – Cozak – 1st 20 NTs 
ii. atta – TCTAGA – gccacc – “1st 20 NTs” 
g. Example reverse primer:  
i. Reverse complement of [Last 20 NTs – EcoRI – overhang] 
ii. Reverse Complement of [“Last 20 NTs” – GAATTC – atta] 
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4. Designing primers for sequencing: 
a. Generally, the 1st 50 base pairs after the primer are noisy, the next 800 base 
pairs are reliable, and the signal is noisy and unreliable beyond 800 base 
pairs. 
b. Design multiple primers from the plasmid sequence regions of interest such 
that the entire construct is sequenced. 
c. Addgene has standard primer sequences listed for specific lentiviral 
backbones and their features. 
5. Order primers from Integrated DNA Technologies (IDT). 
a. 25 nm DNA oligo 
b. Standard desalting 
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F.3 Conversion of mRNA to cDNA 
 
Materials: 
RNA to cDNA EcoDryTM Premix (Oligo dT) kit (Clontech Cat. #639543) 
1-5 µg RNA 
20 µL endotoxin free water 
PCR machine 
Nanodrop 
Microcentrifuge 
 
Protocol for Conversion of mRNA to cDNA: 
1. Measure mRNA using the nanodrop and calculate the volume needed to obtain   
1-5 µg of total mRNA. 
a. Example: 406.6 ng/µL à 5 µL mRNA 
b. 230 nm peak = salt contamination 
c. 280 nm peak = protein concentration (benzene rings) 
2. Dilute mRNA to a final volume of 20 µL. 
a. Example: 5 µL mRNA = 15 µL nuclease free water 
3. Add 20 µL of RNA dilution to each tube of EcoDry premix that is needed. 
4. Pipette up and down several times to dissolve the pellet, then cap the tube(s). 
5. Spin briefly in a centrifuge. 
6. Use the PCR Machine to conduct the reaction: 
a. Incubate at 42 °C for 60 minutes. 
b. Stop the reaction by heating at 70 °C for 10 minutes. 
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7. Store cDNA at -20 °C (4 °C is fine for use the next day). 
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F.4 PCR Amplification 
 
Materials:  
100 ng template DNA 
10 µM primers (forward & reverse) (order from IDT, 25 nmole DNA oligo, standard  
desalting) 
dNTP mixture (New England Biolabs Cat. #N0447S) 
DNA polymerase 
a. Taq (New England Biolabs Cat. #M0273L) 
b. PFU (Agilent Technologies Cat. #600255-52) 
c. LA Taq (Clontech Cat. #RR02AG) 
d. Phusion (New England Biolabs Cat. #M0530S) 
Polymerase buffer 
a. Taq: 10x standard Taq buffer 
b. PFU: 10x cloned PFU reaction buffer 
c. LA Taq: 2x LA Taq GC buffers  
d. Phusion: 5x standard and GC Phusion buffer 
Nuclease free water 
PCR machine 
Microcentrifuge 
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Protocol for PCR Amplification: 
1. Reconstitute lyophilized primers (if necessary). 
a. Spin lyophilized DNA at 12,000 rpm for 1 min. 
b. Reconstitute with autoclaved water to 100 µM (stock solution). 
i. Example: DNA amount = 27.4 nmol, add 274 µL water to get 100 
µM 
c. Shake to mix. 
d. Complete a short spin after mixing (5,000 rpm). 
e. Dilute primers to a working solution of 10 µM.  
i. Example: Add 180 µL of water to 20 µL of primer 
ii. This is good for ~1 month. 
2. Create a PCR master mix. 
a. In order add: water, template, primers, dNTPs, buffer. 
i. Keep enzymes cold in a cryosafe box (-20 °C). 
ii. Buffer should be thawed completely and mixed via inversion. 
b. Aliquot master mix to PCR tubes. 
c. Add polymerases. 
i. The pipette tip should only touch the interface of the enzyme 
stored in viscous glycerol. You do not want excess polymerase on 
the pipette tip to avoid star activity (reduced specificity). 
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d. Example reaction mix: Phusion polymerase: 
i. Template (100 ng)  1 uL 
ii. Forward primer (10 µM) 5 µL 
iii. Reverse primer (10 µM) 5 µL 
iv. dNTPs (10 mM)  1 µL 
v. 5x Phusion buffer   10 µL 
vi. Phusion   1 µL 
vii. Nulcease free water  27 µL 
viii. Total volume   50 µL 
3. Run PCR as per the polymerase specific protocol, which can be optimized from 
NEB software available online. 
a. Modify extension time to fit the product size and polymerase speed  
(i.e. Taq is slower than Phusion). 
b. Cycle 3 is a final extension cycle to complete any fragments that were not 
completely synthesized. 
4. Notes: 
a. The annealing temperature for Taq should be 4-5° lower than the melting 
temperature for the primers without the restriction site. Use what the API 
software predicts without the restriction sites and not what IDT reports on 
the primers. 
b. The annealing temperature for Phusion can be the melting temperature. 
c. In general, the annealing temperature should be 4-5 °C lower than melting 
temperature of primers. 
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i. Higher temperatures drive specificity of primer binding. 
ii. Lower temperatures allow DNA to bind. 
iii. Useful tool: http://tmcalculator.neb.com/#!/ 
d. A Taq/PFU mixture mixes a high efficiency enzyme with a slow, accurate 
enzyme (mix 1:1 ratio). 
i. Taq is the most common and a very efficient enzyme: 1 kB/min. 
Can amplify difficult templates. 
ii. PFU is slow, but very accurate: 800 bp/min. Has an error checking 
function. 
e. Phusion from New England Biolabs is a very accurate and very fast 
enzyme (if it works, use it!). 
i. Sometimes it will not bind GC rich templates. 
ii. Very fast: 1 kB/15 s 
f. LA Taq is a last resort enzyme for difficult transcripts. 
i. It is good for templates that are difficult, but an expensive enzyme. 
g. Hot Start 
i. Add the enzyme after 30 seconds of denaturing. 
ii. Avoids non-specific amplification of DNA by enzymes at lower 
temperatures. 
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F.5 Agarose Gel Electrophoresis 
 
Materials: 
DNA 
Ethidium Bromide – intercalating agent that is carcinogenic 
1x TAE electrophoresis buffer 
Agarose powder 
6x Loading dye (Invitrogen Cat #XR0611) 
1 kB Plus DNA ladder (Invitrogen Cat #10787018) 
Erlenmeyer flask (designated for ethidium bromide) 
Graduated cylinder 
Gel casting tray and combs 
Hot plate (for extraction) 
Microwave 
Surgical blade 
UV trans-illuminator 
 
Protocol for Agarose Gel Electrophoresis: 
1. Prepare 50 mL of 1x TAE electrophoresis buffer and pour it into the Erlenmeyer 
flask. 
a. TAE buffer can be reused 2-3 times for verification gels. 
b. Use fresh TAE buffer if performing gel extraction for a purified product. 
2. Make an agarose gel of the appropriate wt%. 
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a. Measure and the add appropriate amount of agarose powder to 1x TAE 
buffer. 
i. Example: 0.8 % agarose gel: 
1.  ~60 mL of 1x TAE buffer  
2. 0.48 g agarose   
ii. The amount of agarose is dependent on the desired resolution of 
the gel. 
iii. A 0.8 % agarose gel is versatile with the ability to separate 
fragments from 0.5 – 12 kB. 
b. Heat up the agarose solution in the microwave. 
i. Heat for 30 seconds, swirl, heat for 30 seconds. 
c. Allow the agarose solution to cool until it is warm enough to hold. 
i. The warm agarose solution can be cooled by running cold tap 
water along the outside of the flask. 
d. Add ethidium bromide to the warm (40 – 50 °C) agarose solution. 
i. Do NOT add ethidium bromide to hot agarose (Volatile ethidium 
bromide becomes a carcinogenic fume!). 
ii. Add a 10,000 fold dilution of 5 mg/mL ethidium bromide. 
1. Example: 6 µL to 60 mL of agarose solution 
iii. Store extra ethidium bromide in foil (it is a fluorescent molecule). 
e. Pour the warm agarose solution into the gel casting tray and add combs. 
f. Allow the gel to solidify at RT for at least 1 hour OR at 4 °C (cold room) 
for 30 minutes. 
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g. Once the gel is solidified: 
i.  Remove combs. 
ii. Cut the gel to separate each half and to only include the desired 
number of lanes. 
iii. Store extra gel pieces at 4 °C in an empty pipette tip box with 1x 
TAE buffer with 1:10,000 ethidium bromide (extra gels are good 
for ~1 week). 
3. Place the gel in the electrophoresis unit and cover with 1x TAE buffer. 
4. Prepare DNA samples. 
a. For simple verification: 
i. Add 1 µL of DNA to 5 µL of 6x loading dye. 
ii. Mix loading dye and DNA on parafilm. 
b. For gel extraction, use wide lanes and 40 µL of DNA and 5 µL of loading 
dye. 
i. Electrophoresis is constrained by lanes that can only hold 50 µL 
volume. 
ii. Separate lanes by 1 empty lane to avoid contamination. 
iii. Load with the tip at the bottom of the well to avoid losing sample. 
c. Add 2-3 µL of 1 kB plus DNA ladder to an empty well. 
i. To dilute a stock ladder (1 µg/µL to 100 ng/µL), mix the 
following: 
1. 50 µL of [1 µg/µL] stock ladder 
2. 450 µL of nuclease-free water 
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3. 100 µL of 6x loading dye 
5. Turn on the electricity to the electrophoresis unit. 
a. Run black (negative) to red (positive). 
b. Run at high voltage (120 V) for detection. 
c. Run at low voltage (80 or 100 V) for gel extraction. 
i. If the voltage is too high, buffer gets hot and DNA can diffuse out. 
6. If performing gel extraction, heat a hot plate to 50 °C.  
7. Run the gel for the desired level of separation and view it on the UV trans-
illuminator.  
a. For verification, excellent separation is not essential.  
i. View DNA at short wavelengths (302 nm). 
b. Gel extraction requires excellent separation to prevent isolating non-
specific amplified products. 
c. DO NOT view DNA that you want to use under short wavelengths for 
long time periods, as this can crosslink the DNA. 
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F.6 Agarose Gel Extraction 
 
Materials: 
Agarose gel with separated bands 
QIAquick® Gel Extraction Kit (Qiagen Cat. #28704) 
 (or kit components purchased/prepared individually) 
Nuclease-free water 
Ethanol 
1.5 mL Micro-centrifuge tubes 
2 mL collection tubes 
Hot Plate 
Surgical blade 
UV trans-illuminator 
UV glasses 
Nanodrop 
Microcentrifuge 
 
Protocol for Agarose Gel Extraction: 
1. Image the gel under UV trans-illuminator. 
a. Gel extraction requires excellent separation to prevent isolating non-
specific amplified products. 
b. Do NOT view DNA that you want to use under short wavelengths for long 
time periods, as this can crosslink the DNA. 
2. Cut the gel to isolate individual bands for extraction. 
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a. Clean the UV trans-illuminator and surgical blade with ethanol before 
cutting to avoid contamination. 
b. Label a micro-centrifuge tube for each lane you are extracting before 
cutting.  
c. Put on a face shield or UV protective glasses. 
d. Cut the desired product out of the gel at long λ UV (365 nm). 
e. Trim off all extra gel fragments (including below and above well) because 
extra gel lowers the yield.  
3. Weigh the gel fragment containing the DNA (use an empty centrifuge tube as 
blank) and assume a density of 1 mg/µL. 
4. Add 3 volumes of Buffer QG buffer per 1 volume of gel. 
a. Example: Assume 100 mg ≈ 100 µL  
i. DNA in gel = 120 mg  
ii. Add 360 µL QG buffer 
5. Incubate the DNA and QG buffer tube at 50 °C for at least 5 minutes to digest 
completely.  
a. At this time also put nuclease-free water to warm for elution. 
i. Place a tube with nuclease-free water (at least 50 µL) into the hot 
plate at 50 °C. 
6. Add 1 volume of isopropanol to the tube and mix by inverting (Do NOT vortex 
because it will shear the DNA). 
7. Perform a quick spin to bring liquid down from the lid. 
8. Place a QIAquick spin column (silica column) into a 2 mL collection tube. 
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9. Pipette the sample into the spin column (binds DNA to spin column). 
a. Centrifuge for 1 minute at 12,000 rpm. 
b. Discard flow-through. 
c. If the sample volume exceeds 750 µL, load the remaining volume and spin 
again. 
10. Add 300 µL of Buffer QG to the spin column (removes traces of agarose). 
a. Centrifuge for 1 minute at 12,000 rpm. 
b. Discard flow-through. 
11. Add 700 µL of Buffer PE or DNA wash buffer (washes unwanted primers, salts, 
enzymes, unincorporated nucleotides, agarose, dyes, ethidium bromide, oils, and 
detergents).  
a. Centrifuge for 1 minute at 12,000 rpm. 
b. Discard flow-through. 
c. Repeat wash, spin, and discard flow-through. 
12. Spin empty tube for 1 minute at 12,000 rpm (removes traces of Buffer PE). 
13. Swap the collection tube for a clean, new micro-centrifuge tube. 
14. Add [20 µL] of warmed nuclease-free water (or buffer EB) into the spin column 
to elute the DNA. 
a. Water needs to be between pH 7.0 and 8.5 to achieve maximum elution 
efficiency. 
b. Allow the water to sit for a couple minutes (2 – 5 minutes) before 
spinning. 
c. Centrifuge for 1 minute at 12,000 rpm. 
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d. Keep flow-through, discard column. 
e. [Adjust volume of water for elution to tune concentration]. 
15. Measure DNA concentration with the nanodrop and label the side of the tube with 
the value. 
a. Store DNA at -20 °C as DNA may degrade in the absence of a buffering 
agent. 
i. Particularly important if the elution is done with water. 
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F.7 PCR Clean-up and Restriction Enzyme Digestion 
 
Materials: 
PCR product 
Omega E.Z.N.A. Cycle Pure PCR Cleanup Kit (Cat. # D6493-01)  
Restriction enzymes (available from New England Biolabs) 
Restriction enzyme buffer, ex. Cutsmart buffer (often included with enzyme purchase) 
Nuclease free water 
Clean microcentrifuge collection tube 
Microcentrifuge 
 
Protocol for PCR Clean-up and Restriction Enzyme Digestion: 
1. PCR Cleanup: Changes the solvent of a PCR product so it is optimal for 
subsequent digestion reactions. 
a. Warm nuclease free water for elution to 60 °C. 
b. Add 5 volumes of buffer CP (guanine chloride) (kit) to 1 volume PCR 
product. Mix by pipetting. 
i. Example: 500 µL CP for 100 µL PCR product 
c. Add DNA to the silica column (kit). 
d. Spin at 12,000 rpm for 1 min. Discard flow-through. 
e. Wash salt off DNA by adding 700 µL DNA wash buffer (kit) to the spin 
column. 
f. Spin at 12,000 rpm for 1 min. Discard flow-through. 
g. Repeat wash with 700 µL DNA wash buffer (kit). 
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h. Spin at 12,000 rpm for 1 min. Discard flow-through. 
i. Spin at 12,000 rpm for 1 min (empty spin).  
j. Transfer the silica column to a clean microcentrifuge tube. 
k. Elute DNA with warm nuclease free (60 °C) water. 
i. The volume of elution water is dependent on the subsequent 
restriction digest reaction. A typical elution volume is 35 µL. 
ii. Add water directly onto the filter membrane (not onto the side of 
the tube). 
iii. Incubate water in the filter for 10 minutes. 
iv. Spin at 12,000 rpm for 1 min. Keep flow-through. 
2. Prepare the restriction digest reaction in a 1.7 mL micro-centrifuge tube (total 
reaction volume 40 µL). 
a. Add 33 µL of the PCR product to the microcentrifuge tube. 
i. Digestion of plasmids (which are often more concentrated) require 
less DNA, can use 10 µg.  
ii. Add 10 - 12 µg of DNA if the concentration is known. 
b. Add 4 µL of 10x CutSmart buffer. 
c. Add 1.5 µL of restriction enzyme 1 (i.e. XbaI). 
d. Add 1.5 µL of restriction enzyme 2 (i.e. EcoR1). 
e. Add nuclease-free water to reach a final reaction volume of 40 µL. 
f. Incubate reaction overnight at 37 °C. 
i.  Invert tube (gently, so the liquid remains suspended). 
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ii. The liquid should be at the top of the inverted tube so there is no 
evaporation and condensation. 
iii. Can incubate the reaction in a cell culture or bacterial incubator. 
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F.8 Plasmid Ligation 
 
Materials: 
T4 DNA Ligase (stored in CryoSafe box) (New England Biolabs Cat. #M0202) 
10x Ligation buffer (comes with ligase) 
Ice bucket with ice 
DNA substrate 
Nuclease free water  
 
Protocol for Plasmid Ligation: 
1. Thaw ligation buffer on ice. 
a. Temperature sensitive because it contains ATP which can degrade. 
b. Aliquot stock solution into 10 µL aliquots if working with new buffer to 
avoid freeze/thaw cycles. 
2. Determine volume of insert and backbone for ligation. 
a. The mass ratio of insert : backbone should be at least 3 : 1 
i. Example: Fix backbone at 100 ng. If the backbone is 3x as large as 
the insert, 100 ng of the insert will yield a 3 : 1 ratio of insert : 
backbone. 
ii. Increasing the ratio improves the likelihood of forcing the insert 
into the backbone (can use 9 : 1). 
3. Set up the ligation reaction (total reaction volume = 10 µL).  
a. Mix backbone and insert first.  
b. Subsequently add water, buffer, and ligase 
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i. Avoid dipping pipette into glycerol. High amounts of glycerol in 
the reaction mixture lead to star activity (reduced specificity). 
c. Example: Ligation Reaction 
i. Backbone (9200 bp, 71 ng/ µL)  1.5 µL 
ii. Insert (3100 bp, 65.6 ng/ µL)   4.5 µL 
iii. Nuclease free water    2 µL 
iv. Ligation buffer (stored on ice)  1 µL 
v. T4 DNA Ligase (stored in cryosafe box) 1 µL  
vi. Total volume     10 µL 
4. React at room temperature 3-4 hours or overnight. 
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F.9 Plasmid Sequencing 
 
Materials: 
Sequencing tubes (VWR Cat. #16466-052) 
Sequencing primers (Common Common primer sequences for lentiviral backbones are  
available on Addgene or can be designed for your insert F.2) 
 
Protocol for Plasmid Sequencing (at Cornell): 
1. Label sequencing tubes numerically on the caps and sides, i.e. 1, 2, 3, etc. In your 
notebook, document the details of each sample.  
a. Only one primer per tube. 
b. Forward and reverse sequencing primers go in separate tubes. 
2. Combine 1 µg of plasmid DNA with ~8 pmole of primer.  
a. 1 µL of 10 mM plasmid stock is okay. 
3. Add nuclease-free water to a final volume of 18 µL. 
4. Submit an online order with an approved account number at: 
a. https://cores.lifesciences.cornell.edu/userdev/placeorder.php 
b. http://www.biotech.cornell.edu/brc/genomics-facility  
5. Drop-off the physical samples in a Ziploc bag to 147 Biotech from 8:00 am to 4:00 
pm, Monday-Friday. 
a. Results will be emailed. 
6. Analyze the results using a sequence similarity BLAST search.  
a. NCBI Blast Search  
b. First 50 base pairs are noise  
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F.10 Fabrication of LB Broth 
 
Materials: 
Sodium chloride (NaCl) (VWR Cat. #BDH8014-500G) 
Tryptone (EMD Cat. #1.07213.1000) 
Yeast extract (EMD Cat. #1.03753.0500) 
Ampicillin 
0.2 µm sterile syringe filter 
Sterile conical tube 
Syringe 
1 L bottle 
Bunsen burner 
 
Protocol for Fabrication of LB Broth: 
1. Measure 1 L of DI water and add it to the 1 L bottle. 
2. Weigh and add the following: 
a. 10 g NaCl 
b. 10 g Tryptone 
c. 5 g Yeast extract 
3. Swirl to mix. 
4. Autoclave the bottle on the liquid cycle. 
5. [Prepare sterile Ampicillin if needed] 
a. Add 1 g Ampicillin to 10 mL DI water. 
b. Shake and stir to dissolve. 
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c. Sterile filter with a 0.2 µm syringe filter into a sterile conical tube. 
d. Aliquot Ampicillin and store at -20 °C. 
6. Allow the autoclaved broth to cool to ~40 °C (able to hold). 
7. Turn on a Bunsen burner. 
8. Working near the flame, add a 1/1000 dilution of Ampicillin. Or other appropriate 
antibiotic.  
a. Example: 200 µL Ampicillin for 200 mL broth. 
9. Wrap the LB broth + Ampicillin bottle in aluminum foil to protect from light and 
store at 4 °C in the cold room. 
a. Ampicillin is good for 2-3 months in solution in the cold room (degrades 
via hydrolysis). 
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F.11 Fabrication of Agar Plates 
 
Materials: 
Sterile 100 mm Petri dishes 
Sodium chloride (NaCl) (VWR Cat. #BDH8014-500G) 
Tryptone (EMD Cat. #1.07213.1000) 
Yeast extract (EMD Cat. #1.03753.0500) 
Agar (Fisher Cat. #A360-500) 
Ampicillin 
0.2 µm sterile syringe filter 
Sterile conical tube 
Syringe 
1 L bottle 
Bunsen burner 
 
Protocol for Fabrication of Agar Plates: 
1. Measure 200 mL DI water and add it to the 1 L bottle. 
2. Weigh and add the following: 
a. 2 g NaCl 
b. 2 g Tryptone 
c. 1 g Yeast extract 
d. 3 g Agar 
3. Swirl to mix. 
4. Autoclave the bottle on the liquid cycle. 
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5. [Prepare sterile Ampicillin if needed] 
a. Add 1 g Ampicillin to 10 mL DI water. 
b. Shake and stir to dissolve. 
c. Sterile filter with a 0.2 µm syringe filter into a sterile conical tube. 
d. Aliquot Ampicillin. 
6. Allow the autoclaved broth to cool to ~40 °C (able to hold). 
7. Lay out Petri dishes on a clean bench surface near a Bunsen burner. 
8. Turn on a Bunsen burner. 
9. Working near the flame, add a 1/1000 dilution of Ampicillin. Or other appropriate 
antibiotic. 
a. Example: 200 µL Ampicillin for 200 mL broth. 
10.  Working near the flame, add the LB + Ampicillin agar solution to the Petri dishes 
by pouring or using a serological pipette. 
a. Pour enough volume to cover the bottom of the plate and cover. 
b. Allow petri dishes to solidify while covered for 1 hour. 
c. Invert dishes and allow them to cool completely, several hours to 
overnight. 
d. Store dishes in saran wrap and aluminum foil at 4 °C. 
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F.12 Bacterial Transformation 
 
Materials: 
Max Efficiency DH5α Competent Cells (store at -80 °C)  
(Thermo Fisher Cat. #18258 – 012) 
Ligation product plasmid 
pUC19 control DNA 
SOC media 
42 °C water bath 
LB + Ampicillin agar plates (or other appropriate antibiotic)  
Ethanol 
Dry ice 
Bunsen burner 
Bacterial incubator 
 
Protocol for Bacterial Transformation: 
1. Warm LB + Ampicillin agar plates in a 37 °C bacterial incubator. 
2. Warm SOC medium to room temperature. 
3. Thaw competent cells on ice.  
a. Put the ligation product on ice (in the reaction microcentrifuge tube).  
b. Put a positive control microcentrifuge tube on ice (if using). 
4. Pipette 50 µL competent cells into the ligation product (and positive control tube 
if using). 
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a. Do NOT mix. Cell are extremely fragile cells. Expel slowly while moving 
tip through the solution volume. 
b. Make 50 µL aliquots of the remaining competent cell stock.  
i. Refreeze unused cell aliquots in a dry ice/ethanol bath for 5 
minutes. 
ii. Return frozen competent cells to the -80 °C freezer. 
5. Add 5 µL (50 pg) pUC19 control DNA to the positive control tube (if using). 
a. If the competent cell kit is new: 
i.  Aliquot the stock pUC19 control DNA 
ii. 11 µL aliquots 
iii. Return to -80 °C freezer 
6. Incubate cells on ice for 30 minutes. 
7. Heat shock cells in a 42 °C water bath for 45 seconds. Do not shake cells. 
8. Incubate cells on ice for 2 minutes. 
9. Turn on a Bunsen burner. 
10. Working near the flame, add 100 µL of SOC media to the cells. 
11. Shake tubes at 225 rpm at 37 °C for 1 hour in the bacterial incubator. 
12. Turn on a Bunsen burner. 
13. Working near a flame, spread all the reaction volume per tube onto a LB + 
Ampicillin agar plate (use a different antibiotic if necessary for a particular 
plasmid). 
a. Bend the pipette tip on the inside of a Petri dish cover.  
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b. Use the bent pipette tip to pipette the cell volume and spread it without 
scraping the agar. 
c. Allow the liquid on the agar surface to dry near the flame. 
14. Incubate inverted petri dishes overnight at 37 °C in a bacterial incubator.  
a. Maximum incubation time should be ~18 hours to avoid satellite colonies. 
15. Store agar plates with bacterial colonies at 4 °C. 
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F.13 Inoculation and Bacterial Expansion 
 
Materials: 
50% sterile glycerol 
LB + Ampicillin broth (or LB broth with appropriate antibiotic)  
Bacterial colonies on agar plate, live culture, or frozen bacterial stock 
100% ethanol 
Autoclaved 250 mL Erlenmeyer flask 
17 x 100 mm culture tube 
50 mL conical tube 
Bunsen burner 
Bacterial incubator 
Centrifuge 
 
Protocol for Inoculation and Bacterial Expansion: 
1. Prepare a 50% sterile glycerol stock, if necessary. 
a. Combine equal parts water and glycerol, and sterile filter. 
2. Autoclave a 250 mL Erlenmeyer flask for each bacterial culture. 
3. Turn on a Bunsen burner. 
4. Working near the flame add LB + Ampicillin to each culture tube. 
a. Use 2 mL of LB + Ampicillin if expanding to a larger culture volume. 
b. Use 5 mL of LB + Ampicillin if subsequently performing a mini-prep 
5. Add bacteria to the culture. 
a. Dip tweezers in 100 % ethanol and pass over the flame twice to sterilize. 
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b. Use tweezers to pick up a sterile 200 µL (yellow) pipette tip. 
c. Touch a single bacterial colony on an agar plate with the pipette tip OR 
scrape the pipette tip across the top of a frozen glycerol stock. 
d. Drop the tip into the culture tube and cap the tube. 
e. Incubate the culture overnight while shaking at 225-250 RPM at 37 °C.  
6. If needed, prepare a frozen bacterial stock. 
a. Turn on a Bunsen burner. 
b. Working near the flame, add 800 µL of bacterial culture to a sterile 1.5 
mL microcentrifuge tube. 
i. Use a P1000 with a clear tip to “pick-up” the yellow tip that was 
expelled in the overnight culture. This avoids contaminating your 
pipette by dipping it into the bacterial culture.  
c. Add 200 µL of sterile, 50% glycerol. 
d. Mix and store at -80 °C. 
7. Inoculate a 100 mL culture.  
a. Turn on the Bunsen burner. 
b. Add 100 mL of LB + Ampicillin to each Erlenmeyer flask. 
c. Add bacteria to the Erlenmeyer flask: 
i. Frozen source:  
1. Scrape the pipette tip across the top of a frozen glycerol 
stock.  
2. Pipette within the flask, but do not expel pipette tip in the 
culture (less sterile). 
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ii. Live bacterial culture source: 
1. Add 100 µL of bacterial culture to the Erlenmeyer flask. 
d. Loosely cap the Erlenmeyer flask with sterile foil. 
e. Incubate the culture overnight with shaking at 225 RPM at 37 °C. 
8. Pellet bacteria.  
a. Pour 50 mL of the bacterial culture into a 50 mL conical tube. 
b. Spin at 4000 rpm for 8 minutes. Discard supernatant. 
c. Pour the remaining 50 mL of culture into the same 50 mL conical tube. 
d. Spin at 4000 rpm for 8 minutes. Discard supernatant. 
e. Invert tubes onto a kimwipe to remove excess liquid. 
f. Store at -20 °C or proceed directly to a Midiprep.  
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F.14 Midiprep 
 
Materials: 
NucleoBond Xtra Midi EF (Machery-Nagel Cat. #740420.10) 
Isopropyl alcohol 
Endotoxin free water 
Ice bucket with ice 
Microwave 
Centrifuge 
 
Protocol for Midiprep: 
1. Add 8 mL re-suspension buffer (Buffer RES-EF) to a bacterial pellet in a 50 mL 
conical tube. 
a. To prepare the re-suspension buffer in a new kit: 
i. Add 1 mL of re-suspension buffer to RNAse (lyophilized powder) 
and mix. 
ii. Add RNase to the re-suspension buffer. 
iii. Wash the RNAse tube with re-suspension buffer and add it back 
into the re-suspension buffer bottle. 
iv. Store re-suspension buffer at 4 °C. 
2. Vortex until the bacterial pellet is gone. 
3. Add 8 mL lysis buffer (Buffer LYS-EF) to the conical tube.  
a. Gently invert 5x to mix. 
b. Incubate for 5 minutes at room temperature. 
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4. Add 8 mL neutralization buffer (Buffer NEU-EF). 
a. Gently invert until the solution is colorless. 
b. Incubate on ice for 5 minutes to precipitate. 
5. Add 15 mL equilibration buffer to the rim of the column filter (Buffer EQU-EF). 
a. Poke the column bottom through a Styrofoam container, over a collection 
bin. 
6. Invert the precipitated solution in the tube 3 times to homogenize the solution. 
a. Pour the solution into a labeled column filter tube. 
b. Allow the solution to filter via gravity. 
7. Wash the column with 5 mL filter wash buffer (Buffer FIL-EF). 
a. Allow the solution to filter via gravity. 
8. Remove and dispose the filter. 
9. Wash the column (without the filter) with 35 mL Buffer ENDO-EF. 
a. Allow the solution to filter via gravity. 
10. Wash the column (without the filter) with 15 mL Buffer Wash-EF.  
11. Elute the plasmid into a clean 15 mL conical tube with 5 mL of warmed Buffer 
ELU-EF. 
a. Warm elution buffer in the microwave with 10 second spurts until it is 
around 50 °C (remember to loosen the cap when heating). 
12. Measure the initial eluted plasmid DNA concentration with the nanodrop.  
a. Blank with Buffer ELU-EF.  
b. A reading of zero does not necessarily mean your prep failed, just that you 
may have lower yield. 
 232 
13. Add 3.5 mL of room temperature isopropyl alcohol to the eluted plasmid and 
vortex thoroughly. Incubate for 3 minutes to allow the DNA to precipitate.  
a. Increase the incubation to 30 minutes at -20 °C if you want a higher yield. 
b. Pre-cool the centrifuge for Step #14 to 4 °C.  
14. Centrifuge to precipitate the plasmid at 4 °C for 30 minutes. 
a. Speed must be greater than 4,500 x g, preferably greater than 15,000 x g. 
15. Vacuum off supernatant. 
16. Wash plasmid pellet with 2 mL of DNA wash buffer. 
a. Shake to mix. Do not attempt to re-suspend pellet. 
b. Incubate at room temperature for 2 minutes. 
c. Prepare DNA wash buffer in a new kit by adding 21 mL of 200-proof 
ethanol. 
17. Spin to precipitate the plasmid at 4 °C for 5 minutes (same speed as step #14). 
18. Vacuum off the supernatant.  
19. Dry the DNA pellet in a vacuum chamber for 10 minutes. 
20. Re-suspend the pellet with endotoxin free water. 
a. The resuspension volume is dependent on the expected yield.  
i. Typically varies between 100-400 µL. 
b. Transfer plasmid to a clean, new microcentrifuge tube.  
i. Pipette with P1000 to avoid shearing the DNA with P200 
21. Measure the plasmid DNA concentration and label the side of the tube with the 
value. 
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F.15 Transfection 
 
Materials: 
T75 of HEK293 (293T) Cells at approximately 70% confluence 
TransIT-LT1 reagent (store at 4 °C) (Mirus Cat. #2304 or #2300) 
Opti-MEM reduced serum media (Invitrogen Cat. #31985-062)  
Lentiviral plasmid with gene of interest 
Helper plasmid #1: pSPAX2 
Helper plasmid #2: pMD2G 
Complete DMEM media 
 
Protocol for Transfection: 
1. Use the table below to determine the amount of media, DNA, and reagent 
required for the culture vessel being used.  
a. Source: https://www.mirusbio.com/  
 
2. In the biosafety cabinet, assuming a T75 flask for transfection:  
a. Add 1.9 mL of Opti-MEM reduced serum media to a 15 mL conical tube. 
b. Warm the TransIT-LT1 reagent to room temperature, vortex gently. 
c. Add 60 µL of TransIT-LT1 reagent to the same conical tube. 
     
    
  
Technical Support│Toll-free (U.S.) 844.MIRUSBIO│Direct: 608.441.2852│techsupport@mirusbio.com│www.mirusbio.com 
 TransIT®-LT1 Transfection Reagent 
 Protocol for MIR 2300, 2304, 2305, 2306 
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BEFORE YOU START: 
Important Tips for Optimal Plasmid DNA Transfection 
Optimize reaction conditions for each cell type to ensure best transfection results. The suggestions 
below yield high efficiency transfection using TransIT-LT1 Transfection Reagent. Table 1 presents 
recommended starting conditions depending on culture vessel size.  
x Cell density (% confluence) at transfection. The recommended cell density for most cell 
types is ≥80% confluence. Determine the optimal cell density for each cell type in order to 
maximize transfection efficiency. Divide the cells 18–24 hours before transfection to ensure 
that the cells are actively dividing and reach the appropriate cell density at the time of 
transfection. 
x DNA purity. Use highly purified, sterile, and contaminant-free DNA for transfection. 
Plasmid DNA preps that are endotoxin-free and have A260/280 absorbance ratio of 1.8–2.0 are 
desirable. DNA prepared using miniprep kits is not recommended as it might contain high 
levels of endotoxin. We recommend using MiraCLEAN® Endotoxin Removal Kit  
(MIR 5900) to remove any traces of endotoxin from your DNA preparation.  
x Ratio of TransIT-LT1 Reagent to DNA. Determine the best TransIT-LT1 Reagent:DNA 
ratio for each cell type. Start with 3 µl of TransIT-LT1 Reagent per 1 µg of DNA. Vary the 
concentration of TransIT-LT1 Reagent from 2–6 µl per 1 µg DNA to find the optimal ratio. 
Table 1 provides recommended starting conditions based on cell culture vessel size. 
x Complex formation conditions. Prepare TransIT-LT1 Reagent:DNA complexes in serum-
free growth medium. Mirus recommends Opti-MEM I Reduced-Serum Medium.  
x Cell culture conditions: Culture cells in the appropriate medium. The TransIT-LT1 Reagent 
yields improved efficiencies when transfections are performed in complete growth medium 
without a post-transfection medium change. There is no need to perform a medium change to 
remove the transfection complexes. 
x Presence of antibiotics: Antibiotics will inhibit transfection complex formation and therefore 
should be excluded from the complex formation step. Transfection complexes can be added to 
cells grown in omplete culture medium containing serum and low levels of antibiotics (0.1–
1X final concentration of penicillin/streptomycin mixture).  
x Post-transf ction incubation time. Det rmine the best incubation time post-transfec ion for 
each cell type. The optimal incubation time is generally 24–72 hours, but will vary depending 
on the goal of the experiment, nature of the plasmid used, and cell doubling time. 
 
Table 1. Recommended starting conditions for DNA transfections with TransIT-LT1 
Transfection Reagent.  
Culture vessel  96-well plate 
48-well 
plate 
24-well 
plate 
12-well 
plate 
6-well 
plate 
10-cm 
dish 
T75 
flask 
Surface area 0.35 cm2 1.0 cm2 1.9 cm2 3.8 cm2 9.6 cm2 59 cm2 75 cm2 
Complete growth 
medium  92 µl 263 µl 0.5 ml 1.0 ml 2.5 ml 15.5 ml 19.7  ml 
Serum-free medium 9 µl 26 µl 50 µl 100 µl 250 µl 1.5 ml 1.9 ml 
DNA (1µg/µl stock) 0.1 µl 0.26 µl 0.5 µl 1 µl 2.5 µl 15 µl 19 µl 
TransIT-LT1 Reagent 0.3 µl 0.78 µl 1.5 µl 3 µl 7.5 µl 45 µl 57 µl 
 
 
 
 
Do not use serum or antibiotics 
in the medium during 
transfection complex formation. 
 
 
 
Do not use DNA prepared using 
miniprep kits for transfection. 
 
 
Surface areas are based on 
Greiner tissue culture plates and 
Falcon 10-cm dishes and T75 
flasks. All volumes given are per 
well (or per dish) for a given 
culture vessel. 
 
If small volumes of TransIT-LT1 
need to be pipetted, dilute the 
reagent in serum-free medium 
before each use to avoid pipetting 
errors. Do not store diluted 
TransIT-LT1 Reagent. 
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d. Incubate the mixture at room temperature for 10 minutes. 
3. In the biosafety cabinet, mix the 3 plasmids to form a complex: 
a. Need a 10 : 7.5 : 2.5 mass ratio of: target plasmid : pSPAX2 : pMD2G 
i. Total volume should be approximately 19 µL of 1 µg/µL DNA 
(ratios are easier if you assume 20 µg of total DNA are needed). 
ii. Example: 
1. pFUWATP = 1260.6 ng/µL = 7.9 µL 
2.  pSPAX2 = 786.2 ng/µL = 9.5 µL 
3. pMD2G = 855.3 ng/µL = 2.9 µL 
b. Mix the calculated volumes of the target plasmid and both helper plasmids 
in a new microcentrifuge tube. 
i. Incubate the plasmid complex at room temperature for 30 minutes. 
c. Following the 30 minute incubation, add the plasmid complex to the 
media containing the TransIT-LT1 reagent. Incubate for 10 minutes. 
d. During incubations, change the media on the HEK293 cells. 
4. Transfection of HEK293 cells. 
a. The T75 flask should have 20 mL of fresh DMEM media.  
b. Tilt the flask back to expose cells from the media. Pipette the TransIT-
LT1/plasmid complex directly onto the exposed HEK293 cells. 
c. Incubate 24-72 hours in the mammalian cell incubator to harvest the 
lentivirus particles. 
5. Harvest lentivirus over the next 72 hours 
a. Approximately 10 mL of media lasts 1 day in a T75 
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i. At 48 hours collect 20 mL of media containing secreted lentiviral 
particles and replace with 10 mL of fresh complete DMEM media. 
Store collected media with lentiviral particles at 4 °C. 
ii. At 24 hours following the first harvest, collect the media 
containing the secreted lentiviral particles. 
 
  
 236 
F.16 Lentiviral Concentration 
 
Materials: 
HEK293 spent media containing lentivirus 
Lenti-X concentrator (Clontech Cat. #631231) 
Sterile PBS  
Syringe 
0.45 µm syringe filter (Syringe filter should be PVDF, cellulose acetate, or  
polyethersulfone. DO NOT use nitrocellulose, because it binds surface proteins on 
the lentiviral envelope and destroys the product) 
Ice bucket with ice 
Centrifuge 
 
Protocol for Lentiviral Concentration: 
1. Perform work in a biosafety cabinet. 
2. Combine HEK293 spent media volumes into a single 50 mL conical tube. 
3. Filter spent media through a 0.45 µm syringe filter into a new sterile 50 mL 
conical tube. 
4. Thoroughly mix the Lenti-X concentrator by shaking. 
5. Add 1 volume of Lenti-X concentrator to 3 volumes of clarified supernatant. 
a. Example: 
i. 30 mL supernatant 
ii. 10 mL Lenti-X concentration 
6. Mix by inversion. 
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7. Incubate on ice or 4 °C for 30 minutes to overnight (based on your schedule, no 
difference for yield). 
8. Centrifuge at 1,500 x g for 45 minutes at 4 °C (Reinhart-King centrifuge). 
a. Lentiviral particles should form an off-white pellet. 
9. Carefully vacuum aspirate the supernatant. 
10. Gently re-suspend the pellet in 1/10th to 1/100th of the original spent media 
volume in sterile PBS. 
a. i.e. Spent media volume = 30 mL, 1 mL sterile PBS is appropriate. 
b. Avoid introducing bubbles. 
11. Immediately aliquot and store the lentivirus particles at -80 °C. 
a. Additional freeze thaw cycle will reduce efficiency of the virus by 50%.  
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F.17 Transduction 
 
Materials: 
Low passage target cells (T25 or T75) at 40 – 60 % confluence 
Polybrene (store at -20 °C) (Santa Cruz Biotechnology Cat. #SC-134220) 
Target cell complete media 
 
Protocol for Transduction: 
1. Work in sterile biosafety cabinet. 
2. Choose the MOI (Multiplicity of infection, refers to the ratio of vector particles to 
target cells). 
a. Increasing the MOI can increase the transduction efficiency. 
b. Too much virus can be toxic. 
c. It is suggested to use greater than 1 : 1 vector : target cells but less than 
100 : 1 (10 : 1 is a good starting point). 
d. If you do not know the concentration of virus, it is useful to try high and 
low concentrations. You want the lowest amount of virus needed to get 
100% efficiency. 
3. Mix the transduction reagents. 
a. Used a reduced volume of growth media during transduction. 
b. Add 3 mL (T25) or 6 mL (T75) of the target cell media to a 15 mL conical 
tube. 
c. Add a 1/1000 dilution of 10 mg/mL Polybrene.  
i. Example: 3 µL in 3 mL 
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d. Add the appropriate volume of lentivirus. 
4. Transduction: 
a. Aspirate off spent media from the target cells. 
b. Pipette the lentivirus/polybrene/media mixture over the cells. 
c. Change the media in 12 to 24 hours. 
i. Polybrene can be harmful to cells. 
5. Check fluorescence in 24 to 48 hours. 
a. Often weak fluorescence is observed at 24 hours. 
b. Much greater expression and fluorescence are present at 48 hours. 
6. Culture cells normally. Expand and freeze down the transduced cell stock. 
a. Perform antibiotic selection if necessary to increase transduction 
efficiency. 
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APPENDIX G 
 
LIST OF PUBLICATIONS 
 
Cornell 
Published 
1. Lampi MC, Guvendiren M, Burdick JA, Reinhart-King CA. Photopatterned 
Hydrogels to Investigate the Endothelial Cell Response to Matrix Stiffness 
Heterogeneity. ACS Biomaterials Science & Engineering. 2017 Jan 4. 
2. Rahman A, Carey SP, Kraning-Rush CM, Goldblatt ZE, Bordeleau F, Lampi 
MC, Lin DY, García AJ, Reinhart-King CA. Vinculin regulates directionality and 
cell polarity in two-and three-dimensional matrix and three-dimensional 
microtrack migration. Molecular Biology of the Cell. 2016 May 1;27(9):1431-41. 
3. Lampi MC, Faber CJ, Huynh J, Bordeleau F, Zanotelli MR, Reinhart-King CA. 
Simvastatin Ameliorates Matrix Stiffness-Mediated Endothelial Monolayer 
Disruption. PloS one. 2016 Jan 13;11(1):e0147033. 
4. Kohn JC*, Lampi MC*, Reinhart-King CA. Age-related vascular stiffening: 
causes and consequences. Frontiers in Genetics. 2015 Mar 30;6:112. 
*denotes equal contribution 
5. Alcoser TA, Bordeleau F, Carey SP, Lampi MC, Kowal DR, Somasegar S, 
Varma S, Shin SJ, Reinhart-King CA. Probing the biophysical properties of 
primary breast tumor-derived fibroblasts. Cellular and Molecular Bioengineering. 
2015 Mar 1;8(1):76-85. 
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6. Kraning-Rush CM, Carey SP, Lampi MC, Reinhart-King CA. Microfabricated 
collagen tracks facilitate single cell metastatic invasion in 3D. Integrative 
Biology. 2013;5(3):606-616. 
 
Working Papers 
7. Goldblatt ZE*, Miller JP*, Li J, VanderBurgh JA, Lampi MC, King, MR, 
Reinhart-King, CA. Regulation of ATP generation during metastatic cell 
migration by collagen architecture, in revision. 
*denotes equal contribution. 
8. Lampi MC and Reinhart-King, CA. Therapeutically targeting increased 
extracellular matrix mechanics to attenuate disease: From molecular targets to 
clinical trials, in submission. 
9. Lin S, Lampi MC, Reinhart-King CA, Wang J, Nelscon C, Gu L. Eigenstrain as a 
Mechanical Set-Point of Cells, in submission. 
10. Armiger T, Lampi MC, Islam M, Reinhart-King, CA, Dahl KN. Measuring 
intracellular force within monolayers by tracking sub-nuclear sensors, in 
submission. 
11. Carey SP, Goldblatt ZE, Braun A, Hapach L, Lampi MC, Martin KE, Reinhart-
King CA. Phenotypic isolation and characterization of differentially invasive 
tumor cell subpopulations, in preparation. 
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Prior to Cornell 
1. Lampi MC, Wu X, Schilke KF, McGuire J. Structural attributes affecting peptide 
entrapment in PEO brush layers. Colloids and Surfaces B: Biointerfaces. 2013 Jun 
1;106:79-85. 
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